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This  thesis  assesses  the  methods  used  in  economic  evaluation,  the  relationship  of 
economic  evaluation  to  decision-making  and  investigates  the  possible  limitations  of 
economic  evaluation  as  it  is  currently  used  to  support  policies  aimed  at  maximising 
population  health  gain.  It  then  evaluates  alternative  methods  of  analysing  data  from 
economic  evaluations  to  better  inform  policy  decisions. 
The  hypothesis  of  this  thesis  is  that  a  greater  use  of  subgroup  analysis  in  policy  decisions 
could  potentially  improve  the  efficiency  of  allocating  scarce  health  care  resources.  This 
study  aims  to  investigate  the  impact  on  population  health  gain  and  service  cost- 
effectiveness  of  using  subgroup  analysis  within  defined  parameters  to  derive  and  evaluate 
estimates  of  effect,  and  compare  it  to  the  more  traditional  methods  of  statistical  inference. 
Data  from  existing  large  trials  are  used  to  calculate  cost-effectiveness  ratios  for  the  total 
study  population  and  for  subgroups.  Total  and  subgroup  estimates  of  cost-effectiveness 
are  applied  to  patient  populations  through  simulation,  and  outcomes  predicted  on  the 
assumption  that  treatment  decisions  are  guided  by  estimates  derived  from  the  trial.  The 
distribution  of  cost-effectiveness  ratios  based  on  different  rules  for  `allowing'  the  use  of 
subgroup  analysis  results  is  compared  with  the  distribution  of  cost-effectiveness  ratios 
based  on  aggregate  analyses. 
Results  show  that  pre-selected  subgroups  can  provide  a  stronger  likelihood  of  maximising 
overall  health  gain.  This  thesis  argues  for  optimisation  in  the  use  and  interpretation  of 
results  rather  than  an  over  reliance  on  certainty  and  the  resulting  restriction  on  the  use  of 
available  data.  It  concludes  that  under  the  scrutiny  of  a  health  care  system  for  which  the 
primary  goal  is health  gain  maximisation  within  resource  constraints,  policy  decisions 
made  using  the  results  of  subgroup  analysis  could  result  in  a  more  efficient  allocation  of 
resources. CONTENTS 
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The  goal  of  normative  economics  is  the  maximisation  of  the  welfare  of  the  population. 
Since  there  are  not  enough  resources  to  provide  all  the  medical  care  demanded,  choices 
are  inevitable.  Within  most  health  care  systems  the  objective  is  to  maximise  social 
welfare  in  terms  of  total  health  benefits  or  outcomes,  but  the  measurement  of  these 
outcomes  and  the  decision  of  the  priority  given  to  the  different  calls  upon  these  resources 
is  where  economic  theory  must  meet  practical  application. 
The  aim  of  this  thesis  is  to  look  at  the  methods  used  in  economic  evaluation,  its 
relationship  to  decision-making  in  health  care,  to  investigate  possible  limitations  of 
economic  evaluation  as  it  is  currently  used  in  terms  of  supporting  policies  to  maximise 
population  health  gain  and  to  suggest  better  methods.  The  first  section  gives  an  overview 
of  the  three  fields  of  interest; 
"  economic  evaluation  in  health  care  and  the  relationship  between  research  and 
decision-making 
"  the  contrasting  methods  available  to  analyse  economic  data  and  their  roots  in 
probability  theory 
"  Methods  of  data  analysis  that  incorporate  or  accept  the  heterogeneity  of  the  studied 
population 
The  second  section  looks  in  more  detail  into  the  theory  behind  subgroup  analysis.  It  takes 
forward  the  probability  theories  outlined  in  the  first  section  and  explains  the  intrinsic 
logic  behind  subgroup  analysis  that  leads  into  the  conceptual  framework  of  the  thesis. 
I0 It  then  assesses  the  theoretical  argument  for  the  use  of  subgroup  analysis  and  probability 
and  outlines  the  potential  gains  that  could  be  found  when  making  resource  allocation 
decisions  in  health  care. 
The  third  section  compares  subgroup  analysis  results  against  the  results  from  the  analysis 
of  the  data  set  as  a  whole.  Initially  concentrating  on  the  relationship  with  cost  and  then 
with  cost-effectiveness  ratios.  The  value  to  decision-makers  of  a  greater  use  of  subgroup 
analysis  is  assessed  by  comparing  the  usefulness  of  evidence  gained  through  subgroup 
analysis  with  those  gained  from  traditional  analysis  of  cost-effectiveness  ratios.  The  thesis 
concludes  with  a  discussion  on  the  relevance  of  the  results  of  this  study  to  policy  makers 
and  what  further  work  should  be  done  to  further  clarify  the  role  of  subgroup  analysis  in 
decision-making. 
ii 2.  Economic  evaluation  and  decision-making  in  health  care 
2.1  Introduction 
Recently  there  has  been  a  growth  in  the  number  of  clinical  trials  that  have  included  a  form 
of  economic  evaluation'.  The  aim  has  been  to  compare  the  costs  and  benefits  of  new 
treatments  or  prevention  strategies  with  other  more  commonly  used  methods.  The 
primary  objective  of  trials  has  been  the  evaluation  of  both  the  safety  and  efficacy  of 
treatment.  However,  consideration  is  now  being  given  to  other  facets  such  as  resource 
use.  A  world-wide  increase  in  health  care  expenditure  has  been  linked,  among  other 
things,  to  the  emergence  of  new  medical  procedures.  Several  countries  now  require 
information  on  the  cost-effectiveness  of  new  drugs  (e.  g.  Australia'  and  Canada)  and  any 
new  health  care  programme  (e.  g.  in  the  Netherlands4)  to  ensure  greater  efficiency  in  the 
use  of  resources. 
Closer  to  home,  the  recent  introduction  of  the  National  Institute  of  Clinical  Excellence 
(NICE)  has  been  set  up  with  the  primary  aim  to  ensure  that  new  technologies  are  assessed 
for  cost-effectiveness  as  well as  clinical  effectiveness.  The  primary  purpose  of  NICE  is 
summarised  as  follows; 
"NICE  will  produce  clear  guidance  for  clinicians  about  which  treatments  work 
best  for  which  patients.  It  will  assess  new  drugs,  treatments  and  devices  for  their 
clinical  and  cost-effectiveness.  "  5 
The  main  reason  for  this  shift  has  been  the  recognition  of  the  fact  that  diffusion  of  many 
medical  interventions  takes  place  prior  to  the  associated  costs  and  benefits  being 
12 determined'.  The  early  inclusion  of  economic  analysis  can  provide  useful  information  to 
assist  in  the  rational  diffusion  of  new  innovations  in  health  care'.  Economics  can  be  used 
in  conjunction  with  clinical  trials  to  help  answer  the  question  "should  we  do  this?  "  rather 
than  confining  the  conclusion  of  the  trial  to  the  question  "does  it  work?  "  That  is,  in 
comparison  with  current  or  alternative  treatments,  do  the  marginal  benefits  of  the  new 
treatment  outweigh  any  additional  costs?  The  application  of  economics  to  clinical  trials 
does  not  necessarily  mean  that  less  can  or  should  be  spent,  but  rather  that  the  use  of 
resources  might  be  more  efficient. 
It  is  argued  that  clinicians  should  have  an  intrinsic  responsibility  to  society  as  well  as  to 
the  individual,  and  that  these  responsibilities  should  be  incorporated  into  clinical 
decisions'.  Most  clinicians  would  agree  that  the  extra  money  spent  on  achieving 
insignificant  improvements  in  outcome  is  often  not  worthwhile.  The  extra  resources  used 
could  have  been  used  elsewhere  in  the  health  care  system  achieving  greater  benefit.  These 
ideas  come  directly  from  an  understanding  of  the  limitations  of  finite  resources  and  an 
aim  of  maximising  health  gain  through  the  allocation  of  these  resources.  The  term  "health 
gain",  in  this  thesis,  is  defined  as  a  positive  change  in  the  status  of  the  health  of  ` 
communities.  It  occurs  if  an  intervention  either  initiates  or  accelerates  an  improvement  in 
the  health  of  a  community,  or  if  it  prevents  or  delays  deterioration  in  the  health  of  a 
community. 
The  areas  in  which  economics  has  the  ability  to  have  an  impact  on  improving  outcomes 
are  first,  to  reach  definitive  conclusions  on  the  most  efficient  use  of  health  care  resources, 
and  second,  to  provide  evidence  to  enable  decision  makers  to  set  priorities  in  the 
13 allocation  of  total  resources  between  prevention  and  treatment.  However,  there  is  often  a 
sizeable  gap  between  what  researchers  consider  to  be  good  evidence  and  what  decision- 
makers  believe  to  be  good  evidence.  This  concept  is  not  in  any  way  confined  to  economic 
evaluation  but  encompasses  clinical  trials9  and  operational  research1°. 
Despite  the  enormous  investment  in  research,  which  consumes  around  $55bn  World- 
wide,  every  year",  there  is  evidence  to  suggest  that  little  of  this  research  provides 
evidence  which  is  then  used  in  practice  for  either  policy  or  clinical  decisions`2"3  Most  of 
the  literature14as.  '6  on  this  gap  between  research  evidence  and  decision-making  focuses  on 
better  use  of  and  easier  access  to  the  information  produced  by  research,  and  often 
overlooks  issues  raised  more  specifically  by  decision-makers,  that  of  interpretation  and 
generalisation  of  research  evidence".  This  chapter  aims  to  give  an  overview  of  the 
problems  of  economic  evaluation  both  in  terms  of  its  methodology  and  its  relationship 
with  policy  and  decision  making. 
2.2  The  theory  of  economic  evaluation 
Economic  evaluation  is  a  two  dimensional  measurement  of  the  effectiveness  of  an 
intervention,  where  an  intervention  is  assessed  by  it's  ability  to  produce  positive  benefits 
within  the  constraints  of  a  set  level  of  resources.  Resources  are  usually  presented  as  their 
equivalent  in  a  monetary  currency  such  as  pounds  or  dollars.  The  type  of  economic 
evaluation  will  determine  the  method  in  which  benefits  are  presented. 
Economics  looks  at  how  best  to  allocate  scarce,  or  limited  resources  to  best  satisfy 
unlimited  or  infinite  demand.  All  resources  are  scarce,  so  no  matter  how  much  there  is  of 
14 something  it  will  eventually  run  out.  Economists  attempt  to  maximise  aggregate  benefit 
from  within  the  restriction  of  limited  resources.  The  theory  of  benefit  maximisation  is 
best  described  in  terms  of  allocative,  or  Pareto  efficiency. 
Pareto  efficiency  was  named  after  the  economist  who  first  presented  this  theory,  Vilfredo 
Pareto.  He  stated  that  any  redistribution  of  resources  would  improve  efficiency  if  it  made 
at  least  one  person  better  off  without  making  anyone  else  worse  off.  Society  would, 
therefore,  be  most  efficient  where  it  is impossible  to  redistribute  resources  to  make 
someone  better  off  without  simultaneously  making  someone  else  worse  off.  There  could 
be  a  number  of  different  permutations  of  resource  allocation  that  resulted  in  Pareto 
efficiency,  but  they  would  all  produce  the  exact  same  level  of  aggregate  benefit.  This  is 
perfectly  acceptable  in  theory  but  becomes  difficult  to  measure  in  practice.  For  example, 
how  is benefit  defined?  Do  some  things  benefit  some  people  more  than  others? 
The  concept  is developed  further  by  the  compensation  principle  introduced  by  Kaldor18 
and  Hicks19.  It  adds  the  concept  of  relative  or  net  benefit,  making  the  model  more  flexible. 
If  a  redistribution  of  resources  results  in  gainers  and  losers,  it  is  a  move  towards  Pareto- 
efficiency  only  if  the  aggregate  benefits  of  the  gainers  outweigh  the  costs  of  the  losers.  In 
principle  the  gainers  can  then  compensate  the  losers  while  still  achieving  a  net  benefit. 
Kaldor  and  Hicks  proposed  that  the  measurement  of  benefit  should  be  directly 
comparable  with  the  costs  of  redistribution  and,  as  such,  benefits  should  be  given  a 
monetary  value. 
15 These  are  the  roots  of  the  economic  evaluation  method  known  as  cost-benefit  analysis 
(CBA),  the  aim  of  which  is  to  measure  the  effect  of  changes  in  resource  allocation  in 
terms  of  the  net  benefit  to  society. 
The  other  form  of  economic  efficiency  is  technical  efficiency.  The  definition  of  technical 
efficiency  is  that  of  a  production  process  that  utilises  the  minimum  resources.  In  terms  of 
health  care,  technical  efficiency  is  achieved  where  a  utilisation  of  resources  produces  a 
level  of  benefit  that  cannot  be  exceeded  by  utilising  those  resources  in  any  other  way.  It  is 
this  view  of  efficiency  that  forms  the  basis  of  cost-effectiveness  analysis,  which  does  not 
attempt  to  measure  benefits  against  cost,  but  generally  aims  to  compare  interventions  with 
the  same  goal.  Comparisons  are  made  by  fixing  either  the  costs  or  the  outcomes,  and 
comparing  the  remaining  variable. 
There  are  limitations  with  this  method  in  terms  of  comparing  different  strategies  or 
intervention  that  may  have  different  outcome  measures.  However,  a  version  of  cost- 
effectiveness  analysis  (CEA),  known  as  cost-utility  analysis  (CUA)  attempts  to  overcome 
this  by  using  a  common  measure  of  outcome,  so  the  relative  cost-effectiveness  of  all 
interventions  can  be  compared.  In  CUA  the  benefits  are  expressed  in  terms  of  quality- 
adjusted-life-years  (QALYs),  disability-adjusted-life  years  (DALYs)  or,  the  more  recently 
introduced  healthy-year-equivalents  (HYEs).  These  methods  can  be  used  to  compare 
interventions  with  different  outcomes. 
Although  CBA  is  the  original  method  of  economic  appraisal,  CEA  is  now  preferred  by 
decision  makers  because  it  doesn't  require  the  translation  of  health  consequences  into 
16 monetary  units  (i.  e.  quantifying  the  value  of  human  life).  However,  there  have  been  signs 
recently  of  a  re-emergence  of  CBA20,  with  the  introduction  of  a  number  of  new  methods 
that  have  made  the  valuation  of  health  consequences  less  problematic.  CUA  continues  to 
be  the  fastest  growing  form  of  economic  evaluation,  although  there  is  an  ongoing  debate 
about  the  use  and  calculation  of  the  generic  measure  of  benefit,  be  it  QALYs,  DALYs  or 
HYEs. 
The  application  of  these  methods  is  under  continuous  review,  lacking  any  consensus  of 
opinion21.  The  choice  of  method  is  often  not  straightforward.  Options  may  be  limited  due 
to  the  type  and  quality  of  the  information  available,  as  well  as  possible  restraints  on  time 
and  resources.  Although  the  ideal  method  can  be  identified  it  may  not  be  possible  to 
conduct  given  such  restraints.  The  goal  must  therefore  be  to  maximise  what  can  be 
achieved  and  to  choose  the  method  most  appropriate  to  the  data. 
A  key  issue  which  must  also  be  considered  before  embarking  on  an  economic  evaluation 
of  any  kind  is  the  economic  viability  of  economic  analysis,  i.  e.  whether  it  is  worthwhile 
spending  resources  on  the  evaluation.  The  quality  or  the  availability  of  information  for 
economic  analysis  may  be  such  that  it  is  not  perceived  efficient  to  conduct  an  economic 
evaluation  due  to  the  unreliability  of  the  results.  Ideally  economic  evaluation,  with  its 
associated  costs,  should  only  be  undertaken  if  the  benefits  of  improving  efficiency  in  the 
use  of  health  care  resources  outweigh  these  costs.  Conversely  it  may  not  be  worthwhile 
undertaking  the  evaluation  because  the  evidence  already  exists  to  substantiate  the  cost- 
effectiveness. 
17 2.3  Research  evidence  and  decision-making 
There  has  long  been  an  underlying  tension  between  decision-makers  and  researchers. 
Much  of  this  tension  comes  from  the  belief  that  those  doing  research  do  not  understand  or 
appreciate  the  complexities  involved  in  decision-making.  No  matter  how  impressive  or 
definitive  the  research,  it  still  has  to  be  interpreted  at  a  local  level.  The  problem  is due  to 
the  fact  that  researchers,  who  are  trying  to  reach  the  widest  audience,  tend  to  generalise 
upward  towards  a  generic  or  "average"  result,  whereas  those  who  wish  to  take  advantage 
of  this  evidence  are  trying  to  generalise  downward  within  a  specifically  defined 
population.  The  result  is  a  dichotomy  of  interest  between  both  players. 
Classical  statistical  techniques  compound  this  problem  by  limiting  results  of  trials  to  a 
simple  right  or  wrong  (or  better  or  worse)  outcome,  across  a  general  sample.  There  has 
been  a  growing  movement  towards  alternative  methods  of  statistical  proof  and  the 
summarising  of  trial  results  for  the  benefit  of  decision-makers.  Most  of  these  have  tended 
towards  either  greater  sensitivity  analysis  or  the  use  of  alternative  statistical  techniques 
such  as  Bayesian  theory  or  decision  analysis  (defined  in  detail  in  chapters  3  and  4).  The 
advantages  of  Bayesian  techniques  lie  in  the  fact  that  it  is  possible  to  incorporate 
additional  information  into  the  analysis  of  a  particular  study  (such  as  specific  patient 
characteristics).  This  makes  it  easier  for  the  decision-maker  to  apply  the  results  of  generic 
research  to  specific  situations  and  allows  the  formal  inclusion  of  the  heterogeneity  of 
populations  into  analysis  of  data,  something  that  cannot  be  done  when  using  classical 
statistical  techniques. 
18 For  example,  consider  a  study  that  shows  that  intervention  "A  "  leads  to  a  lower  rate  of 
post-operative  infection.  The  results  using  classical  statistics  will  only  show  the  mean 
difference  in  infection  rate  between  those  who  received  the  intervention  and  those  who 
didn't,  along  with  a  significance  test  to  inform  the  decision-maker  of  the  likelihood  of  the 
results  of  the  trial  being  true.  The  decision-maker,  however,  is  also  aware  that  there  are  a 
number  of  other  aspects  of  the  treatment  that  a  surgical  patient  can  receive  that  would  also 
affect  the  post-operative  infection  rate,  for  example,  whether  they  received  blood  or  not. 
In  Bayesian  analysis  the  relationship  between  the  presence  of  a  blood  transfusion  and 
post-operative  infection  rate  would  have  been  included  in  the  analysis  as  prior 
information,  thus  the  results  of  the  analysis  would  be  more  appropriate  for  decision- 
makers. 
It  is  not  only  in  the  clinical  trial  arena  that  there  is  a  need  to  bridge  the  gap  between 
research  and  policy,  but  also  in  the  field  of  economic  evaluation.  There  has  been  much 
progress  in  the  methods  used  for  economic  evaluation  in  health  care  in  recent  years.  The 
majority  of  the  mathematical  work  has  centred  on  improving  the  measurement  of  the 
statistical  inference  of  cost-effectiveness  ratios,  rather  than  the  search  for  alternative 
methods  of  presenting  economic  information  and  improving  its  application  in  decision 
making22,23"24,25  However,  there  is  a  growing  body  of  research  that  has  started  to  challenge 
the  use  of  classical  statistics  to  present  economic  data  and  a  move  towards  methods  which 
b 
.  are  more  relevant  for  decision-making' 
Claxton  and  Posnet",  along  with  many  others,  express  the  view  that  a  decision-analytic 
framework  should  be  pursued  when  attempting  to  answer  economic  questions.  The  reason 
19 for  this  view  is  that  traditional  trial  design  is  not  consistent  with  the  concept  of  efficiency, 
whereas  the  decision-analytic  approach  is  as  well  as  with  methods  used  to  set  priorities  in 
service  provision.  Claxton  and  Posnet  also  state  the  advantage  of  incorporating  "prior 
information"  as  being  "handled  consistently  and  open  to  criticism,  alternative  formulation 
and  empirical  testing,  "  whereas,  classical  statistical  techniques  exclude  the  use  of  related 
or  prior  information  in  producing  results. 
Lilford  et  al16  also  supports  the  incorporation  of  prior  information  via  the  use  of  Bayesian 
statistical  methods.  They  argue  that  conventional  statistical  testing  is "an  improper  basis 
for  making  decisions  because  they  dichotomise  results  according  to  whether  they  are  or 
are  not  significant,  and  do  not  allow  decision  makers  to  take  explicit  account  of  additional 
information.  "  Similar  arguments  are  found  in  Hornberger  et  a129,  Van  Hout  et  al3°  and 
McCloskey  et  a131. 
2.4  The  relationship  between  economic  evaluation  and  decision  making 
Evidence  suggests  that  economic  evaluations  are  seldom  used  as  a  tool  for  decision 
making  in  policy  or  management32,33'34'35  These  studies  concluded  that  the  majority  of 
economic  evaluations  have  been  done  by  researchers  without  prior  consultation  with 
policy  makers,  however,  changes  are  beginning  to  take  place.  For  example  in  the  UK  the 
Cochrane  Collaboration  and  NICE  are  initiatives  aimed  at  boosting  the  acceptance  of 
evidence-based  medicine  in  practice.  In  Australia  a  set  of  economic  evaluations36  have 
been  done  in  collaboration  with  the  appropriate  decision-makers  in  health  departments, 
which  had  a  definitive  impact  on  policy.  This  supports  the  theory  that  an  increased 
20 involvement  with  decision-makers  would  improve  the  impact  economic  appraisals  have 
on  health  care  policy. 
The  connection  between  research  and  policy  has  always  been  a  tenuous  one,  and  as 
economics  is  still  a  relatively  new  facet  to  the  measurement  of  the  effectiveness  of  health 
care  interventions,  the  connection  with  policy  is  even  more  tenuous.  Australia  and  Canada 
are  the  only  countries  to  have  affected  an  introduction  of  mandatory  economic  evaluation 
for  new  pharmaceutical  products37,  however  a  number  of  other  countries  are  now 
requesting  information  on  economic  evaluation  in  order  to  aid  decisions  such  as  Finland, 
Switzerland,  Sweden  and  the  UK. 
A  review38  has  cited  how  economic  evaluation  has  grown  in  the  past  three  decades.  In  the 
five  years  from  1970-74  there  were  just  56  published  economic  evaluations  whereas  in 
the  period  1985-89  there  were  718.  The  majority  of  these  have  been  cost  analyses  and 
cost-effectiveness  analyses.  There  is  evidence,  then,  that  the  use  of  economic  evaluation 
in  policy  and  decision-making  is  starting  to  grow.  Nevertheless  there  is  still  scepticism 
about  the  value  of  economic  evaluation  in  health  care,  due,  in  part,  to  the  wide  variety  in 
the  quality  of  published  economic  evaluations.  In  response  to  this  a  number  of  guidelines 
on  conducting  and  reporting  economic  evaluations  (e.  g.  the  BMJ  guidelines)  have  been 
developed  to  help  define  appropriate  methodological  standards". 
One  of  the  major  reasons  cited  by  decision  makers",  for  not  using  information  from 
economic  evaluation,  is  the  inability  of  economists  to  present  the  results  of  their  research 
in  a  way  that  is  both  agreeable  and  useable  for  people  in  the  position  of  making  decisions. 
21 If  the  results  of  economic  evaluations  are  to  be  considered  in  clinical  decision-making,  a 
common  language  must  be  found  between  clinicians  and  economists.  Although  economic 
evaluations  have  increased  in  both  quantity  and  quality  over  the  years,  their  acceptance 
and  influence  on  decision-makers  has  not  grown  significantly.  The  question,  therefore,  is 
what  forms  of  clinician/manager  education  and/or  changes  in  presentation  of 
methodologies  and  results  are  required?  There  have  already  been  a  number  of 
developments  that  have  aided  the  communication.  Firstly  there  is  the  introduction  of 
health  outcomes  as  a  measure  of  productivity  or  benefit.  There  have  been  a  number  of 
innovations  in  health  outcome  measures,  for  example  quality  adjusted  life  years,  which 
combined  the  outcomes  of  mortality  and  morbidity  into  one  measure40.  Second,  decision- 
making  has  started  to  move  away  from  the  benefit  of  the  individual  and  towards  being 
based  on  the  benefits  to  society  as  a  whole.  This  makes  it  easier  to  understand  the  need  to 
compare  benefits  with  costs. 
In  addition  to  the  need  of  presenting  economic  evaluations  in  such  a  way  that  is both 
understandable  and  generalisable  to  decision-makers,  there  is  also  the  more  practical 
problem  of  integration  of  economic  analysis  into  routine  decision-making. 
An  article  by  John  Hutton4'  recently  highlighted  the  fact  that  economic  evaluation  is  only 
done  on  a  one-off  basis  to  solve  a  specific  problem  and  very  rarely  used  routinely.  Hutton 
drew  parallels  with  the  evolution  of  economic  evaluation  and  Lewis  Thomas' 
classification  of  medical  technologies.  Here  he  states  that  economic  evaluation  has 
moved  on  from  being  a  non-technology  to  a  half-way  technology,  but  for  it  to  become  an 
22 advanced  technology  it  would  have  to  become  routine,  and  an  accepted  part  of  clinical 
decision-making. 
2.5  Summary 
Economic  evaluation,  despite  the  lack  of  direction  of  its  methodologies  and  the 
difficulties  of  it  being  accepted  in  practice,  has  the  potential  to  be  a  very  valuable  tool  in 
helping  to  maximise  health  gain  within  the  restraints  of  limited  resources.  However 
evidence  suggests  that  the  current  methods  of  presenting  results  of  economic  evaluations 
are  not  consistent  with  this  goal.  Although  there  has  been  much  talk  of  bringing  economic 
information  and  clinical  decision  making  closer  together,  there  has  been  less  evidence  of 
it  happening.  A  first  step  must  be  to  shift  the  goals  of  economic  evaluation  in  terns  of  the 
presentation  of  results  closer  to  those  that  are  relevant  and  practical  to  those  making  the 
decisions. 
The  relationship  between  research  and  policy  is  of  vital  importance,  to  both  groups.  They 
rely  heavily  on  each  other  for  their  continued  existence,  yet  often  seem  to  have  no 
common  language.  There  is  a  growing  belief  among  some  that  movement  away  from  the 
strict  rules  of  classical  statistics  and  a  wider  acceptance  of  new  techniques  that  take  into 
account  the  issue  of  heterogeneity  should  be  considered.  These  techniques  have  the 
advantage  of  incorporating  the  specific  characteristics  of  both  patient  and  population, 
methods  such  as  Bayesian  statistics,  decision  analysis  and  subgroup  analysis  could  bring 
the  information  requirements  of  the  policy  maker  and  the  research  efforts  of  the 
economist  closer  together. 
23 3.  Incorporating  heterogeneity  into  data  analysis 
3.1  Introduction 
The  aim  of  this  thesis  is  to  investigate  the  possibility  that  for  the  purpose  of  answering  the 
question,  "which  health  care  interventions  should  be  provided  and  for  whom?  "  we  need  to 
focus  more  on  the  relative  cost-effectiveness,  both  costs  and  outcomes,  of  health  care 
services  within  different  subgroups. 
When  policy  makers  decide  what  health  care  interventions  should  be  funded  they  do  so  on 
a  basis  of  knowledge  of  the  demands  of  their  population.  Where  a  population  has  a  high 
incidence  of  a  certain  disease  investment  in  treatment  of  that  disease  may  take  priority 
over  another.  Despite  the  acknowledgement  of  the  heterogeneity  of  populations  there  is 
little  acceptance  that  evidence  on  the  cost-effectiveness  of  these  interventions  for  different 
groups  within  the  population  itself  may  be  useful  in  making  these  decisions. 
The  purpose  of  the  next  two  chapters  is  to  look  at  the  theory  behind  three  methods  most 
associated  with  analysing  data  sets  which  take  into  account  the  issue  of  heterogeneity. 
These  are  Bayes  theory,  decision  analysis  and  subgroup  analysis.  Bayes  theory  brings  the 
incorporation  of  prior  evidence  to  the  issue  of  heterogeneity;  subgroup  analysis 
concentrates  mainly  on  the  issue  of  heterogeneity  alone,  and  decision  analysis  takes  the 
complex  issue  of  the  non-homogenous  effects  of  interventions  into  the  realm  of  decision 
making. 
& 
24 Many  of  these  alternative  methods  of  analysis  of  clinical  trial  data  have  been  the  subject 
of  widespread  debate4'.  In  order  to  assess  the  relative  benefits  of  all  three  and  to 
understand  how  they  incorporate  the  issue  of  heterogeneity  these  methods  and  the  theory 
underlying  them  will  be  reviewed  in  detail. 
This  chapter  reviews  the  importance  of  heterogeneity  and  looks  in  more  detail  at  the 
potential  benefits  and  problems  with  subgroup  analysis.  Chapter  4  then  goes  onto  review 
the  theoretical  concepts  underpinning  these  alternative  methods  and  assesses  in  more 
detail  the  techniques  of  Bayesian  and  decision  analysis. 
3.2  The  potential  benefits  of  incorporating  heterogeneity  into  analysis 
The  benefits  of  incorporating  heterogeneity  when  undertaking  analysis  of  data  is best 
shown  graphically  as  in  figures  3.1  and  3.2.  Figure  3.1  shows  the  average  cost- 
effectiveness  ratios  for  a  general  population  with  the  minimal  data  on  the  characteristics 
of  the  population  and  their  impact  on  cost-effectiveness.  Within  the  block  where  the 
resource  constraint  falls,  a  proportion  of  people  who  have  an  average  cost-effectiveness 
ratio  of  "x"  will  forgo  treatment  even  though  some  of  the  people  who  receive  treatment 
will  have  a  cost-effectiveness  ratio  lower  than  "x"  and  some  who  don't  receive  treatment 
will  have  a  cost-effectiveness  ratio  greater  than  "x".  Figure  3.2  demonstrates  that  with 
greater  information  on  the  characteristics  of  the  population  and  the  relationship  between 
those  characteristics  and  cost-effectiveness  a  clearer  picture  emerges  of  the  proportion  of 
the  population  likely  to  benefit  most.  This  would  result  in  a  more  efficient  allocation  of 
resources.  The  average  cost-effectiveness  ratio  of  those  receiving  the  intervention  in 
25 Figure  3.1  would  be  "x",  and  the  average  cost-effectiveness  ratio  of  those  receiving  the 
intervention  in  Figure  3.2  would  be  between  "x"  and  "y",  approximately  (x  +y)  /  2. 
This  method  could  also  help  us  to  achieve  a  more  efficient  balance  between  different 
sectors  of  health  care.  For  example  let  us  assume  that  there  are  only  two  interventions  in 
the  prevention  and  treatment  of  colorectal  cancer,  screening  and  surgery.  These 
interventions  would  have  marginal  cost-effectiveness  ratio  curves  (see  figure  3.3)  and 
these  curves  would  be  made  up  of  subgroups  of  the  population  and  could  be  listed  in 
order  (see  figure  3.4)  to  give  a  picture  of  the  extent  to  which  resources  are  better  spent  on 
surgery  or  screening. 
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In  many  trials  in  addition  to  the  main  outcomes  there  are  often  other  results  based  on  one 
or  a  number  of  specific  subsets  of  the  population  studied.  These  subsets,  or  "subgroups", 
are  connected  by  a  specific  common  characteristic,  such  as  age,  sex  or  some  other 
common  demographic,  diagnostic  or  biological  trait.  The  reason  they  are  highlighted  is 
usually  because  the  group  in  question  is  shown  to  derive  a  much  greater  benefit  or  are  at  a 
higher  risk  from  the  intervention  being  studied.  This  would  seem  to  be  a  potentially  useful 
source  of  information.  However  it  is  often  argued  that  subgroup  analyses  is  used  without 
due  regard  to  protocol,  and  furthermore  to  produce  positive  results  in  any  form  is 
surrounded  by  a  degree  of  scepticism".  This  has  meant  that  attempts  to  produce  useful 
insights  into  the  relative  effectiveness  of  interventions  across  populations  with  different 
characteristics  have  been  looked  upon  with  distrust,  regardless  of  their  scientific  strength 
or  importance.  In  reality  the  identification  and  use  of  subgroups  in  this  way  may  allow  a 
more  efficient  use  of  resources. 
27 
Ci[  ratio Like  most  studies,  subgroup  analysis  uses  a  sample  of  a  population  to  draw  conclusions 
about  the  population  as  a  whole.  Also  like  most  studies  the  results  are  always  at  risk  of 
interference  from  confounders  and  bias.  A  number  guidelines  have  been  published44  21'22 
suggesting  that  subgroup  analysis  must  be  treated  with  extreme  caution  and  that  a  number 
of  steps  must  be  taken  to  minimise  the  possibility  of  chance  entering  into  the  results,  as 
well  as  how  to  interpret  the  results  if  you  are  the  intended  audience.  These  guidelines  and 
checklists  could  be  equally  applicable  to  any  form  of  trial  analysis. 
3.3  The  potential  pitfalls  of  subgroup  analysis 
It  has  been  reported  that  subgroup  analysis  can  be  misleading,  and  that  there  has  been  a 
tendency  to  over  emphasise  the  importance  of  subgroup  analyses  without  attention  paid  to 
statistical  rigour.  However,  the  majority  of  criticism  aimed  at  published  subgroup 
analyses  has  been  concerned  with  the  potential  dangers  of  misinforming  decision-makers 
while  avoiding  a  more  constructive  view  that  points  out  the  poor  practical  applications  of 
the  method.  Like  any  other  form  of  analysis,  statistical  or  otherwise,  if  undertaken 
without  due  regard  to  the  rules  by  which  it  is  drawn,  the  results  will  be  unreliable. 
For  clinical  trials  good  design  requires  elements  of  randomisation,  masking,  completeness 
of  follow-up,  and  other  methods  associated  with  minimising  both  error  and  bias.  A 
number  of  papers  have  attempted  to  summarise  the  problems  with  conducting  and 
interpreting  sub-group  analyses'.  46,47  Consensus  moves  us  to  list  four  main  areas  of 
concern.  These  are; 
1)  Statistical  significance, 
28 2)  Clinically  important  difference, 
3)  Hypothesis  preceding  analysis, 
4)  Dose  response  and  indirect  evidence  to  support  the  findings. 
Statistical  significance  is  an  important  issue.  Subgroup  analyses  will  always  include  fewer 
patients  than  does  the  overall  analysis  and  as  such  carries  a  greater  risk  of  a  type  II  error* 
There  are  a  number  of  techniques  for  conducting  subgroup  analyses  that  are  suggested  to 
reduce  this  such  as  the  Bayesian  method4a.  °9  or  those  used  in  decision  analysis  models. 
Statistical  significance  is,  however,  only  a  tool  for  assessing  the  likelihood  of  an  observed 
event  happening  by  chance.  The  possibility  of  the  result  being  due  to  chance  can  be 
minimised,  but  never  dismissed  entirely.  This  leads  onto  the  second  point,  the  importance 
of  observing  a  clinically  important  difference.  No  trial  can  control  for  everything  and  as 
such  there  will  always  be  a  measure  of  difference  between  different  subgroups.  It  is  only 
when  the  difference  is  large  enough  does  the  interaction  warrants  attention.  There  are  no 
ground  rules  for  size  of  effect,  but  generally  the  larger  the  difference  between  a  particular 
subgroup  and  the  overall  effect,  the  more  likely  that  it  will  be  real. 
The  third  factor  is  the  issue  of  the  hypothesis  preceding  the  analysis.  It  is  generally 
believed  that  sifting  through  data  for  possible  interactions  is  bad  science.  There  are  a 
number  of  examples  of  studies  finding  "apparent"  interactions  in  subgroups  where  none 
were  found  in  the  overall  population.  Nevertheless,  the  issue  of  whether  a  hypothesis 
preceded  analysis  is  not  always  a  cut  and  dried  one.  At  one  end  of  the  spectrum  you  might 
have  unexpected  results  in  a  subgroup  detailed  after  the  event  that  cannot  be  explained, 
where  a  relationship  shown  is  more  likely  to  be  due  to  chance. 
29 whereas  at  the  other  end,  you  may  have  a  subgroup  result  clearly  explained  in  a  protocol 
beforehand  that  was  suggested  by  previous  research.  Between  these  two  extremes  are  an 
infinite  number  of  combinations.  It  is  normal  to  discourage  conclusions  to  be  drawn  from 
an  unexpected  correlation,  however,  if  they  possess  a  degree  of  statistical  power  they  may 
form  a  very  useful  hypothesis  for  future  research. 
This  brings  us  to  the  last  point,  where  results  of  subgroup  analyses  may  be  strengthened 
by  a  dose-response  or  by  indirect  evidence  such  as  known  human  biology  or  behaviour. 
An  example  may  be  where  an  intervention  has  minimal  benefits  across  a  population,  but 
in  older  age  groups  its  effects  are  more  pronounced.  The  effects  of  the  lower  age  groups 
may  have  pulled  down  the  overall  average.  The  evidence  could  be  supported  if  there  was 
a  linear  trend  in  dose-response  across  the  age  groups  or  if  there  was  a  physiological  or 
psychological  reason  why  the  intervention  would  be  more  likely  to  benefit  older  people. 
3.4  Summary 
When  studying  a  multidimensional  subject  such  as  a  population,  there  are  inevitably 
issues  surrounding  the  heterogeneity  of  that  sample.  It  is  not  under  debate  that  this 
heterogeneity  exists  or  that  there  are  groups  within  the  population  defined  by  certain 
characteristics  that  will  mean  that  a  given  health  care  intervention  is  more  or  less  likely  to 
be  cost-effective  for  them.  What  is  an  issue  of  conjecture  is  whether  this  information  and 
these  relationships  are  attainable  and  whether  knowledge  of  them  can  be  used  to  improve 
efficiency  in  resource  allocation. 
30 Subgroup  analysis  or  the  measurement  of  the  relative  cost-effectiveness  of  groups  within 
a  population,  rather  than  the  population  as  a  whole  can  theoretically  improve  the 
efficiency  of  health  care  systems.  Despite  the  concern  surrounding  the  methods 
employed  to  undertake  subgroup  analysis,  most  of  these  can  be  overcome  with  a 
concentration  on  good  science  and  the  use  of  accepted  methods  of  measurement. 
Having  given  an  overview  of  the  importance  of  heterogeneity  and  the  value  of  subgroup 
analysis,  the  next  chapter  will  review  the  theory  behind  the  two  more  mainstream 
methods  associated  with  heterogeneity-friendly  data  analysis,  Bayes  and  decision 
analysis. 
31 4.  Probability,  inference  and  decision  analysis 
4.1  Introduction 
To  understand  where  the  heterogeneous  methods  differ  from  the  more  common  classical 
analysis,  we  must  go  back  to  the  roots  of  inference  with  a  description  of  probability 
theory  and  its  relation  to  the  various  theories  of  inference  and  decision  analysis.  Once  we 
have  described  the  varying  theories  of  probability  and  their  perceived  strengths  and 
weaknesses,  the  mainstream  methods  of  Bayesian  inference  and  decision  analysis  will  be 
reviewed. 
This  chapter  then  goes  on  to  provide  a  critical  analysis  of  both  of  these  methods  in 
comparison  to  subgroup  analysis.  It  will  look  at  the  strengths  and  weaknesses  of  these 
methods  both  in  terms  of  the  information  it  provides  to  decision  makers  and  the 
acceptance  of  the  tools  it  uses  to  achieve  these  results. 
4.2  Theories  of  Probability. 
All  theories  of  statistical  inference  are  rooted  in  probability  theory.  Looked  at 
simplistically,  it  could  be  said  that  each  different  classification  of  probability  theory  has 
led  to  a  theory  of  statistical  inference.  As  will  become  apparent,  this  is  not  necessarily  so. 
There  are  no  fixed  boundaries  in  terms  of  belief  of  one  particular  theory  of  probability 
that  automatically  disqualifies  you  from  any  one  theory  of  statistical  inference,  but  there 
are  some  obvious  common  links  that  obviate  likelihood  of  one  over  that  of  another. 
32 There  are  basically  four  theories  of  probability;  the  classical,  the  frequentist,  the  logical  or 
objective,  and  the  subjective  or  personalistic  theory. 
All  theories  of  probability  have  a  number  of  simple  properties.  The  most  obvious  of  these 
is  that  if  we  have  a  set  of  events  that  are  mutually  exclusive  and  which  include  all  the 
possible  events  in  the  given  circumstances  then  the  sum  of  the  probabilities  of  these 
events  happening  will  be  one.  The  set  of  these  probabilities  makes  up  a  probability 
distribution.  Of  the  four  theories  of  probability,  the  oldest  and  simplest  is  the  classical 
theory  of  probability. 
4.2.1  Classical  probability 
The  first  recognisable  work  on  probability  was  done  in  the  1600s  and  centred  itself  on  a 
framework  of  "equally  likely"  outcomes.  At  this  stage  there  was  no  attempt  to  define 
probability,  although  some  years  later  Laplaces'S°  classical  definition  ofprobability  as  the 
ratio  of  the  number  of  outcomes  favourable  to  the  event  to  the  total  number  of  possible 
outcomes,  each  assumed  to  be  equally  likely  became  the  accepted  definition.  Although 
forming  the  roots  of  modern  day  thoughts  and  theories  of  probability  the  classical  view  of 
probability  is  generally  thought  not  to  stand  up  to  modem  methodological  standards, 
mainly  due  to  it's  reliance  on  the  concept  of  "equally  likely"  outcomes'. 
The  definition  of  "equally  likely"  is  thought  to  come  from  the  symmetry  or  homogeneity 
of  the  experimental  situation.  If  a  two-sided  coin  is  spun,  what  reasons  are  there  for  one 
side  to  be  favoured  over  the  other?  Are  the  outcomes,  therefore,  equally  likely?  This  is 
known  as  the  "principle  of  cogent  reason".  The  difficulty  arises  when  we  study  the  basis 
of  such  reason,  for  on  what  basis  do  the  physical  properties  of  such  objects  imply  equal 
33 probability?  The  basis  for  the  reasoning  seems  to  rely  on  some  prior  knowledge  about  the 
effect  of  these  physical  properties,  and  at  this  point  the  theory  becomes  somewhat 
circular.  What  is  really  being  considered  is  a  theoretical  coin  that  approximates  to  our 
chosen  coin. 
The  other  attitude  to  this  concept  is  the  "principle  of  insufficient  reason",  which  argues 
that  if  we  have  no  good  reason  to  believe  that  either  side  of  the  coin  is  more  likely  to  fall 
face-up,  then  we  must  assume  that  both  sides  are  equally  likely  to  appear.  This  then 
becomes  a  subjective  argument  based  on  the  level  of  information  we  may  or  may  not  have 
about  the  properties  of  the  coins. 
These  restrictions  aside,  the  concept  of  equally  likely  outcomes  can  conceivably  be  used 
in  only  a  small  number  of  basic  problems.  Most  attempts  to  use  classical  probability 
theory  in  more  widely  defined  terms  have  tended  to  move  more  towards  introduction  of 
the  concept  of  "frequency"  probability  theory,  with  the  connection  of  the  principle  of 
cogent  reason. 
4.2.2  Frequency  probability  theory 
A  frequency  theory  of  probability  started  to  arise  from  the  attempts  to  study  more  diverse 
topics  with  the  more  limited  classical  theory.  Venn52  first  formally  defined  it  as 
expressing  "probability  in  terms  of  the  limiting  values  of  relative  frequencies  in  infinite 
sequences  of  repeatable  situations".  The  mathematical  basis  for  the  frequency  theory  was 
34 not  developed  until  much  later  by  von  Mises53,  who,  rejecting  the  limitations  of  the 
classical  standpoint,  saw  frequentist  probability  as 
"the  rational  concept  of  probability...  (applying)  only  to  problems  which  either  the 
same  event  repeats  itself  again  and  again,  or  a  great  number  of  uniform  elements 
are  involved  at  the  same  time.  In  order  to  apply  (this)  theory  of  probability  we 
must  have  a  practically  unlimited  sequence  of  uniform  observations.  " 
In  essence  the  restriction  of  the  use  of  frequency  theory  seems  to  be  that  within  the 
collective  or  group  of  identical  events  being  studied,  along  with  the  condition  of 
uniformity  is  a  condition  that  requires  the  properties  of  these  events  are  not  restricted  by 
their  position  within  the  collective.  This  means  that  if  a  selection  or  subset  of  those  events 
were  selected  according  to  some  specific  rule,  the  properties  of  those  events  would  tend 
towards  the  properties  of  the  whole.  The  basis  of  this  limitation  von  Mises  calls  the 
principle  of  randomness" 
It  is  the  inclusion  of  this  concept  that  differentiates  frequency  theory  from  that  of 
subjective  probability  theory,  as  in  the  former  an  event  is  not  specific  but  typical.  That  is, 
the  probability  of  an  event  is  the  probability  that  the  coin  will  fall  heads  face-up  at  any 
observable  occasion.  Whereas  the  subjective  viewpoint  takes  a  more  personal  view  of 
each  event,  looking  to  assess  the  probability  of  the  coin  coming  up  heads  on  the  10th  or 
11th  toss. 
35 It  is  may  be  suggested  by  subjective  probability  theorists  that  like  classical  probability 
theory,  frequency  probability  theory  has  implied  limitations  to  where  it  can  be  used.  It's 
use  and  wide  acceptance,  as  the  basis  for  much  of  the  statistical  methods  used  in 
population  sciences,  tends  to  suggest  that  these  limitations  are  not  very  important. 
The  views  range  from  the  admission  that  situations  that  do  not  encompass  repetition  of 
events  of  uniformity  are  not  within  the  realm  of  vigorous  statistical  enquiry.  Whereas 
other  go  so  far  as  to  suggest  that  this  concept  itself  makes  frequentist  theory  untenable  in 
the  study  of  complex  bodies  such  as  populations.  It  all  depends  on  your  viewpoint  on  the 
uniformity  of  the  events  in  question,  and  how  important  any  amount  of  lack  of  uniformity 
is  to  the  outcomes  being  studied.  No  doubt  any  collective  being  studied  using  these 
concepts  could  be  acceptably  defined  as  uniform  or  heterogeneous,  depending  on  the 
viewpoint  of  the  discussant. 
4.2.3  Logical  probability  theory 
The  logical  theory  is  thought  to  be  somewhat  of  a  bridge  between  the  frequentists  and  the 
subjective  probability  theorists  with  an  objective  and  typical  approach  to  the  collective, 
but  also  with  an  aim  to  incorporate  the  degree-of-belief  approach.  The  logical  view  of 
probability  stands  in  contrast  to  the  classical  or  frequentist  views  of  probability,  in  that  it 
is  not  designed  to  be  applied  to  everyday  problems  of  uncertainty.  Logical  probability  is 
the  implication  of  a  certain  piece  or  set  of  information  that  makes  up  evidence,  E,  to  a 
likely  outcome,  0.  It  is  the  degree  to  which  E  implies  0,  what  has  been  called  the 
"credibility"  of  0,  given  E. 
Iýz 
36 The  background  of  logical  probability  is  said  to  come  from  an  intention  to  understand  the 
formal  structure  of  probability,  rather  than  to  formulate  an  application  to  problem  solving, 
while  others  have  used  logical  probability  in  conjunction  with  frequency  theory,  arguing 
that  the  different  theories  have  their  roles  in  distinct  circumstances. 
With  their  insistence  on  the  fact  that  there  is  no  need  for  numerical  values  to  represent 
these  probabilities,  without  a  great  deal  of  justification,  the  main  criticism  of  the  logical 
view  is  precisely  that.  That  is  the  method  of  calculating  or  measuring  an  appropriate 
rational  degree-of-belief.  Subjectivists  go  further,  in  criticising  the  concept  of  uniqueness 
of  these  probabilities.  They  state  that  probability  will  always  relate  to  the  individual,  as 
inherent  within  that  individual  is  a  set  of  information  and  body  of  evidence  that  is  unique. 
4.2.4  Subjective  probability  theory 
This  viewpoint  is  an  important  part  of  subjective  probability  theory,  in  that  it's  most 
prominent  concept  and  that  which  holds  it  apart  from  the  other  theories  is its 
concentration  on  the  personal,  and  it's  insistence  on  the  heterogeneity  of  these  persons.  It 
is  essentially  a  personal  degree-of-belief  model,  but  can  be  used  to  assess  probability  just 
as  well.  The  manufacturing  of  a  probability  score  is in  reality  simply  the  representation  of 
someone's  degree  of  belief.  In  each  case  subjective  probability  measures  the  probability 
of  an  event  based  on  conditional  information  specific  to  said  individual.  It  contrasts  with 
the  logical  view  only  in  that  it  supposes  no  common  rational  thread  of  common 
circumstance  that  weighs  the  subjectivity  independent  of  the  individual. 
37 In  attempts  to  quantify  a  formal  theory  of  subjective  probability,  the  emphasis  has  been 
on  expressing  the  probability  of  an  event  through  betting  situations.  It  is  the  price  an 
individual  would  be  willing  to  pay  for  an  amount  of  money  on  condition  of  an  event,  E, 
occurring.  For  example  if  a  coin  was  thought  to  be  unbiased,  one  half  of  that  unit  would 
be  the  maximum  that  individual  would  pay  in  exchange  for  one  unit  of  that  money 
conditional  on  the  coin  landing  head-up.  Where  subjective  probability  differs  is in  that  the 
conditions  and  the  probability  considered  for  that  toss  of  the  coin  are  specific  only  to  that 
toss.  If  the  coin  falls  head-up  what  will  the  individual  be  willing  to  `bet'  on  a  head  for  the 
next  toss?  This  is  a  separate  event  and  as  such  does  not  use  the  same  conditions  and 
information  as  the  original  toss  of  the  coin. 
There  has  been  movement  away  from  the  bet  analogy  in  subjective  probability  theory,  as 
the  rational  effect  of  the  size  of  stake  became  embroiled  in  criticism  of  the  theory.  The 
concept  is  irrelevant,  but  nevertheless  was  thought  to  detract  from  the  purpose  of  the 
analogy.  The  concept  of  comparison  of  propositions  was  used  first  by  Ramsey".  Here  the 
approach  uses  an  expression  of  personal  probabilities  for  two  events,  a  head  on  a  toss  of  a 
coin  and  the  likelihood  of  rain  before  Thursday.  If  the  individual  has  no  reason  to  believe 
that  the  coin  is  biased,  the  degree-of-belief  of  the  individual  concerning  the  outcome  of 
imminent  precipitation  can  be  measured  relative  to  that  of  the  coin  toss.  This  method  does 
not  completely  overcome  the  issue  of  the  need  for  measures  of  relative  utility  connected 
with  different  outcomes  or  events,  but  subjective  theorists  argue  that  this  is  irrelevant  to 
the  proposal  of  the  underlying  concept  of  individual  subjectivity  in  probability. 
Nevertheless,  most  work  on  subjective  probability  has  tended  to  combine  subjective 
38 probability  theory  with  utility  to  understand  the  behaviour  of  individuals  in  circumstances 
of  uncertainty. 
4.3  Probability  theory  and  statistical  inference 
The  evolution  of  these  different  theories  discussed  above  can  in  part  be  explained  by  the 
reason  for  their  original  contemplation.  Taking  the  two  most  commonly  considered  of  the 
two  theories  to  simplify  the  argument.  The  frequentist  views  came  primarily  from 
wanting  to  understand  and  solve  problems  associated  with  uncertainty.  A  rational, 
measurement-based  approach  to  the  problem  caused  by  uncertainty  and  how  to  overcome 
them,  prior  to  making  the  decision.  The  subjective  approach  on  the  other  hand  comes 
from  the  act  of  decision  making  itself.  A  study  of  why  decisions  are  made,  the  reasons 
why  individuals  make  the  choices  they  do  and  why  different  individuals  make  different 
decisions.  Studied  after  the  event  of  the  decision  itself  6. 
At  first  glance  the  former  methods  seem  the  more  rational  and  the  more  easily  quantified. 
These  are  important  factors  when  the  consideration  is how  best  to  judge  the  effectiveness 
of  health  care  interventions.  Is  what  is  required  here  certainty,  a  method  based  on  good 
science  and  rationality?  Almost  certainly  the  answer  is  yes,  but  these  methods  are  also 
marked  by  a  lack  of  flexibility. 
The  frequency  theory  is  a  straightforward  one.  If  a  coin  is  completely  unbiased  and  is 
tossed  an  infinitesimal  number  of  times,  half  of  the  time  the  coin  will  land  head  up.  There 
is  no  need  for  subjectivity  here.  There  is,  nevertheless,  a  reliance  on  the  coin  being 
39 unbiased,  a  prior  conception  based  on  the  theoretical  nature  of  the  idea,  and  due  in  no 
small  part  to  the  construction  of  theory  at  a  point  before  the  decision  takes  place.  How 
easy  is it  to  ensure  an  unbiased  coin?  How  many  foibles  does  the  average  coin  possess?  Is 
it  more  than  the  hypothetical,  unbiased,  coin? 
If  a  coin  were  found  to  be  more  aerodynamic  on  one  side  (heads)  than  the  other  (tails), 
then  while  in  the  air  it  would  spend  fractionally  more  time  head  up,  with  the  less 
aerodynamic  side  (tails)  fighting  against  air  resistance,  than  tail  up.  This  would  lead  to  an 
inevitable  higher  likelihood  of  landing  in  that  position.  Head  up.  If  we  accept  this  to  be 
true,  then  there  is  additional  information  that  can  be  drawn  on  to  come  to  a  more  accurate 
conclusion  of  the  probability  of  a  `heads'  outcome  for  any  one  coin. 
It  is  these  foibles  or  imperfections,  both  in  coins  and  in  people,  which  give  us  reason  to 
consider  the  use  of  subjectivity  in  the  study  of  the  effectiveness  of  health  care 
interventions.  The  knowledge  that  an  average  person  studied  will  gain  four  additional 
quality-adjusted  life  years  at  a  cost  of  £20,000  is  useful  information  in  the  decision  on 
how  to  treat  all  the  average  people  in  the  population.  The  question  is,  how  useful  is  this 
information  in  deciding  how  to  treat  the  rest  of  the  population? 
There  is  a  similar  dichotomy  when  taking  these  theories  forward  into  the  world  of 
statistical  inference.  This  separation  is  caused  by  the  need  to  use  information  to  make 
decisions  under  circumstances  of  uncertainty.  Where  data  is  used  to  inform  or  to  describe 
a  situation  is  by  definition  inferential.  Whereas  where  the  aim  is  to  go  one  step  further  and 
use  these  data  to  inform  a  decision  under  uncertainty,  this  goes  beyond  simple  statistical 
40 inference  and  into  statistical  decision  making.  Although  most  commentators  believe  the 
functions  to  be  inter-linked  or  at  least  reliant57'58,  there  is  still  no  consensus  on  where,  if  at 
all,  subjectivity  becomes  relevant. 
The  classical  approach  to  inference  is  designed  specifically  for  the  reporting  of  data 
alone.  It  does  not  attempt  to  enable  decision-making.  Neither  does  it  consider  prior 
information  or  the  consequences  or  costs.  This  additional  or  prior  information  may  affect 
the  decisions  on  what  to  test  using  the  classical  inference  approach,  but  this  informality  is 
thought  to  be  imprecise  and  lacking  a  scientific  basis,  the  exact  criticism  classicists  have 
about  the  more  subjective  theories.  This  said,  it  is  widely  accepted  that  were  there 
instances  where  there  was  no  prior  information  on  the  subject  at  stake,  then  there  is  no 
need  for  subjectivity.  The  problem  is,  how  much  is  there  that  we  can  say  we  know 
absolutely  nothing  about. 
With  the  Bayesian  or  decision-analytic  approaches  being  rooted  in  subjective 
probability,  sample  data  is  combined  with  prior  information  and  utility  measures 
respectively.  Thus  making  results  immediately  attributable  to  a  probability  interpretation. 
The  problem  arises  in  the  quantification  of  this  information.  Sometimes  this  information 
is  easily  quantified  while  other  times  it  is  less  so.  Theoretically  purist  subjectivists  would 
argue  that  the  uniqueness  and  complexity  of  individual  cases  within  each  sample  would 
make  it  almost  impossible  to  apply  universal  affects  of  any  prior  information  or  utility 
values.  The  virtues  of  this  approach  are  weighted  on  reliance  of  both  the  quality  of  the 
information  available  and  its  relationship  to  the  outcomes  studied. 
41 The  only  pure  decision  making  approach  is  the  decision-analytic  approach,  or  decision 
theory.  This  method  again  uses  both  sample  data  and  prior  information  but  also 
incorporates  the  quantification  of  losses  and  gains.  Whereas  the  other  two  systems  aim  to 
show  only  the  likelihood,  probability  or  risk  of  events,  the  decision  theory  model  goes 
one  step  further  and  attempts  to  answer  the  question  of  what  to  do  rather  than  just  giving 
you  information  on  likely  outcomes. 
In  essence  the  movement  between  these  three  methods  is  an  increase  in  risk  and  belief  in 
the  ability  to  quantify  the  previously  unquantifiable.  The  classical  approach  is  ruled  by 
certainty.  Information  that  is  subjective,  or  even  directly  attributable,  to  data  being  studied 
is  ignored  either  because  of  a  lack  of  belief  in  the  stated  relationship  or  scientific 
obstinence  against  quantifying  these  relationships.  The  Bayesian  accepts  the  existence  of 
other  information  that  helps  to  explain  the  behaviour  of  the  studied  variables  and  attempts 
to  quantify  it.  Similarly  decision  theory  tells  us  that  as  we  can  quantify  external  factors 
influencing  our  chosen  variables,  we  can  also  quantify  the  importance  of  the  various 
outcomes. 
This  movement  away  from  certainty  and  towards  taking  a  greater  risk  with  the  data  in  an 
attempt  to  reach  more  truly  representative  outcomes  is  not  just  an  issue  of  scientific 
rigour,  but  a  moral  one.  A  debate  between  the  gains  of  improving  the  efficient  use  of 
resources  and  taking  risks  with  outcomes  that  are  thought  of  as  "life-dependent". 
42 Having  described  and  discussed  the  various  theories  on  probability  and  how  they  relate  to 
the  movement  towards  classical  or  heterogeneous  methods  of  analysis,  we  now  describe 
the  methods  of  both  Bayesian  inference  and  Decision  Analysis. 
4.4  Bayes  Theory 
Bayesian  statistical  inference  was  the  earliest,  and  is  still  the  accepted,  method  of 
calculation  of  subjective  or  additional  information  in  inference.  The  statement  of  Bayes 
theorem  comes  directly  from  a  statement  of  probability,  where  A;  is  a  collection  of  events, 
of  which  one  will  happen,  and  Y  is  another  event.  Taking  the  multiplication  rule  of 
probability  theory,  the  probability  of  A;  given  Y  is  the  probability  of  both  events  divided 
by  the  probability  of  the  event  of  Y,  or: 
P(A,  Y)_ 
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the  probability  of  events  A;  and  Y  can  be  shown  as  the  probability  of  Y  given  A;  times  the 
probability  of  A..  For  a  number  of  events  j  this  is  shown  as: 
p(AIIY)  _ 
P(")P(A-) 
,; 
' 
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None  of  this,  as  theory,  is  seen  as  particularly  contentious  by  frequentist  or  subjectivist 
alike.  The  area  of  disagreement  is  it's  use  in  practice  and  the  ability  to  scientifically 
quantify  A.  as  a  statement  of  belief  or  as  a  hypothesis  about  the  relationship  between  the 
43 subjector  and  the  subjected.  Thus  Bayesian  inference  involves  making  subjective 
statements  about  probability  and  quantifying  them  in  a  way  classical  inference  and 
frequentist  probability  theorists  believe  to  be  unscientific.  Their  view  being  that 
subjectivity  is  an  issue  outside  inference  that  must  be  used  in  addition  to  the  results  of 
classical  inference  in  making  decisions.  The  opposing  view  of  the  Bayesian  is  that  it  is  in 
fact  unscientific  to  ignore  the  potential  effect  of  subjective  information  at  this  stage,  as 
any  results  would  be  misleading. 
Bayesian  analysis  uses  what  it  calls  priors  as  an  addition  to  sample  data.  Let  us  go  back 
to  our  coin,  not  the  hypothetical  one,  but  the  real  one  (the  one  with  the  foibles),  and  we 
assume  that  we  believe  that  the  curving  of  one  of  the  surface  edges  discussed  earlier  gives 
the  coin  an  increased  probability  of  landing  heads  up.  We  also  quantify  as  the  likelihood 
of  this  as  saying  that  it  will  land  head-up  75%  of  the  time.  I  will  come  back  to  the  issue  of 
quantification  later.  We  can  also  state  that  we  are  95%  certain  of  this  effect.  We  can  then 
state  the  probability  of  a  heads  outcome  at  this  stage  as: 
P  (h  =  0.75)  =  0.95 
P  (h  =  0.50)  =  0.05 
The  next  step  is  to  undertake  our  trial.  We  toss  the  coin  one  hundred  times  and  it  lands 
head-up  sixty  times  of  that  hundred.  Our  sample  data  on  it's  own  suggests  to  us  that  P= 
0.6.  Combining  our  prior  information  and  our  sample  data  we  can  produce  a  third  version 
of  our  probability  of  heads,  known  as  the  posterior.  This  combines  our  prior  knowledge 
44 of  the  likelihood  of  the  event  with  the  information  we  have  gathered  on  this  from  our 
sample.  Writing  the  equation  in  the  form, 
P(AIIY)  °:  PM4)I'(`ß) 
(where  the  proportionality  applies  over  different  choices  of  i,  and  the  denominator  is  a 
constant  independent  of  i) 
Our  priors  were,  P  (h  =  0.75)  =  0.95 
P  (h  =  0.50)  =  0.05 
Our  likelihoods  are,  f  (Y  (h=0.75)  =  0.756  *  0.25'  =  0.0028 
f(Y  Ih=0.50)  =  0.506  *  0.503=0.0019 
Our  posteriors  become,  P  (h  0.75  1  Y)  oc  0.95  *  0.0028  =  0.00266 
P  (h  =  0.501  Y)  x  0.05  *  0.0019  =  0.000095 
The  denominator  in  Bayes  is  the  sum  of  these,  0.002755,  so  the  correct  posteriors  are, 
P  (h  =  0.75  1  Y)  =  0.00266  /  0.002755  =  0.97 
P  (h  =  0.50  1  Y)  =  0.000095  /  0.002755  =  0.03 
We  are  now  even  more  certain  that  the  curving  of  the  surface  has  an  effect  on  the 
likelihood  of  the  coin  landing  head  up.  The  measure  of  our  belief  has  risen  from  95%  to 
97%.  Realistically  we  would  not  limit  our  data  to  point  estimates  but  have  distributions 
45 around  a  mean.  For  example  Ph  has  a  Normal  distribution  with  mean  of  0.75  and  standard 
deviation  of  0.01,  similarly  the  prior  and  hence  the  posterior  will  possess  these  attributes. 
The  weakest  part  of  Bayesian  theory  lies  not  in  its  use  of  subjective  information  within 
the  formula  of  inference  but  in  the  quantification  of  such  information.  When  the  basis  of 
the  formula  relies  on  the  level  of  trust  or  knowledge  invested  within  one  individual,  it 
loses  a  degree  of  certainty.  The  question  for  debate  is  whether  this  loss  of  certainty 
outweighs  the  benefits  in  terms  of  added  information  brought  to  bare  on  the  task  of 
answering  the  question  in  hand.  Classicists  say  that  it  must  (or  that  at  least  it  is impossible 
to  say),  Bayesians  that  it  does  not. 
4.4.1  Quantifying  prior  information 
For  simplicity,  let  us  assume  an  economic  evaluation  has  been  undertaken  to  compare  two 
interventions,  A  and  B,  which  show  mean  ICERs  of  p.  and  µB,  with  variance  a'.  An 
additional  question  is  being  asked  of  the  data,  regarding  the  difference  of  effectiveness 
within  two  distinct  subgroups.  Let  us  say  that  a  proportion  PIA  receives  treatment  A  and 
P,  B  receive  treatment  B  in  subgroup  1.  Denote  the  observed  difference  in  means  between 
treatment  A  and  B  in  stratum  1  as  d￿  where  d,  is  the  sample  estimate  of  A￿  the  unknown 
mean  difference  in  effectiveness  for  these  patients.  Denote  the  same  for  subgroup  B, 
where  P2A  =1-  PIA  and  P2B  =1-  PIB,  as  shown  in  table  4.1. 
We  now  use  the  Bayesian  method  to  incorporate  our  previous  evidence  of  the  effect  of 
our  chosen  subgroup  strata  1  and  2,  what  we  will  call  p  and  a,  2,  and  attempt  to  estimate 
46 the  unknown  effect  in  subgroup  1.  This  estimate,  denoted  by  M,,  is  the  posterior  mean  of 
A1. 
Table  4.1:  Samples  and  mean  differences  of  subgroups 
Subgroups  Number  of  patients  Observed  mean  Unknown  mean 
Treatment  A  Treatment  B  difference  difference 
1  nPIA  nI'is  d,  A, 
2  nP2A  nPss  d2  A2 
Total  n  n 
Firstly  we  calculate  the  quantities  which  measure  the  precision  of  the  sample  information 
in  each  stratum  relative  to  the  corresponding  amount  of  prior  information.  These 
quantities  are  given  as, 
r,.  =  QP  /  Var(d,  ),  i  =  1,2.  Where  Var(d  j)  denotes  the  sampling  variance  of  d;.  Thus 
large  values  of  r,  and  r2  imply  that  there  is  relatively  little  prior  information  available  to 
the  investigator  as  compared  to  the  information  supplied  by  the  sample  data.  From  table 
1,  Var(d)  can  be  calculated  as, 
Var(d,  )  =  are(nPiA 
1+1i=1,2, 
nP  .e 
)' 
where  a2  may  be  estimated  from  the  sample  observations.  The  posterior  mean  can  now  be 
derived59  as, 
_ 
r,  [rz(1-pZ)+1]dl+r2pd2 
M' 
{[r(1-p2)+1][rz(1-p2)+1]-p2}/(1-p2) 
Thus  M,  is  a  linear  function  of  d,  and  d2,  whose  coefficients  depend  on  the  values  of  r￿  r2 
and  p,  and  can  be  interpreted  as  the  most  likely  value  of  0,  given  all  the  available 
information.  At  p=  0,  M,  =  (dlrl)/(r1+1)  and  thus,  as  would  be  expected  with 
47 independent  subgroups,  the  value  of  d2  has  no  effect  on  d,  or  A,.  A  small  value  of  r￿  that 
is  strong  prior  evidence  to  suggest  that  a  large  value  of  A,  is  unlikely,  will  tend  to  pull 
back  the  estimated  effect  towards  zero.  Alternatively  as  p  tends  towards  unity,  it  can  be 
shown  that, 
__ 
rld,  +  r2d2  M' 
r,  +r2+1 
Therefore  in  the  limiting  case  where  A,  and  A2  are  regarded  as  indistinguishable,  d,  and  d2 
are  weighted  by  the  values  of  r,  and  r2,  respectively,  although  strong  prior  evidence  of  a 
lack  of  difference  will  tend  to  pull  back  the  estimate,  M￿  towards  zero.  Furthermore  by 
altering  the  values  of  p  and  apZ  in  M,  to  represent  differing  degrees  of  belief,  the 
relationship  between  the  strength  of  prior  belief  and  various  levels  of  confidence  intervals 
can  be  explored. 
To  describe  the  use  of  this  method  here,  we  have  used  a  continuous  response  variable 
with  only  two  strata  of  subgroups.  For  dichotomous  variables,  the  normal  approximation 
to  the  binomial  distribution  may  be  used  if  the  number  of  cases  in  each  stratum  is 
relatively  high.  For  the  case  of  more  than  two  strata,  Donner60  has  derived  general 
expressions  for  the  stratum  specific  posterior  means  M￿  M2,....  Mk  of  a  normally 
distributed  response  variable  under  the  assumption  of  a  k-dimensional  multivariate  prior. 
Moreover  the  results  here  may  be  generalised  to  include  different  prior  variances,  non- 
zero  means  and  other  distribution  shapes61. 
48 4.5  Decision  theory 
The  use  of  subjective  probability  and  the  incorporation  of  such  information  into  a 
decision-making  tool  rather  than  simply  for  inference  is  only  tackled  in  decision  theory. 
The  primary  distinction  of  decision  theory  is  of  course  that  it  aims  not  only  to  give  best 
evidence  or  merely  to  inform,  but  also  to  direct  towards  a  best  course  of  action  under 
particular  circumstances.  As  a  result  the  expression  of  results  of  decision  theory  are  not 
expressed  in  probability  terms,  as  in  classical  and  Bayesian  methods.  Decision  theory 
prescribes  a  course,  or  courses,  of  action  based  on  average  benefit  or  loss.  A  disadvantage 
being  that  there  is  no  recognition  within  the  final  result  that  the  relative  advantages  of  one 
over  another  may  vary  in  relation  to  the  probability  of  it  occurring.  This  is  a  problem  that 
will  be  discussed  in  more  detail  later.  At  the  same  time  there  is  an  obvious  advantage  to  a 
mechanism  designed  specifically  for  prescription  of  action  in  the  face  of  uncertainty, 
rather  than  simply  minimising  uncertainty  on  the  issue  and  leaving  the  decision  unmade. 
To  illustrate  the  basic  formula  of  decision  theory,  the  example  of  a  cancer-screening 
programme  is  used.  Apologies  are  made  for  any  simplification  of  the  issues,  but  these  will 
be  explained  and  justified  as  we  progress.  People  are  screened  for  presence  of  colorectal 
carcinoma  using  a  faecal  occult  blood  test  (FOBT).  These  people  then  present  with  either 
a  negative  or  positive  result.  We  are  interested  only  in  those  who  present  with  a  positive 
result. 
Looking  at  the  problem  under  the  framework  of  decision  theory,  there  are  two 
possibilities,  or  what  is  known  in  decision  theory  as  two  possible  "states  of  nature'62. 
These  are  that  the  individual  has  a  presence  of  small  polyps,  that  may  or  may  not  lead  to 
49 cancer,  or  that  the  presence  of  blood  in  the  stool  is  unrelated  to  the  presence  of  cancer  or 
polyps.  We  therefore  have  two  actions  open  to  us.  One  is  to  repeat  the  FOBT  test  at 
another  time.  This  assures  us  that  the  reason  for  the  positive  result  is  more  likely  to  be 
cancer-related,  or  to  refer  the  individual  straight  away  for  a  colonoscopy,  an  invasive 
procedure  that  can  detect  the  presence  of  polyps  and  tumours  as  well  as  being  able  to 
remove  polyps.  If  we  denote  actions  by  a  and  states  of  nature  by  0  then  we  have: 
a,  =  second  FOBT, 
a2  =  colonoscopy, 
8,  =  no  presence  of  tumour,  and 
02  =  presence  of  tumour. 
Dependent  on  the  different  states  of  nature,  the  actions  will  have  different  implications.  If 
we  limit  these  implications  to  cost,  ignoring  the  ethics  of  subjecting  a  host  of  healthy 
individuals  to  a  colonoscopy.  We  can  produce  a  cost  table,  or  what  is  known  as  a  "table  of 
losses",  that  covers  each  eventuality.  Let  us  assume  that  an  FOBT  costs  £200  and  a 
colonoscopy  costs  £500. 
Table  4.2:  Table  of  losses 
e,  eZ 
a,  E200  £700 
a2  1  £500  £500 
50 If  we  knew  0  for  every  individual,  there  would  be  no  decision  problem,  but  it  is  this  very 
`state  of  nature'  that  is  not  known.  Although  we  do  not  know  0  for  each  individual,  we  do 
have  information  of  the  specificity  of  the  single  FOBT.  Evidence  suggests  that  only  30% 
of  those  with  an  initial  positive  result  on  the  first  FOBT  will  have  a  tumour.  Therefore  we 
have  some  prior  probability  for  0,  and  therefore  for  02.  With  this  information  we  can  now 
calculate  the  average  loss  from  taking  action  a,  and  a2; 
a,  =  (200  *  0.7)  +  (700  *  0.3)  =  £350,  and 
a2  =  (500  *  0.7)  +  (500  *  0.3)  =  £500. 
So  in  the  long  run  it  is  worth  giving  all  positives  a  second  FOBT.  The  result  of  course 
relies  heavily  on  the  specificity  of  the  test.  If  this  were  as  high  as  70%,  then  the  loss  table 
would  point  to  a  system  that  would  mean  lead  us  to  give  colonoscopies  to  everyone.  If 
this  was  the  case,  and  a  group  of  people  with  irritable  bowel  syndrome  came  along,  then 
under  this  form  of  decision  theory,  they  will  just  have  to  suffer. 
This  is  where  the  concept  of  the  prior  information  and  subgroups  enables  us  to  take  this 
system  further,  and  make  it  more  reactive  to  a  particular  set  of  individuals.  Let  us 
consider  other  information  on  these  individuals  that  we  are  presented  with.  For  each  of 
our  number  who  has  tested  positive  we  have  additional  information  on  symptoms.  Either 
they  have; 
x,  =  they  also  complained  of  pain  when  passing  faeces, 
xz  =  they  also  complained  of  diarrhoea,  and 
51 x3  =  no  additional  symptoms,  other  than  the  positive  FOBT. 
Such  information  gives  us  additional  information  on  the  relationship  to  the  state  of  nature 
due  to  the  likelihood  principle.  This  could  be  known  from  past  records,  from  published 
literature  or  from  expert  opinion.  Suppose  that  from  a  mixture  of  these,  we  create  a 
likelihood  table: 
Table  4.3:  Likelihood  table 
X,  X2  X3 
e,  0.1  0.4  0.5 
e2  0.7  0.2  0.1 
We  can  now  use  this  additional  information  on  x  to  help  guide  our  decisions,  by  taking 
different  decision  rules  or  strategies.  A  decision  rule,  6(x),  determines  what  action  to  take 
given  x.  In  our  example  there  are  eight  possibilities: 
Table  4.4:  Decision  rule  table 
1  8,82  83  64  65  66  67  8 
X,  a,  a,  a,  a,  a2  a2  a2  a2 
x2  a,  a,  a2  a2  a,  a,  a2  a2 
x3  a,  a2  a,  a2  a,  a2  a,  a2 
52 In  terms  of  likelihood  alone,  x,  favours  82,  whereas  x2  and  x3  support  A,.  From  the  loss 
table,  table  1,8,  seems  to  be  intuitively  correct  as  it  reads  a2  a￿  a,.  Whereas  S4  seems 
intuitively  to  be  the  worst.  However,  looked  at  with  recourse  to  the  rule  of  decision  theory 
that  states  that  we  represent  each  decision  as  an  average  loss  over  all  different  values  of  x 
in  each  state  of  nature,  we  represent  the  decision  rule  of  x,  S(x),  as  a  pair  of  representing 
0,  and  02  calculated  from  the  risk  function; 
R(8,9)  =  L[ö(x),  9]pe(x)  ,  where  0=  (01,02) 
X 
For  example,  for  S5  we  have  (R5,, 
,  R5,2  .... 
),  where, 
R(S5,  O)  =  L(a2,01)  pe1(x1)  +  L(a,,  01)  peI(x2)  +  L(a»  01)  pe1(x3) 
=  500  *  0.1  +  200  *  0.4  +  200  *  0.5 
=  230 
This  gives  us  a  risk  function  table  for  all  our  decision  rules,  as  follows; 
Table  4.5:  Risk  function  table 
81  82  83  g4  85  86  67  68 
01 
02 
200  350  320  470  230  380  350  500 
700  680  660  640  560  540  520  500 
53 Once  calculated,  we  can  see  that  no  one  decision  gives  us  least  cost  for  both  states  of 
nature,  even  though  some  can  be  immediately  ruled  out  as  having  higher  costs  for  both 
events.  These  are  S2  S3  S4  and  S6. 
A  principle  that  comes  from  game  theory  is  often  considered  for  making  a  final  choice 
between  the  remaining  decision  strategies,  known  as  the  "minimax"  principle.  This  aims 
to  choose  the  decision  where  the  maximum  possible  risk  is  minimised.  This  would  leave 
us  with  6,  the  choice  to  refer  to  colonoscopy  whatever  the  circumstances,  as  at  maximum 
risk  this  produces  the  lowest  overall  costs.  This,  though,  is  the  pessimistic,  slave  to 
certainty  attitude  that  with  decision  theory  we  are  trying  to  escape.  How  can  we  logically 
base  our  actions  on  the  most  pessimistic  outlook  of  an  event,  a  point  that  is  all  likelihood 
at  the  tail-end  of  a  probability  distribution. 
This  brings  us  back  to  the  use  of  prior  information,  the  knowledge  we  have  on  the 
likelihood  of  0,  that  is  the  specificity  of  our  first  FOBT.  Using  this  in  conjunction  with 
our  data  on  symptoms  we  can  use  the  prior  probability  information  to  avoid  both 
pessimism  and  over  reliance  on  certainty.  Using  Bayes  equation  for  posterior  probability 
(page  38)  we  can  create  a  measure  of  "posterior  expected  loss"  for  the  decision  rule  8,  as 
follows, 
r  (8,7r)  =  R(S,  91)  ir(91)  +  R(8 
9 
82)  ßc(02)  ,  where  (7t9)  is  prior  probability  of  81  9  02 
It  seems  reasonable,  now  to  choose  the  so-called  Bayes'  decision  rule  (or  Bayes' 
solution),  where  r  (6,7t)  is  minimised.  This  is  known  as  the  Bayes'  risk.  Therefore 
54 returning  to  the  specificity  of  the  FOBT  at  30%,  we  have  7r(6,  )  =  0.7  and  7E(9Z)  =  0.3.  This 
gives  us  values  for  Bayes'  risk  as  below 
Table  4.6:  Bayes  risk  table 
S,  62  83  S4  85  86  67  88 
r  (6,  ir)  1  350  449  422  541  329  428  401  500 
Therefore  the  Bayes'  solution  is  S5,  which  dictates  that  for  those  presenting  with  a 
positive  FOBT  and  also  complaining  of  pain  when  passing  faeces,  they  should  be  referred 
directly  for  a  colonoscopy,  whereas  those  with  no  other  symptoms,  or  those  with 
diarrhoea  should  undertake  an  additional  FOBT. 
This  gives  us  an  average  loss  (or  cost)  of  £329  compared  to  our  minimax principle  ruling 
of  an  average  loss  of  £500  and  the  initial  choice  of  universal  action  of  a,  of  £350.  The 
saving  of  the  Bayes'  solution  of  the  initial  decision  is  just  £21.  Therefore  the  transactions 
costs  involved  in  acquiring  the  additional  symptom  information  must  have  an  average 
cost  of  less  than  £21  to  make  it  the  allocatively  efficient  choice. 
So  far  we  have  limited  our  information;  losses,  probabilities,  risks  and  priors  as  point 
estimates.  Without  great  over  complication  it  is  possible  to  incorporate  distributions  as 
well  as  means  for  these  variables63.  This  enables  us  to  incorporate  the  strength  of  the  data 
55 being  used  as  well  as  the  shape  of  the  distribution  of  each  variable,  which  will  lead  to  a 
more  representative  picture  of  risk  and  hence  overall  average  loss. 
4.6  Critical  appraisal  of  heterogeneous  methods 
It  is  evident  that  both  of  these  methods  of  analysis  carry  the  same  potential  benefits  of 
subgroup  analysis,  or  indeed  any  other  methods  that  incorporate  heterogeneity,  in  that 
they  tend  towards  optimisation  and  away  from  an  over  reliance  on  certainty  and  risk 
minimisation.  Nevertheless  it  is  only  subgroup  analysis  as  explained  in  the  previous 
chapter  that  retains  the  objectivity  of  interpretation  that  both  Bayes  and  decision  analysis 
methods  do  not. 
This  is  not  a  criticism  of  the  methods  themselves  but  more  a  criticism  of  the  approach 
used.  The  difficulty  with  which  the  pro-Bayes  and  pro-Decision-analysis  lobbies  have  had 
in  incorporating  these  systems  into  mainstream  economic  evaluation  is  a  sign  of  the 
mistrust  of  the  scientific  establishment  of  the  use  of  subjective  information.  It  may  be  too 
much  to  expect  the  acceptance  of  incorporating  the  opinions  of  experts  and  the 
independently  constructed  values  of  benefit,  when  the  community  has  been  brought  up  to 
base  their  decisions  on  nothing  less  than  certainty  and  proof. 
The  difficulties  with  the  more  heterogeneous  methods  of  analysis  come  from  what  many 
consider  to  be  its  strengths,  the  use  of  subjective  or  value  judgements  within  the 
framework.  Both  Bayesian  and  decision  theories  attempt  to  take  a  further  step  towards 
answering  the  question  that  reduces  the  need  for  subjective  interpretation  of  the  data 
56 policy  decision  makers  are  presented  with.  Bayesian  data  analysis  takes  uncertainty  and 
tries  to  make  it  seem  more  certain.  This  is  a  laudable  cause  but  it  relies  still  heavily  in 
both  belief  in  the  method  being  used,  and  a  strong  subjective  element  for  which  there  will 
always  be  room  for  disagreement. 
Decision  theory  has  the  strongest  acceptance  of  the  presence  of  heterogeneity,  as  it  uses 
probability  rather  than  inference  and  values  rather  than  outcomes.  Once  again  the 
movement  towards  a  greater  incorporation  of  the  subjective,  this  time  through 
incorporating  the  `values'  of  different  outcomes  is  a  movement  towards  bridging  the  gap 
between  research  and  decision  making.  Once  again  it  relies  on  the  acceptance  by  all 
concerned  on  the  values  it  lays  down  in  order  to  construct  the  answers  it  produces. 
It  is  the  belief  of  this  thesis  that  the  use  of  subgroup  analysis  framework  for  evaluation  of 
cost-effectiveness  data  has  the  benefit  of  incorporating  heterogeneity  without 
compromising  the  objective  nature  of  conventional  methods  of  analysis.  Although,  in  the 
following  chapters  consideration  will  be  given  to  moving  the  levels  of  acceptance  away 
from  that  of  the  95%  confidence  interval,  throughout  the  process  of  subgroup  analysis  all 
evidence  used  will  be  empirical  and  objective. 
4.7  Summary 
It  is  deep  within  the  construction  of  inference  methods  derived  from  the  various  theories 
of  probability  that  we  find  justification  for  examining  the  value  of  the  less  popular,  but 
perhaps  more  appropriate,  methods  of  inference  in  reference  to  economic  decision 
making.  Techniques  such  as  Bayesian  and  decision  analysis  enables  greater  utilisation  of 
57 information  and  is  more  geared  towards  an  action-orientated  approach.  It  is  the  movement 
out  of  the  traditional  realm  of  providing  information  and  into  the  process  of  decision 
making  that  has  required  the  introduction  of  more  subjective  measurement.  Subgroup 
analysis  itself  has  many  of  the  advantages  of  these  methods  and  in  addition  has  the 
advantage  of  providing  the  decision-maker  with  more  objective  information. 
It  is  the  belief  of  this  thesis  that  subgroup  analysis  is  the  preferred  method  for 
incorporating  heterogeneity  into  data  analysis.  The  next  chapter  looks  in  more  detail  at 
subgroup  analysis  alone  and  discusses  the  theory  and  conceptual  background  of  the  use  of 
subgroup  analysis  as  a  tool  for  decision  making.  It  is  then  followed  by  a  description  of  the 
research  question  and  the  methods  that  will  be  used  to  test  the  hypothesis  that  subgroup 
analysis  can  improve  resource  allocation  and  efficiency. 
58 5.  Conceptual  framework 
5.1  Introduction 
Very  large  sums  of  money  are  spent  every  year  on  clinical  trials  and  economic 
evaluations.  Conventionally  these  are  designed  to  produce  `average'  results  for  groups  of 
subjects.  Conclusions  are  typically  of  the  form  `treatment  X  was/was  not  found  to  be 
more  cost-effective  than  the  existing  standard'.  Some  trials  are  designed  to  provide 
estimates  for  specific  subgroups  of  subjects  but  this  adds  to  the  costs  through  the  need  for 
greater  sample  size.  Also  researchers  and  decision-makers  are  cautious6'  about  estimates 
with  low  precision  and  are  particularly  on  their  guard  against  false  positive  results 
The  pursuit  of  health  gain  requires  an  efficient  use  of  health  care  resources  which  in  turn 
relies  on  the  presence  of  allocative  efficiency,  i.  e.  in  order  to  maximise  overall  benefit, 
priority  for  treatment  should  be  given  to  patients  with  the  greatest  benefit/cost  ratio.  The 
finer  the  differentiation  between  patients  in  this  respect,  the  more  efficient  allocative 
decisions  can  be.  The  crucial  difficulty  is  between-patient  variability  in  response  to  a 
given  treatment.  If  patient  response  is highly  uncertain,  prioritisation  in  pursuit  of 
efficiency  is  made  much  more  difficult.  For  the  pursuit  of  allocative  efficiency,  the  ability 
to  differentiate  between  groups,  which  within  them  have  a  greater  certainty  of  patient 
response,  leads  to  a  higher  benefit/cost  ratio,  and  resource  efficiency  becomes  more 
attainable. 
The  debate  over  QALYs65  and  the  Oregon  experiment66,  for  example,  has  drawn  attention 
to  the  difficulty  of  seeking  to  blacklist  treatments  which  can  be  shown  to  be  beneficial  in 
59 some  cases,  while  giving  undiscriminating  priority  to  other  treatments  which  are  in  some 
cases  ineffective  and  in  others  potentially  harmful. 
However,  there  is  a  deep-rooted  concern  among  scientists  that  subgroup  analysis  may 
propagate  untrue  statements.  As  a  result,  there  is  a  preference  for  giving  broad-brush  but 
reliable  messages  about  average  patients,  and  leaving  clinical  decision-makers  to  bridge 
the  gap  between  the  average  and  the  specific  as  best  they  may.  This  protects  the  integrity 
of  science,  but  denies  decision-makers  evidence  that  could  be  more  informative  because 
there  is  a  risk  that  it  could  be  misleading.  However,  a  utilitarian  approach  to  efficiency 
would  suggest  that  the  pursuit  of  health  gain  at  a  population  level  would  imply  that 
getting  decisions  wrong  sometimes  is  the  price  to  be  paid  for  getting  them  right  as  often 
as  possible. 
The  purpose  of  this  thesis  is  to  explore  the  trade-off  between  the  needs  for  more  specific 
information  for  decision  making  and  the  loss  of  precision  this  leads  to.  This  question  is 
inherently  asking  whether  or  not  current  attitudes  to  subgroup  analysis,  which  tend 
towards  scientific  caution,  are  having  adverse  effects  on  health  gain.  The  literature  on  this 
issue  is  sparse.  An  approach  to  the  question  is  suggested  by  some  recent  work  on  the 
construction  of  confidence  intervals  for  cost-effectiveness  ratios.  It  found  that  "non- 
parametric  boot-strapping"t  provided  the  best  results  when  costs  and  effects  were 
positively  correlatedb'"68.  However,  discussion  of  subgroup  analysis  has  mainly  been  from 
an  epidemiological  or  statistical  perspective,  rather  than  a  public  health  or  economic 
tA  method  of  simulating  confidence  intervals  for  cost-effectiveness  ratios. 
60 one69'70'".  The  tension  involved,  or  echoes  of  it,  occasionally  surfaces  in  the  literature,  but 
mostly  in  the  form  of  theoretical  discussions"  or  disputes  in  correspondence7'. 
There  has  been  no  research  so  far  that  has  looked  at  the  effect  a  variety  of  rules  for 
identifying  or  accepting  subgroup  analyses,  could  potentially  have  in  terms  of  health  gain. 
Being  a  methodological  study,  the  impact  of  this  thesis  could  potentially  be  pervasive.  If 
it  transpires  that  the  current  cautious  approach  to  subgroup  analysis  is  appropriate,  the 
study  will  strengthen  the  hand  of  advocates  of  caution  and  make  a  small  contribution  to 
the  avoidance  of  inappropriate  care.  If  on  the  other  hand  it  transpires  that  a  less  cautious 
approach  can  be  justified,  then  this  could  be  a  precursor  of  changes  in  the  approach  to  the 
analysis  of  current  and  future  trials.  The  extent  of  the  effect  on  actual  health  gain  and 
service  cost-effectiveness  will  depend  on  the  heterogeneity  of  effect  among  subgroups  in 
different  trials,  and  on  clinical  judgement,  but  it  should  be  widespread. 
The  advancing  cause  of  evidence-based  health  care  has  brought  into  focus  the  gap 
between  the  evidence  provided  by  scientists  and  the  information  needed  by  decision- 
makers.  The  response  to  this  has  been  the  introduction  of  institutions  such  as  NICE,  but 
to  make  appropriate  decisions  they  will  still  require  the  right  tools.  Pressure  on  scientists 
for  more  subgroup  analyses  is  likely  to  grow,  and  the  response  to  this  pressure  needs  to  be 
demonstrably  appropriate. 
It  is  on  the  axes  of  the  relationship  between  information  and  decision  making  that  these 
issues  lie.  Classical  statistical  analysis  provides  us  with  clear  and  distinct  information 
about  the  effects  of  an  intervention  throughout  a  population.  Unfortunately  this 
61 information,  or  the  form,  in  which  this  information  is  presented,  is  not  always  helpful  to 
decision-makers. 
5.2  Conceptual  approach  to  subgroup  analysis 
The  problem  we  have  is  that  an  intervention  is  generally  assigned  a  cost-effectiveness 
ratio  that  is  taken  to  apply  to  all  subjects.  The  cost-effectiveness  of  an  intervention  is 
measured,  with  some  exceptions,  as  the  mean  of  a  sample  (with  a  range  within  which  the 
mean  of  the  population  is  expected  to  lie).  In  fact  the  cost-effectiveness  of  an  intervention 
is  a  distribution,  both  in  the  case  of  the  sample  studied  and  the  population  it  represents. 
This  may  or  may  not  approximate  to  a  Normal  distribution,  but  whatever  the  shape  of  the 
distribution,  for  approximately  half  of  the  sample  the  cost-effectiveness  of  the 
intervention  will  be  higher  than  the  stated  mean.  Additionally,  for  the  other  half  of  the 
sample  the  intervention  will  have  a  level  of  cost-effectiveness  that  is  lower  than  the  mean. 
Mean 
J 
vanance 
Figure  5.1:  little  variance 
about  the  mean. 
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Figure  5.2:  Large  variance  about  the  mean. 
62 Therefore  let  us  assume  a  limit  is  set  where  provision  is  too  costly  for  the  obtained 
benefits.  If  the  measure  for  our  chosen  intervention  lies  above  that,  then  it  is  assumed  that 
this  intervention  is  cost-effective  for  the  population  as  a  whole.  If  the  distribution  of 
relative  cost-effectiveness  throughout  the  population  is  wide,  then  in  reality  there  is  every 
likelihood  that  if  policy  decisions  are  made  using  this  information,  for  much  of  the 
population  this  intervention  may  not  be  cost-effective  under  the  same  constraints.  If  this  is 
so  then  resources  are  being  inefficiently  allocated. 
The  importance  of  the  variability  of  this  distribution  is  the  key  to  the  extent  of  this 
inefficiency.  If  variance  is  small  (fig.  5.1),  any  possible  benefits  lost  or  increased  costs 
incurred  will  be  correspondingly  small,  but  if  variance  is  high  (fig  5.2),  then  the 
inefficiency  and  inequity  resulting  could  be  large. 
It  is  therefore  the  degree  of  variation  and  the  kurtosisx  in  this  distribution,  which  is  of 
most  interest  to  us.  Where  this  variation  is large  (or  the  distribution  is  platykurtic)  a  large 
sample  is  needed  to  demonstrate  a  difference  in  mean  effects  between  intervention  and 
control  groups.  However,  in  some  cases  there  is  a  large  average  effect,  but  also  a  large 
variance  (e.  g.,  in  cases  where  the  new  treatment  can  be  seen  as  `kill  or  cure').  Even  when 
this  is  the  case  it  is  normal  for  the  recommendation  from  the  trial  to  adopt  the  new 
treatment  on  grounds  that  this  will  increase  health  gain.  Implicitly  this  is  supporting  the 
introduction  of  treatment  that  may  be  systematically  inferior  for  some  of  the  patients. 
I  the  depth  and  shape  of  the  distribution. 
63 In  figure  5.3  the  incremental  cost  effectiveness  ratio  (ICER)  of  an  intervention  is  shown, 
(CT 
- 
CC) 
marked  with  the  sparsely  broken  line  that  goes  through  the  origin,  with  its  confidence 
intervals  shown  as  the  more  regular  broken  lines  either  side,  tangential  to  the  circle.  Our 
chosen  limit  for  assessing  the  cost-effectiveness  of  new  interventions  is  shown  as  a  thick 
line.  Axes  are  shown  as  difference  in  effectiveness  (ET-Ec)  and  cost  (CT-Cc)  between 
treatment  and  control  groups. 
For  our  intervention  to  be  cost-effective  the  ICER  slope  of  the  intervention  must  be 
shallower  and  hence  below  this  line.  In  the  case  of  our  intervention  it  clearly  is  not.  Figure 
5.4  shows  the  intervention  split  into  clearly  defined  subgroups.  Here  the  mean  of  one  of 
the  groups  (m3)  is  clearly  below  the  line.  Unfortunately  we  cannot  say  with  95% 
confidence  that  the  mean  of  this  population  will  lie  under  our  hypothetical  limit.  What  we 
can  say  about  these  results  is  that  the  probability  that  the  slope  of  the  population  mean  is 
in  the  positive  section  below  the  thick  line  is  higher  than  the  probability  of  it  being  above 
the  line. 
(E*r  -  Ec) 
(CT  -  CC) 
Figure  5.3:  Mean  and  confidence  intervals 
of  an  intervention,  with  the  thicker  line 
marking  the  acceptable  limit  of  ICER. 
(Er  -  Ec) 
Figure  5.4:  Means  of  sub  groups 
and  their  confidence  intervals. 
64 It  is  therefore  "probable"  that  a  specific  subset  of  the  population  can  be  cost-effectively 
treated  with  this  intervention,  but  under  normal  circumstances  will  either  receive  no 
intervention  or  will  receive  an  alternative  intervention  that  is less  cost-effective.  Therefore 
in  most  circumstances  we  are  likely  to  have  one  of  three  possible  alternatives: 
1)  There  are  no  discernible  differences  between  the  cost-effectiveness  of  an  intervention 
across  the  whole  population  (sample)  and  the  cost-effectiveness  of  that  intervention 
within  specific  subgroups  of  that  population. 
2)  Although  the  intervention  is  not  seen  as  cost-effective  across  the  whole  population,  it 
is  seen  as  cost-effective  within  one  (or  more)  distinct  subset(s)  of  the  population  at  a 
statistically  significant  level. 
3)  Although  the  sample  size  may  not  allow  sub-group  analysis  to  produce  differences  that 
are  detectable  at  conventional  levels  of  significance,  subgroups  can  be  identified  as 
being  distinct  at  lower  than  conventional  significance  levels.  What  this  may  say  is  that 
one  tail  of  the  distribution  is  in  the  area  that  defines  the  limits  between  "positive"  and 
"negative"  results. 
It  is  this  third  group  which  is  the  area  of  debate  in  the  probability  theory  and  statistical 
inference,  the  concept  of  the  trade-off  between  certainty  and  optimisation.  Summarised  by 
Fry  74  when  he  says, 
65 "How  much  more  conclusive  must  the  test  data  be....  To  accept  too  little  implies 
running  greater  risks  or  error  than  we  often  desire.  To  demand  too  much  spells 
extravagance" 
It  is  the  trade-off  between  optimisation  and  certainty  that  is  at  the  heart  of  the  debate 
around  greater  use  of  the  data  available  from  trials.  The  historical  link  between  traditional 
inference  and  the  need  in  medical  trials  to  show  safety  as  well  as  effectiveness  as  pushed 
economic  evaluation  medical  interventions  towards  a  greater  reliance  on  certainty  than  it 
should.  It  is  the  belief  of  this  thesis  that  greater  use  of  subgroup  analysis  can  go  someway 
to  remedying  this. 
5.3  Summary 
The  purpose  of  this  chapter  was  to  consider  the  conceptual  and  methodological  bases  of 
the  system  proposed  to  overcome  the  issues  associated  with  improving  evidence  for 
decision-makers.  The  use  of  subgroup  analysis  in  achieving  solutions  has  the  advantage 
of  both  utilising  all  available  information,  while  being  both  internally  and  externally 
objective  with  its  use  of  the  evidence. 
If  this  conceptual  approach  to  subgroup  analysis  works  in  practice  it  could  potentially 
lead  to  an  improvement  in  overall  health  gain  for  society.  This  benefit  comes  with  a  trade- 
off  against  certainty  of  results  (although  not  likelihood)  and  it  is  by  no  means  certain  that 
such  a  wide  distribution  of  patient  specific  cost-effectiveness  ratios  across  a  diverse 
sample  exists  in  any  or  most  studies.  Even,  if  such  variance  does  exist  it  is  known 
whether  this  level  of  uncertainty  around  the  mean  can  be  put  to  use  advantageously  by  the 
66 selection  of  subgroups  with  specific  characteristics.  However,  it  is  the  intention  of  this 
thesis  to  find  out  whether  it  is  possible  and  whether  such  methods  can  be  productive. 
The  next  chapter  will  look  at  the  practical  steps  of  selecting  and  undertaking  a  subgroup 
analysis. 
67 6.  The  Research  Question 
6.1  Introduction 
The  purpose  of  this  chapter  is  to  define  the  research  question  and  to  outline  the  plan  of 
investigation.  The  hypothesis  is  that  a  cautious  attitude  to  subgroup  analysis  has  had 
adverse  consequences  for  clinical  decision-making  and  public  health,  because  it 
potentially  recommends  inappropriate  treatment  and  a  less  resource  efficient  package  of 
services.  This  study  aims  to  investigate  the  impact  on  population  health  gain  and  service 
cost-effectiveness  of  a  variety  of  `rules'  for  deriving  and  evaluating  estimates  of  cost- 
effectiveness. 
The  study  involves  using  data  from  existing  large  trials  to  produce  a  series  of  datasets, 
yielding  different  estimates  of  costs  and  then  cost-effectiveness,  in  aggregate  and  for 
subgroups  derived  by  different  rules.  In  the  second  study  aggregate  and  subgroup 
estimates  of  cost-effectiveness  will  then  be  used  to  make  hypothetical  resource  allocation 
decisions,  the  outcomes  of  which  will  be  discussed. 
6.2  Methods 
Subgroup  analysis  itself  is  not  a  complex  procedure.  It  is  simply  the  analysis  of  a 
particular  group  within  a  studied  data  set,  which  are  identified  by  one  or  more  common 
characteristics.  What  makes  subgroup  analysis  complex  is  the  lack  of  empirical  rules 
associated  with  its  execution.  Subgroup  analysis,  when  not  used  properly,  can  do  more 
harm  than  good  in  terms  of  providing  decision-makers  with  information  on  relative 
effectiveness.  This  is  why  there  is  the  need  to  lay  a  number  of  ground  rules  on  exactly 
68 how  we  will  select,  or  determine  our  subgroups  and  how  we  will  calculate  ICERs  for 
subgroups.  Each  of  these  areas  will  be  discussed  in  turn. 
6.2.1  Subgroup  selection 
There  are  three  important,  as  well as  interrelated,  points  often  quoted  when  discussing  the 
issue  of  subgroup  selection  75.76"".  The  time  at  which  the  subgroup  is identified,  the  reason 
for  selecting  a  particular  subgroup  and  the  source  of  the  reasoning  for  it's  identification. 
As  has  been  discussed  in  chapter  three  it  is  generally  accepted  that  the  risk  of  erroneous 
results  emanating  from  subgroup  analysis  can  be  greatly  reduced  if  subgroups  are 
identified  prior  to  analysis,  or  where  possible  prior  to  randomisation  and  data  collection. 
Additionally  it  is  preferable  to  have  some  degree  of  justification  for  the  choice  of  this 
grouping,  such  as  previous  evidence  of  a  relationship  between  the  variable  concerned  and 
the  outcome  being  measured. 
The  choice  of  variable  for  grouping  will  be  based  on  a  combination  of  both  practical  and 
theoretical  grounds.  On  the  practical  side  it  will  be  limited  to  variables  that  are  either 
collectable  or  already  contained  within  the  data  set,  as  well as  being  limited  to  variables 
that,  for  obvious  reasons,  can  be  identified  before  the  intervention  in  question  takes  place. 
The  theory  on  which  selection  is  based  will  be  an  accepted  or  empirically proven  reason 
for  likely  differences  in  cost-effectiveness.  In  short  these  variables  can  be  classified  into 
three  distinct  groups; 
"  demographic, 
"  diagnostic,  and 
"  characteristic. 
69 Demographic  involves  the  variables  of  age  and  sex.  Diagnostic  includes  the  specifics  of 
any  diagnosis,  for  example  stage  of  disease,  as  well  as  other  factors  relating  to  likely 
prognosis,  such  as  co-morbidity  and  risk  factors.  Characteristics  contain  all  other 
population  grouping  variables  such  as  social  class,  education  or  ethnicity.  For  some 
characteristics  the  variables  may  overlap  into  other  areas,  for  example  age  may  well  be  a 
risk  factor  for  certain  interventions.  The  classification  of  variables  into  one  group  or 
another  is  nevertheless  irrelevant,  it  does  not  change  the  analytical  method  used  but  is 
merely  there  for  simplicity  of  explanation. 
The  final  element  of  the  selection  process  involves  the  source  of  the  reasoning  behind  the 
selection  of  the  subgroup.  There  are  three  types  of  evidence  that  can  be  used  for  the 
specification  of  subgroups;  published  and  non-published  research  evidence,  and  expert 
opinion.  Expert  opinion  is  often  difficult  to  quantify  and  may  be  unreliable  as  a  source  of 
information,  and  as  such  the  intention  is  to  limit  the  evidence  for  subgroups  in  this  model 
to  published  data  that  show  a  statistically  significant  relationship  between  the  variable 
concerned  and  the  primary  outcome. 
6.2.2  Measurement  of  ICERs 
The  calculation  of  ICERs  will  be  done  taking  the  incremental  change  in  cost  and 
incremental  change  in  effectiveness.  The  two  methods  used  to  calculate  the  ICER  of  a 
specific  subgroup,  once  selected,  will  be  the  bootstrapping  approach  using  a  Monte  Carlo 
simulation°.  Unlike  those  methods,  used  by  Morris78  and  others,  such  as  by  Rubin79  and 
A  detailed  description  of  these  methods  is  shown  in  appendix  3. 
70 that  used  by  Laird  and  Louis80,  the  method  we  will  use  does  not  attempt  to  counter  any 
effect  of  regression  to  the  mean. 
This  problem  of  regression  to  the  mean  lies  in  the  fact  that  subgroups  that  lie  to  the  end  of 
a  distribution,  tend  to  infer  that  the  reason  for  any  increase  (or  decrease)  in  cost- 
effectiveness  could  have  been  for  mathematical  reasons  rather  than  relating  to  the  chosen 
variable  of  study.  It  is  considered  not  to  be  an  issue  of  importance  in  the  calculation  of 
ICERs  for  the  following  reasons. 
Let  us  assume  that  the  individuals  being  studied  were,  for  example,  in  an  anti-obesity 
intervention.  At  the  beginning  of  the  trial,  some  of  these  people  could  have  been  very 
overweight.  Therefore  at  the  end  of  an  intervention  that  attempts  to  help  people  to  reach  a 
target  body  mass  index  (BMI),  the  net  difference  of  these  individuals  is  more  likely  to  be 
higher  than  those  people  just  slightly  overweight,  regardless  of  the  relative  effectiveness 
of  the  intervention  upon  those  individuals.  They  just  had  more  to  lose.  In  essence  the 
method  used  by  Morris,  similar  to  the  others,  shrinks  the  point  estimate  of  the  subgroup 
towards  the  overall  estimate  of  the  intervention. 
The  problem  of  regression  to  the  mean  is  only  relevant,  when  particular  outcome 
measures  are  being  used.  Measures  such  as  height,  weight,  BMI  and  blood  pressure  are 
obviously  effected  by  this.  The  question  is  are  the  outcomes  used  in  the  construction  of 
ICERs  liable  to  be  affected  by  regression  to  the  mean?  These  being  costs  and  measures 
such  as  QALYs  and  "Life  years  gained".  If  an  individual  within  the  study  is  associated 
with  larger  than  average  incremental  change  in  life  years  gained,  or  indeed  costs,  this  is 
71 unlikely  to  be  due  to  the  fact  that  at  the  start  of  the  trial  we  expected  him  or  her  to  live  to 
be  a  hundred  and  fifty.  It  is  more  likely  to  be  the  fact  that  this  individual  is  more  likely  to 
have  possessed  a  number  of  characteristics  that  enable  the  studied  intervention  to  be  more 
effective.  If  it  is  the  latter,  which  is  the  more  logical,  then  it  is  part  of  what  we  are  trying 
to  discover  an  integral  part  of  the  outcome.  As  such  there  is  no  reason  for  this  to  be  of 
concern  when  dealing  with  incremental  cost-effectiveness  ratios. 
6.3  Plan  of  investigation 
The  aim  is  to  use  data  from  a  randomised  controlled  trial  which  has  reported  the  overall 
cost-effectiveness  of  an  intervention  and  demonstrate  that  for  many  patients  in  the  trial 
the  statement  made  on  cost  effectiveness  (be  it  positive  or  negative)  will  not  be  true. 
These  are  the  cases  where  use  of  data  on  the  differences  in  subgroups  is  most  likely  to 
yield  increases  in  expected  health  gain. 
The  basic  procedure  will  be  as  follows: 
1.  Choose  a  trial. 
2.  Select  a  number  of  subgroups  for  which  the  variable  concerned  has  an  empirical 
relationship  with  the  primary  outcome  as  dictated  by  a  published  study  that  shows 
a  statistically  significant  odds-ratio  at  the  5%  level. 
3.  Derive  an  estimate  of  overall  incremental  cost-effectiveness,  and  measures  of 
variance,  for  the  main  comparison  groups  using  Monte  Carlo  simulation. 
4.  For  each  subgroup  derive  estimates  of  the  incremental  cost-effectiveness  ratios, 
and  measures  of  variance,  using  Monte  Carlo  simulation. 
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and  the  overall  trial  effect 
6.  Compare  the  likelihood  of  outcomes  for  both  subgroups  and  the  overall  trial  effect 
7.  Assess  the  likely  health  gain  from  a  policy  decision  based  on  the  overall  trial 
results  against  the  use  of  the  evidence  from  subgroups. 
There  will  be  a  number  of  variants  on  this  basic  procedure,  with  rules  for  choosing 
subgroups  being  derived  from  the  literature.  The  baseline  is  `no  subgroup  analysis'. 
Subgroups  will  be  chosen  according  to  a  priori  biological,  behavioural  or  organisational 
plausibility,  ignorant  of  any  subgroup  results  from  the  trials. 
The  `baseline'  estimation  procedure  in  this  case  will  involve  standard  methods 
appropriate  to  the  outcomes  at  issue.  The  fewer  the  subjects  in  any  given  subgroup,  the 
greater  the  variability  of  derived  parameter  estimates  in  relation  to  the  actual  true  values. 
6.4  Trial  selection 
Two  trial  data  sets  have  been  identified.  They  involve  both  the  measurement  of  costs  and 
the  measurement  of  the  cost-effectiveness  of  health  care  interventions.  The  first  is  The 
PRAIS  UK  study  that  is  a  resource-use  study  on  people  presenting  with  acute  coronary 
syndrome.  The  purpose  of  the  analysis  of  this  first  data  set  is  to  look  at  how  the 
characteristics  of  certain  subgroups  can  have  a  sizeable  effect  on  cost  alone,  and  as  such 
why  subgroup  analysis  can  be  so  important  in  the  measurement  of  cost-effectiveness. 
73 The  second  data  set  is  from  the  Extracorporeal  Membrane  Oxygenation  (ECMO)  study, 
which  is  a  study  comparing  the  cost-effectiveness  of  extra  corporeal  membrane 
oxygenation  with  conventional  management  in  neonates  born  with  serious  respiratory 
disease.  It  is  with  this  data  set  that  a  practical  attempt  to  compare  the  cost-effectiveness  of 
subgroups  versus  the  overall  study  results  will  take  place. 
6.5  Summary 
Having  outlined  the  methods  to  be  used  to  test  the  value  of  subgroup  analysis  these  will 
be  put  into  practice  in  the  next  two  chapters.  Firstly,  chapter  7  looks  at  the  value  of 
subgroup  analysis  in  looking  at  the  variation  in  cost  distributions  alone,  whereas  chapter  8 
looks  at  cost-effectiveness  ratios  under  subgroup  analysis  compared  to  traditional 
methods  for  summarising  study  data. 
74 7.  Variation  in  cost 
7.1  Introduction 
This  is  the  first  of  two  chapters  that  use  actual  data  sets  to  test  the  theory  that  subgroups 
can  provide  worthwhile  additional  information  to  the  decision-maker.  The  cost- 
effectiveness  ratio  is  made  up  of  two  parts;  the  cost  of  an  intervention  and  the 
effectiveness  of  that  intervention  in  achieving  a  desired  outcome.  In  both  traditional  and 
subgroup  analysis  the  measurement  of  cost-effectiveness  has  traditionally  centred  on  the 
movement  of  the  level  of  effectiveness  within  a  population  and  given  little  consideration 
to  the  patient  specific  cost  of  interventions. 
More  recently  methods  of  economic  evaluations  have  moved  more  towards  incorporating 
patient  specific  cost  data  and  as  a  result  more  consideration  is  given  to  the  distributions 
and  variation  in  costs  as  compared  to  effects.  This  chapter  looks  at  the  value  of  using 
subgroup  analysis  in  the  evaluation  of  costs  and  their  distributions. 
It  starts  by  looking  at  the  shape  of  a  cost  distribution  and  the  strengths  and  weaknesses  of 
classical  methods  of  describing  these  distributions.  It  addresses  how  the  debate  around 
cost  measurement  has  led  to  costs  being  estimated  for  individual  patients  so  that  the 
distribution  tends  to  be  a  specific  shape  and  form. 
The  traditional  methods  used  for  measuring  inference  in  costs  and  the  limitations  of  this 
information  for  decision  making  is  assessed.  Alternative  descriptive  statistics  are 
evaluated  leading  to  a  discussion  of  the  value  to  decision-makers  of  pre-selected 
75 subgroups  of  costs  and  whether  they  are  in  fact  being  undervalued  as  a  source  of 
information  to  the  decision  maker.  Finally  these  theories  are  tested  when  cost  data  from 
an  audit  of  patients  presenting  with  myocardial  infarction  (MI)  are  analysed  for  inference 
and  variance  by  subgroup.  These  distributions  are  then  simulated  using  the  Monte  Carlo 
technique,  from  which  conclusions  are  drawn  on  the  value  of  the  various  descriptive 
statistics. 
7.2  The  shape  of  a  cost  distribution 
The  distribution  of  individual  patient  costs  tends  to  have  a  very  specific  pattern,  with  the 
majority  of  values  being  grouped  around  a  mean  at  the  lower  end  of  the  range,  with  a  long 
flat  tail.  This  is  both  empirically common81  and  makes  intuitive  sense.  With  most  cases 
being  closely  grouped  around  a  mean  there  tends  to  be  a  minimum  or  fixed  cost  element 
for  every  value  of  each  process  being  studied. 
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Figure  7.1:  Right-skewed  curve  and  histogram  most  closely  associated  with  a  cost 
distribution 
76 Because  of  this  the  possibility  of  having  outliers  to  the  left  of  the  mean  is  theoretically 
impossible.  Whereas  the  possibility  of  outliers  to  the  right  of  the  mean  is  quite  probable 
as  variation  in  the  requirements  of  each  individual  case  allow  high  variation  in  the  other 
element  of  each  value,  that  of  variable  cost.  We  therefore  tend  to  have  the  shape  shown  in 
figure  7.1,  one  that  is  skewed  to  the  right  rather  than  symmetrical  around  the  mean82. 
7.3  Measurement  of  cost 
There  is  much  debate  surrounding  costing  of  interventions  in  health  economicsas,  sa,  as,  most 
of  which  can  be  summarised  into  a  debate  surrounding  the  trade-off  between 
generalisability  of  costs  to  wider  settings  and  the  detail  required  to  estimate  the  `true' 
costs  of  the  intervention  being  studied. 
The  generalisation  camp  argue  that  as  costs  become  more  and  more  detailed  within  the 
intervention  being  studied,  the  more  it  will  incorporate  elements  of  geographical  and 
organisational  specificity.  For  example,  it  is  thought  to  be  unhelpful,  or  at  least  not 
resource-efficient  to  cost  in  detail  the  transport  costs  of  a  community-nursing  project  that 
was  evaluated  in  a  rural  area,  which  will  make  the  results  irrelevant  to  an  urban  setting. 
Similarly  the  costing  of  a  medical  intervention  being  evaluated  in  a  city  teaching  hospital 
will  not  be  generalisable  to  smaller  suburban  district  or  community  hospitals.  As  such  it 
puts  forward  a  proposal  to  use  nation-wide  or  other  representative  average  costs  so  that 
firstly  decision-makers  can  interpret  them  themselves,  and  so  that  different  costs  within 
economic  evaluations  can  be  comparable" 
77 The  alternative  view  is  that  measuring  cost  is  an  integral  part  of  economic  evaluation  and 
that  true  cost  will,  by  definition  be  explicit  to  the  intervention  being  studied  and  hence  to 
the  outcomes  the  costs  are  being  associated  with87  88.  For  example  the  cost  of  employing  a 
specialist  nurse  in  a  particular  field  should  be  emphasised  as  a  part  of  the  intervention 
itself,  and  that  assuming  a  national  average  cost  of  a  nurse,  gives  the  wrong  message  to 
the  decision  maker  as  to  the  true  value  of  the  resources  used. 
It  is  widely  acknowledged  that  this  is  a  true  trade-off  and  as  such  there  may  not  be  a 
`right'  answer  to  the  problem89.  Therefore  a  best-fit  approach  is  usually  suggested,  most 
of  these  suggestions  rely  on  a  greater  degree  of  transparency  of  the  costing  process  and 
the  splitting  up  of  costing  into  two  parts;  resource-use  and  unit  costs3. 
A  measure  of  resource-use  is  simply  a  measure  of  the  amount  or  degree  of  a  specific 
resource  being  used.  This  can  be  a  bed,  or  a  drug  or  a  nurse  or  doctor.  It  is  this  that 
attempts  to  deal  with  the  problem  of  specificity.  Once  a  measure  of  this  resource  has  been 
calculated,  a  unit  cost  is  attributed  to  it.  These  are  usually  based  on  national  averages  or 
other  pooled  sample  data,  hence  approaching  the  problem  of  generalisability. 
7.4  Statistical  inference  and  measuring  cost 
The  other  advantage  of  the  resource-use  measurement  method  is  that  each  individual 
being  studied  has  a  specific  cost  for  the  intervention,  rather  than  being  limited  to  taking 
an  average  of  all  subjects.  There  has  been  a  tendency  to  assume  a  normal  distribution 
around  this  mean  as  in  the  equivalent  measure  of  effectiveness,  which  makes  up  the  other 
side  of  the  cost-effectiveness  ratio'.  It  is  here  where  we  can  begin  to  approach  the  problem 
78 of  using  confidence  intervals  for  assessing  value  of  the  evidence  of  cost.  Economics 
concerns  itself  with  finding  the  optimal  use  of  resources  within  a  population,  whereas 
confidence  intervals  are  used  to  specify  the  level  of  confidence  we  have  in  an  average. 
In  statistical  inference  confidence  intervals  that  surround  a  mean  are  a  measure  of  the 
level  of  confidence  that  the  mean  itself  will  lie  within  this  range,  not  a  level  of  confidence 
that  the  majority  of  the  distribution  of  values  itself  will  lie  within  this  range. 
As  a  decision-maker,  the  information  you  really  need  to  assess  whether  an  intervention  is 
likely  to  be  an  efficient  use  of  resources  is  the  total  cost  and  total  benefit  of  the 
intervention  under  local  conditions.  If  the  distribution  around  the  mean  used  to  create 
cost-effectiveness  ratios  is  normal  then  this  information  may"  be  useful,  but  we  know  that 
in  the  case  of  cost,  this  is  not  true.  When  measuring  the  cost  in  a  cost-effectiveness  ratio, 
consideration  has  to  be  taken  of  the  shape  of  the  distribution,  as  well  as  the  mean  itself.  If 
the  long  tail  associated  with  cost  distributions  is  not  accounted  for,  there  is  a  risk  that  a 
programme  set  up  on  the  basis  of  a  cost-effectiveness  ratio  will  create  higher  costs  than 
expected. 
In  essence  the  message  is  that  the  length  of  the  tail,  or  the  width  of  the  range  of  true 
values  within  a  sample  are  as  important  an  indicator  of  cost  as  the  mean  cost  and  the 
confidence  intervals  surrounding  it.  It  is imperative  then  that  we  incorporate  the 
"  The  word  `may'  is  used  because  even  where  the  distribution  is  normal  the  kurtosis  and/or  range  of  the 
distribution  of  true  values  may  be  significantly  different  to  that  of  the  confidence  intervals.  So  even  then 
the  decision-maker  does  not  have  a  true  representation  of  the  cost  of  the  intervention. 
79 measurement  of  both  the  skew  of  the  distribution  and  the  kurtosis,  or  shape  of  the 
distribution. 
7.5  Measuring  the  shape  and  range  of  a  distribution 
The  shape  and  size  of  a  distribution  can  be  measured  in  a  number  of  ways.  The  three  key 
elements  are  length  or  width  of  the  points  in  a  distribution,  the  shape  of  the  distribution 
and  symmetry  of  the  distribution.  The  width  or  length  of  a  distribution,  which  shows  the 
distance  between  the  lowest  point  on  the  distribution  and  the  highest,  is known  as  the 
range  of  the  distribution.  Another  measure  which  is  useful  for  measuring  the  size  of 
distribution  that  have  long  tails  is  the  inter-quartile  range,  which  measures  the  range 
between  the  25'  and  75`h  percentile  of  all  points  within  the  distribution.  Probably  the  most 
vigorous  method,  though  is  the  standard  deviation. 
The  standard  deviation  is  measured  as  the  square  of  the  differences  between  each  value 
within  the  distribution  and  the  mean.  The  differences  are  squared  only  because  if  they 
were  not  they  would  add  up  to  zero,  the  squaring  process  is  therefore  used  to  get  rid  of 
negative  values.  If  a  distribution  is  wide  it  will  tend  to  have  values  of  difference  with  the 
mean  that  are  high,  and  therefore  a  high  standard  deviation.  Similarly  with  a  narrow 
distribution  this  will  give  a  low  value  for  the  standard  deviation.  The  formula  for  the 
standard  deviation  (SD)  is  thus: 
SD  =1  -xy  n-1E(x' 
80 The  shape  of  a  distribution  has  two  areas  of  comparison;  its  symmetry  and  its  relative 
weighting  across  the  range.  The  symmetry  of  a  distribution  is  measured  by  its  degree  of 
skew  and  the  weighting  by  the  measure  of  kurtosis.  The  first  graph  in  figure  7.2  is 
symmetrical  and  has  zero  skew,  whereas  the  second  graph  is  positively  skewed,  or 
skewed  to  the  right.  The  relative  distance  between  the  mean  of  the  distribution  and  the 
median  measures  the  degree  of  skew. 
Skew  is  a  measure  of  the  asymmetry  of  the  data  around  the  sample  mean.  If  skew  is 
negative,  the  data  are  spread  out  more  to  the  left  of  the  mean  than  to  the  right.  If  skew  is 
positive,  the  data  are  spread  out  more  to  the  right.  The  skew  of  the  normal  distribution  (or 
any  perfectly  symmetric  distribution)  is  zero. 
The  skew  of  a  distribution  is defined  as: 
y=  E(x  -  µ)3 
Cy3 
where  E(x)  is  the  expected  value  of  x. 
The  inter-quartile  range  of  a  distribution  (IQR)  computes  the  difference  between  the  75th 
and  the  25th  percentiles  of  the  sample  in  X.  The  IQR  is  a  robust  estimate  of  the  spread  of 
the  data,  since  changes  in  the  upper  and  lower  25%  of  the  data  do  not  affect  it.  If  there  are 
outliers  in  the  data,  then  the  IQR  is  more  representative  than  the  standard  deviation  as  an 
estimate  of  the  spread  of  the  body  of  the  data.  The  IQR  is less  efficient  than  the  standard 
deviation  as  an  estimate  of  the  spread,  when  the  data  is from  a  normal  distribution. 
81 Figure  7.2:  Graphical  representation  of  relative  mean  and  inter-quartile  range,  of  a 
symmetrical  and  positively  skewed  distribution. 
Kurtosis  is  a  measure  of  how  outlier-prone  a  distribution  is.  The  kurtosis  of  the  normal 
distribution  is 3.  Distributions  that  are  more  outlier-prone  than  the  normal  distribution 
have  kurtosis  greater  than  3;  distributions  that  are  less  outlier-prone  have  kurtosis  less 
than  3.  A  flat-topped  distribution  tends  to  have  a  low  value  of  kurtosis  and  is  said  to  he 
platykurtic  (flat  bulging).  A  sharp-peaked  distribution  will  tend  to  have  a  high  value  of 
kurtosis  and  is  called  leptokurtic  (thin  bulging).  The  kurtosis  of  it  distribution  is  defined 
as: 
k=E(x-µ)4 
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82 where  E(x)  is  the  expected  value  of  x. 
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Figure  7.3:  Graphical  representation  of  platykurtic  and  leptokurtic  distributions 
It  is  the  shape  and  size  of  cost  distributions  that  makes  the  mean  and  confidence  intervals 
an  insufficient  means  of  summarising  the  data.  When  making  a  decision  based  on 
expected  costs  of  an  intervention  the  degree  to  which  the  distribution  of  costs  is  skewed  is 
likely  to  be  of  some  importance.  If  there  is  a  likelihood  that  a  proportion  of  those 
receiving  the  intervention  may  cost  well  in  excess  of  the  average  cost  for  the  intervention, 
this  provides  an  added  risk  to  funding  the  intervention.  Similarly  if  the  cost  distribution  is 
particularly  platykurtic  this  also  implies  a  degree  of  unpredictability  of  the  likely  cost  of' 
any  individual. 
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In  theoryihe  decision  as  to  whether  to  fund  an  intervention  relies  heavily  on  the  level  of 
risk  associated  with  the  probable  cost  and  benefits  of  any  particular  individual.  The 
83 average  costs  and  benefits  across  a  wide  and  varied  population,  although  providing  a 
guide,  may  not  be  all  that  helpful  to  a  decision-maker  if  this  means  it  is  not  representative 
of  the  vast  majority  of  individuals  within  the  population. 
7.6  The  measurement  of  the  distribution  and  confidence  in  the  mean 
It  is  the  relative  importance  of  both  the  shapes  of  the  distribution  and  confidence  in  the 
mean,  which  is  of  interest  to  us  in  the  issue  of  using  evidence  from  subgroup  analysis. 
The  reason  for  this  is  that  confidence  intervals  are  heavily  affected  by  sample  size,  which 
is inevitably  smaller  in  subgroup  analyses  than  in  the  sample  as  a  whole,  hence  subgroups 
will  always  have  relatively  wide  confidence  intervals. 
The  confidence  intervals  around  a  mean  are  a  constant  (for  example  for  95%  C.  I.  it  is 
96)  multiplied  by  the  size  of  the  standard  error  around  the  mean.  The  standard  error  in 
turn  is  reliant  on  two  measures,  the  sample  size  (n)  and  the  level  of  variance,  measured  by 
the  standard  deviation  of  the  distribution  (a),  in  the  formula; 
SE  =QI,  In. 
In  terms  of  the  range  of  values,  if  subgroups  are  selected  due  to  a  predicted  variance  in 
outcome,  in  this  case  cost,  it  is likely  that  the  chosen  variable  is  a  key  cost  driver.  Given 
this  it  is  acceptable  to  assume  that  the  variance  within  the  subgroups  is likely  to  be 
narrower  than  in  the  sample  as  a  whole.  The  effect  will  be  twofold,  a  reduction  in  the 
numerator  due  to  lower  variation  and  a  reduction  in  the  denominator  due  to  a  smaller 
sample  size.  In  reality  the  effect  on  reducing  sample  size  has  a  disproportionately  large 
effect  on  the  standard  error  as  although  the  measure  of  variance  is  an  average  across  all 
84 variables,  the  sample  size  is  a  sum.  Therefore  any  reduction  in  sample  size  is  unlikely  to 
be  offset  by  reduced  variance  within  the  sample. 
In  addition  under  the  method  used  for  calculating  confidence  in  the  mean  the  measure  of 
variance  is  solely  based  on  standard  deviation,  and  takes  no  account  of  skew.  This  is 
because  methods  of  statistical  inference  were  devised  for  calculations  inferred  from  a 
normal  distribution,  which  is  rarely  seen  with  cost  data.  As  a  result  we  have  a  trade-off 
between  restricting  the  unpredictability  of  the  cost  of  treating  each  individual  and  keeping 
narrow  confidence  intervals  for  the  mean.  This  is  shown  graphically  in  figure  7.4.  Either 
we  have  a  reliable  estimate  of  the  mean  when  concentrating  on  the  total  sample,  at  the 
expense  of  a  leptokurtic,  heavily  skewed  distribution.  Or  we  have  the  possibility  of  a  less 
skewed  more  playtykurtic  distribution  with  a  less  reliable  mean. 
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Figure  7.4:  A  graphical  representation  of  the  hypothetical  mean,  confidence 
intervals  and  distribution  of  costs  of  a  total  sample  (top)  and  a  pre-selected 
subgroup  (bottom). 
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Range The  intention  of  this  thesis  is  to  evaluate  whether  resource  allocation  decisions  can  be 
aided  by  considering  the  extra  information  that  analysing  both  costs  and  outcomes  by  pre- 
selected  subgroups  can  achieve.  To  do  this  we  need  to  answer  two  questions;  firstly  do 
pre-selected  subgroups  tend  towards  having  the  characteristics  discussed  above,  while 
secondly  does  this  information  provide  us  with  a  better  way  of  measuring,  or  drawing 
conclusions  from  cost  information? 
7.7  Evaluation  of  cost  data 
7.7.1  Methods 
To  test  the  value  of  describing  distributions  of  cost  with  measures  of  shape  and  form  as 
well  as  inference  of  data  from  a  study  into  patients  presenting  with  an  acute  myocardial 
infarction  was  analysed.  The  Prospective  Registry  of  Acute  Ischaemic  Syndrome 
(PRAIS)  was  designed  as  a  prospective  observational  cohort  registry  of  patients  admitted 
to  UK  hospitals  with  Acute  Coronary  Syndrome  (ACS).  A  total  of  56  UK  hospitals 
participated.  Each  hospital  was  asked  to  collect  data  on  20  consecutive  patients  admitted 
with  ACS  without  ST  elevation,  irrespective  of  admission  location  or  consultant  team. 
Patients  had  a  follow-up  visit  at  6  months  following  their  initial  hospital  admission.  A 
total  of  1046  patients  were  entered  into  the  registry  from  56  participating  centres  between 
23'  May  1998  and  Yd  February  1999. 
Information  was  collected  on  events,  treatment  and  resource-use  across  the  duration  of  the 
admission  and  a  follow-up  period  of  the  next  six  months.  Table  7.1  lists  the  measures  of 
resource-use,  the  unit  cost  attributed  to  them  and  it's  source.  These  unit  costs,  along  with 
the  measure  of  resource-use  from  the  PRAIS  data,  are  used  to  create  an  estimated  total 
87 cost  for  each  patient  presenting.  Figure  7.3  is  a  histogram  of  total  initial  admission  cost 
for  all  patients  in  PRAIS. 
A  literature  search  was  conducted  using  `PubMed',  `Medline'  and  `HealthPro',  looking 
for  evidence  of  any  relationship  between  a  series  of  patient  characteristics  at  admission 
and  total  cost  of  intervention  in  the  treatment  of  suspected  myocardial  infarction  (MI).  A 
search  was  made  for  published  research  showing  a  strong  relationship  between  cost  and 
the  following  characteristics;  sex,  age,  ECG  reading,  previous  history  of  event  and 
previous  diagnosis  of  CHD. 
The  selected  subgroups  for  cost  variation  were  age90,  B'  (below  65,65  -74,75+)  and  ECG 
category  (normal  or  complications)"',  93,9a,  9s.  96  These  were  selected  for  having  a  strong 
empirical  relationship  with  levels  of  cost  or  resource-use.  The  empirical  evidence  of  the 
relationship  between  cost  and  sex,  previous  history  of  event  and  previous  diagnosis  of 
CHD,  was  either  too  small  or  inconclusive. 
The  intention  is  to  compare  the  relative  value  of  the  various  statistical  descriptive 
measures  of  each  distribution,  both  the  overall  data  and  the  individual  subgroups,  for 
relevance  to  the  decision-maker.  Also  to  discover  whether  the  affect  that  reduced  sample 
size  has  on  measures  of  inference  of  subgroups  is likely  to  be  similarly  negative  or 
conversely  positive  when  measuring  distribution  shape.  The  distribution  of  each  subgroup 
will  be  plotted  and  all  the  descriptive  statistics  discussed  above  will  be  calculated  for 
each.  This  will  then  be  used  to  construct  probability  distribution  simulations  using  the 
Monte  Carlo  technique. 
88 The  Monte  Carlo  simulation  takes  a  sample  distribution  and  translates  it  into  a  probability 
distribution  where  the  likelihood  of  each  outcome  has  a  probability  and  where  the 
probabilities  of  all  possible  outcomes  sum  to  one.  This  helps  us  gauge  the  likelihood  of 
one  and  a  group  of  outcomes.  With  only  one  uncertain  variable,  cost,  the  shape  of  the 
probability  distributions  will  be  the  same  as  the  sample  distributions. 
Table  7.1  Resources,  unit  costs  and  sources. 
Resource  Unit  cost  (£) 
1998-9  prices 
Source 
Hospital  stay  (LOS  x  1) 
CCU  bed-day  348  CHD  costing  study  97 
Medical  bed-day  119  CHD  costing  study  " 
In-hospital  events 
Angiography  500  Literature  98 
PTCA  1428  CHD  costing  study  " 
CABG  2310  CHD  costing  study 
Stress  test  110.50  Literature  99 
Drugs  (daily  dose  x  LOS-except  TT) 
aspirin  0.10  British  National  Formulary 
beta  blocker  0.40  BNF  '99 
calcium  antagonist  0.42  BNF  '99 
nitrate(oral)  0.29  BNF  '99 
potassium  channel  opener  0.33  BNF  '99 
nitrate(IV)  16.50  BNF  '99 
GPIIb/IIla  1.00  BNF  '99 
Oral  anticoagulant  0.89  BNF  '99 
Thrombolytic  therapy  85.00  BNF  '99 
heparin  0.62  BNF  '99 
drugs  on  discharge  (per  month) 
antiplatelet  (aspirin)  1.55  BNF  '99 
beta  blocker  11.20  BNF  '99 
calcium  antagonist  11.85  BNF  '99 
nitrate  (oral)  8.17  BNF  '99 
potassium  channel  opener  9.93  BNF  '99 
statin  29.69  BNF  '99 
lipid-lowering  (other)  13.38  BNF  '99 
anticoagulant  (oral)  24.92  BNF  99 
ACE  inhibitor  13.43  BNF  99 
Angiotensin  2  inhibitor  15.75  BNF  '99 
89 7.7.2  Results 
The  distributions  of  the  `cost  per  admission  by  individual'  for  the  study  as  a  whole  and 
for  the  pre-selected  subgroups  were  analysed  for  both  measures  of  variance  and  for 
inference  around  the  mean  (table  7.2).  As  anticipated  confidence  intervals  around  the 
mean  were  much  wider  in  the  subgroups  than  in  the  sample  as  a  whole,  with  sample  sizes 
much  smaller  but  with  only  marginal  differences  in  standard  deviation.  In  terms  of 
measures  of  variance,  there  was  a  tendency  for  subgroups  to  have  lower  values  for  skew 
and  kurtosis.  This  was  not  universal  but  where  the  skew  or  kurtosis  of  a  subgroup  was 
higher  than  the  total  it  was  predictable.  For  example,  the  ageband  subgroup  of  patients 
over  the  age  of  75,  it  would  be  anticipated  that  a  large  proportion  of  the  skew  of  the  total 
was  due  to  outliers  in  the  highest  ageband  and  because  of  this  their  length  of  stay  is  the 
least  predictable. 
An  example  of  the  limitation  of  the  confidence  interval  when  dealing  with  the  value  of 
subgroups  is  illustrated  with  the  comparison  of  the  cost  distributions  of  the  total  data  set 
and  the  subgroup  of  patients  who's  ECG  was  normal.  As  would  be  expected  the  subgroup 
with  its  smaller  sample  size  (141  versus  868  in  the  main  sample)  has  far  wider  confidence 
intervals  (£275  versus  £153).  But  within  the  smaller  subgroup  distribution  there  is  far  less 
variance  (SD  of  825  versus  1145),  far  less  skew  (2.14  versus  2.92)  and  far  less  kurtosis 
(4.98  versus  11.67). 
This  would  suggest  that  the  probability  of  the  cost  of  a  random  patient  being  close  to  the 
mean  is  higher  in  the  subgroup  than  in  the  main  sample.  This  is  the  essential  difference  re- 
90 between  what  the  confidence  interval  on  a  cost  distribution  tells  us,  compared  to  the 
information  as  to  the  probability  of  random  subject  having  a  cost  close  to  the  mean. 
Table  7.2  Descriptive  statistics  of  the  distributions  of  subgroups 
Group  N  Mean  SD  Skew  Kurtosis 
Total  868  1092.76  1145.59  2.92  11.67 
Age 
<  60  263  1030.63  1079.58  2.29  6.31 
60-74  364  1128.83  1210.49  2.73  9.68 
75+  241  1106.09  1116.22  3.88  20.76 
ECG 
Normal  141  852.55  825.22  2.14  4.98 
Complications  731  1130.03  1192.70  2.89  11.21 
Distributions  and  details  of  simulations  can  be  found  in  Appendix  1 
Group  Mean  95%  confidence  intervals  Range  of  CIs 
Total  1092.76  1016.45  1169.08  152.63 
Age 
<  60  1030.63  899.55  1161.71  262.16 
60-74  1128.83  1004.06  1253.60  249.54 
75  +  1106.09  964.45  1247.73  283.28 
ECG 
Normal  852.55  715.15  989.94  274.79 
Complications  1130.03  1043.57  1216.48  172.91 
Distributions  and  details  of  simulations  can  be  found  in  Appendix  1 
To  take  our  example  further  we  have  simulated  both  of  the  distributions  using  the  Monte 
Carlo  method  to  estimate  the  likelihood  of  a  random  patient  falling  within  the  inter- 
quartile  range  of  the  given  distribution  as  compared  to  the  95%  confidence  interval  range. 
The  distribution  of  both  groups  was  simulated  using  the  descriptive  statistics  of  the 
91 distributions  shown  in  tables  7.2  and  7.3.  Simulations  were  repeated  for  a  series  of 
iterations  between  100  and  one  million,  but  little  change  was  seen  in  the  results  beyond 
10,000".  Table  7.3  shows  a  comparison  of  the  simulations  of  the  total  data  set  against  the 
subgroup  for  Normal  ECG. 
Table  7.3  Results  of  Monte  Carlo  probability  distribution  simulation 
Group  All  patients  ECG-Normal 
subgroup 
Ratio 
(All  /  subgroup) 
Mean  1065.87  851.09 
Standard  deviation  1102.86  815.51 
Skew  2.91  2.16 
Kurtosis  14.60  7.92 
First  quartile  395.03  396.08 
Third  Quartile  1207.25  965.88 
Inter-quartile  range  812.22  569.80  1.42 
5"'  percentile  207  189 
95`h  percentile  3391  2606 
90  percentile  range  3184  2417  1.32 
95%  C.  I. 
lower  1016.45  715.15 
upper  1169.08  989.94 
range  152.63  274.79  0.55 
The  simulation  shows  that  although  the  confidence  intervals  surrounding  the  mean  are 
narrow  in  the  main  sample,  the  likelihood  of  a  random  patient  falling  into  this  range  is 
relatively  low  due  to  the  shape  and  variance  of  the  distribution,  which  in  turn  is due  to  its 
unpredictability  regarding  outliers.  The  proportion  of  values  within  the  inter  quartile 
tt  Distributions  and  details  of  the  simulations  are  shown  in  full  in  appendix  1. 
92 range  that  are  likely  to  fall  into  the  range  of  the  confidence  interval  is  just  19%  in  the 
main  sample  as  compared  to  48%  in  the  subgroup.  To  give  some  idea  of  the  importance 
of  predicting  the  effect  of  the  variance  within  a  distribution,  for  all  the  distributions 
simulated  the  average  proportion  of  total  costs  in  the  upper  quartile  was  60%. 
7.8  Summary 
The  purpose  of  this  chapter  was  to  show  that  as  well  as  measures  of  effectiveness,  costsi 
can  also  be  affected  by  characteristics  of  the  population  and  as  such  are  just  as  likely  to 
benefit  from  subgroup  analysis.  The  example  shown  in  this  chapter  also  shows  that, 
although  confidence  intervals  are  a  good  gauge  of  the  predictability  of  the  mean  value, 
because  of  the  shape  of  cost  distributions  they  may  not  be  the  only  measure  needed  for 
decision  makers  to  make  definitive  choices  on  resource  allocation. 
The  measurement  of  the  mean,  and  confidence  in  that  mean,  are  an  important  descriptive 
of  a  distribution.  If  the  distribution  is  a  normal  one,  it  can  be  argued  that  it  is  the  only 
descriptive  required  to  make  conclusions  of  that  distribution.  Where  a  distribution  is  not 
normal,  there  are  other  factors  to  take  into  account.  When  assessing  the  likely  cost  of  an 
intervention  it  is  the  area  under  the  curve  that  guides  the  decision-maker  and  the  likely 
effect  that  outliers  may  have  on  total  cost.  The  examples  analysed  in  this  chapter  show 
that  cost  distribution  can  be  skewed  to  the  extent  where  60%  of  total  costs  will  be  due  to 
25%  of  the  sample.  It  is  therefore  important  that  the  analysis  of  a  cost  distribution 
incorporates  a  measure  of  the  variance  and  shape  of  the  distribution. 
93 This  chapter  has  also  shown  that  pre-selected  subgroups  for  which  there  is  good  prior 
evidence  of  a  dependent  relationship  may  in  fact  be  being  undervalued  by  the  limits 
enforced  by  the  measurement  of  a  sample  based  purely  on  confidence  intervals.  With  an 
objective  of  minimising  the  risk  of  unpredictable  costs,  pre-selected  subgroups  have  been 
shown  to  be  a  potential  tool  in  cost  analysis.  The  next  section  will  take  this  further  by 
looking  at  measures  of  effectiveness  and  its  combination  with  cost  information  to  inform 
cost-effectiveness. 
94 8.  Measurement  of  cost-effectiveness 
8.1  Introduction 
The  potential  advantages  and  dangers  of  using  evidence  from  subgroup  analysis  to  inform 
policy  decisions  have  been  discussed  in  detail.  In  the  previous  chapter  we  started  to  look 
at  the  characteristics  of  subgroup  analysis  in  comparison  to  traditional  analysis.  We  have 
shown  that  costs  as  well  as  outcome  measures  can  have  strong  relationships  with 
covariates  and  that  when  the  relationship  is  strong,  the  variance  around  the  mean  of  a 
subgroup  can  be  smaller  than  the  study  data  as  a  whole.  This  chapter  takes  the  theory  of 
the  potential  advantages  of  subgroup  analysis  one  step  further  and  looks  at  both  the  costs 
and  effects  of  a  specific  intervention. 
Here  we  look  at  the  data  from  a  trial  that  evaluated  the  incremental  cost-effectiveness  of  a 
new  technology  in  treating  severely  ill  new  born  babies,  the  Extracorporeal  Membrane 
Oxygenation  (ECMO)  trial.  First  we  give  details  of  the  background  to  the  ECMO  trial, 
and  the  results  and  conclusions  that  were  published.  The  data  is  then  re-analysed  to  obtain 
the  measures  of  variance  that  had  not  been  calculated  in  the  original  study.  We  then 
calculate  ICERs  for  selected  subgroups  and  assess  the  potential  value  of  this  information 
in  improving  overall  health  gain. 
8.2  Extracorporeal  Membrane  Oxygenation  (ECMO)  Trial 
The  ECMO  trial  looked  to  compare  the  costs  and  outcomes  of  conventional  treatment  and 
the  incorporation  of  the  ECMO  technology.  Conventional  treatment  for  infants  in 
95 respiratory  failure  is  ventilation  with  high  level  oxygen.  Extracorporeal  membrane 
oxygenation  is  a  technique  that  oxygenates  blood  outside  the  body,  obviating  the  need  for 
gas  exchange  in  the  lungs,  and,  if  necessary,  providing  cardiovascular  support.  Intention 
to  treat  analysis  showed  that  extracorporeal  membrane  oxygenation  was  highly  clinically 
effective". 
A  preliminary  economic  evaluation  carried  out  before  the  trial  suggested  that 
extracorporeal  membrane  oxygenation  was  probably  more  effective  and  more  expensive 
than  conventional  management1°'.  It  also  showed  that  the  existing  evidence  on  cost 
effectiveness  was  inadequate  for  setting  priorities  because  the  uncertainty  surrounding  the 
data  was  too  great'oz 
The  economic  evaluation  of  the  ECMO  trial  was  a  cost-effectiveness  analysis  comparing 
extracorporeal  membrane  oxygenation  with  conventional  management  based  primarily  on 
the  principal  clinical  outcome  of  the  trial  (survival  without  severe  disability  at  age  1  year). 
The  economic  evaluation  was  conducted  from  the  viewpoint  of  the  NHS  and  so  includes 
only  direct  costs  to  the  health  service'o3 
Extracorporeal  membrane  oxygenation  was  provided  in  five  centres  and  babies  were 
recruited  from  55  UK  neonatal  centres.  Babies  were  eligible  for  the  trial  if  they  were 
mature  new-born  infants  with  severe  respiratory  failure.  They  were  randomised  either  to 
be  transferred  for  extracorporeal  membrane  oxygenation  or  to  receive  conventional 
management.  There  were  185  babies  in  the  trial,  of  which  93  (50.3%)  were  randomised 
into  the  ECMO  arm  with  92  (49.7%)  in  the  conventional  treatment  arm.  A  summary  of 
96 descriptive  variables  comparing  the  two  groups  at  randomisation  is  shown  in  Table  8.1, 
with  results  at  the  end  of  the  year  one  follow-up  in  Table  8.2. 
Health  service  use  was  divided  into  three  components:  mode  of  transport  used  for 
transfers  made  after  randomisation  until  discharge;  services  received  in  the  initial  hospital 
inpatient  stay  after  randomisation,  subdivided  by  level  of  intensity;  and  use  of  health 
services  from  discharge  up  to  1  year  of  age.  The  babies'  initial  hospital  treatment  was 
described  in  terms  of  five  levels:  days  receiving  extracorporeal  membrane  oxygenation; 
days  receiving  maximal  intensive  care  (more  than  90%  oxygen);  days  on  a  ventilator 
(receiving  less  than  90%  oxygen);  days  on  supplementary  oxygen;  and  days  in  normal 
care. 
Health  service  costs  for  each  patient  were  calculated  for  initial  hospital  stay,  post 
discharge  health  service  utilisation  and  transport  costs.  The  initial  stay  was  estimated 
based  on  unit  costs  of  days  under  extracorporeal  membrane  oxygenation,  days  under 
maximal  intensive  care  (more  than  90%  oxygen),  days  on  a  ventilator  (receiving  less  than 
90%  oxygen),  days  on  supplementary  oxygen  and  days  in  normal  care.  The  costs  for  each 
group  are  outlined  in  Table  8.3. 
Table  8.1:  Comparison  of  ECMO  and  `conventional  treatment'  arms 
Mean  Age  (hours) 
Mean  Gestation  (weeks) 
Mean  Birthweight  (grams) 
Most  recent  Oxygenation  Index  (01) 
ECMO  (n=93)  Conventional  (n=92) 
47.2  57.6 
38.8  39.2 
3261  3346 
69.4  72.1 
97 (Source:  Roberts  TE,  1998  `) 
Table  8.2:  Outcomes  at  one  year  of  ECMO  and  `conventional  treatment'  arms 
ECMO  (n=93)  Conventional  (n=92) 
Death  30  54 
Severe  disability  1  1 
Impairment  and  some  disability  12  4 
Impairment  and  no  disability  4  5 
No  impairment  or  disability  45  27 
Lost  to  follow-up  1  1 
(Source:  Roberts  TE,  1998  4) 
98 Table  8.3:  Costs  at  one  year  of  ECMO  and  `conventional  treatment'  arms 
ECMO  (n=93)  Conventional  (n=92) 
£f 
Initial  hospital  stay  1,603,267  476,409 
Additional  cost  of  death  30,352  58,536 
Transport  150,146  20,475 
Post  discharge  health  service  utilisation  153,059  88,739 
Total  1,936,824  644,180 
Mean  cost  per  case  20,826  7,002 
(Source:  Roberts  7 
A  cost-effectiveness  ratio  for  ECMO  in  new-born  babies  was  constructed  using  the  data 
set  described  above.  The  mean  cost  per  case  in  the  conventional  management  arm  was 
£7,002  compared  to  £20,826  in  the  ECMO  arm,  a  difference  of  £13,824  (95%  C.  I.  £9,660 
-;  E  17,984).  The  primary  outcome  of  the  intervention  was  number  of  lives  saved  without 
resulting  in  severe  disability.  For  the  conventional  arm  the  resulting  outcome  was 
achieved  in  36  of  92  (39.1  %)  whereas  in  the  ECMO  arm  this  was  achieved  in  61  of  93 
(65.6%),  a  difference  of  26.5%  (95%  C.  I.  12.4%  -  40.5%).  The  resulting  incremental  cost 
per  life  without  severe  disability  achieved  can  be  estimated  as  £52,244  within  the 
parameters  of  the  calculations  shown  in  table  8.4. 
99 Table  8.4:  Cost-effectiveness  estimation  at  one  year  of  ECMO  over  conventional 
treatment. 
ECMO  (n=93)  Conventional  Conventional  #  -1 
(n  =92)  (n  equivalent  93) 
Initial  hospital  stay  £1,603,267  £476,409  £481,587 
Additional  cost  of  death  £30,352  £58,536  £59,172 
Transport  £150,146  £20,475  £20,698 
Post  discharge  costs  £153,059  £88,739  £89,704 
Total  £1,936,824  644,180  £651,161 
Survival  no  disability  61  36  36.4 
Average  cost  per  survival 
with  no  disability  £31,751  £17,894 
Incremental  cost  of  ECMO  £1,285,663 
Incremental  cost  per  extra 
survival  with  no  disability  £52,244 
#  `Conventional'  costs  have  been  weighted  so  as  both  sets  of  costs  relate  to  93  patients. 
(Source:  Roberts  TE,  1998  4) 
The  conclusions  of  the  study  group  were  that  the  evidence  so  far  suggests  that 
Extracorporeal  membrane  oxygenation  can  be  as  cost  effective  as  many  other  life 
extending  technologies  regularly  used  in  developed  countries.  However,  it  does  include 
the  caveat  that  until  the  results  of  the  long  term  follow  up  studies  become  available,  this 
conclusion  should  be  viewed  with  some  caution. 
8.3  Stochastic  measurement  of  cost-effectiveness  of  ECMO 
As  has  been  discussed  in  earlier  chapters,  cost-effectiveness  analysis  has  moved  on 
recently  in  an  attempt  to  incorporate  measures  of  uncertainty  and  this  has  in  general  been 
through  the  introduction  of  confidence  intervals  for  cost-effectiveness  ratios.  The 
ii  , 
100 derivation  of  ICERs  where  there  are  individual  measures  of  effectiveness  and  cost  of  n 
patients  allows  us  to  calculate  a  stochastic  ICER.  Stochastic  measurement  is  where 
variables  are  determined  from  data  sampled  from  the  individuals  in  the  study,  as 
compared  to  deterministic  measurement  where  variables  are  analysed  as  point  estimates. 
If  both  costs  and  effects  are  determined  from  data  sampled  from  the  individual  patients  in 
the  study,  variances  are  available  and  so  formal  statistical  tests  can  be  performed  on 
observed  differences  in  costs  and  effects. 
Here  effectiveness  is  measured  as  a  binary  outcome  where  1  denotes  survival  without 
severe  disability  and  0  denotes  death  or  the  presence  of  severe  disability.  Our  ICER  is 
calculated  as 
R=  (CT  -  CC)  /  (ET  -  Ec),  where  CT  and  Cc  are  the  cost  of  new  treatment  and  conventional 
treatment  respectively  and  ET  and  Ec  are  the  effects  of  each. 
This  gives  us  a  two-dimensional  box  with  the  confidence  intervals  for  both  our  effects  and 
cost  sizes,  which  gives  us  a  quasi-confidence  area  shown  in  figure  8.1.  In  reality  the 
probability  of  the  true  ICER  of  the  ECMO  intervention  lying  on  either  slope  X  or  Y  is 
very  low,  less  than  0.5%,  and  that  both  intuitively  and  mathematically  the  true  confidence 
interval  area  is  likely  to  be  elliptical  in  shape1'. 
101 Figure  8.1:  Incremental  cost-effectiveness  ratio  (ICER)  of  ECMO 
technology  on  likelihood  of  survival  without  severe  disability 
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The  next  step  is  to  move  towards  this  true  form  of  our  confidence  area  through  the 
estimation  of  the  sampling  distribution  of  the  ratio.  The  most  common  application  for  this 
has  been  non-parametric  bootstrapping10s,  'ob  The  observed  data  for  cost  and  effects  are 
treated  as  an  empirical  probability  distribution  that  is  resampled  with  replacement  a  given 
number  of  times.  Each  resample  is  used  to  give  an  estimate  of  R.  These  estimates  are  then 
used  to  create  an  empirical  distribution  of  R  from  which  the  confidence  intervals  are 
constructed.  The  results  of  such  an  exercise  with  the  ECMO  data  are  shown  in  figures  8.2 
and  8.3  and  summarised  in  table  8.5. 
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Figure  8.2:  Scatterplot  of  (CT  -C,  )  against  (EE  -  E(.  )  on  cost-effectiveness  plane 
103 Figure  8.3:  Histogram  of  bootstrap  replicates  of  R (ICER)  probability  distribution. 
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Table  8.5:  Resulting  95%  percentile  ranges  from  bootstrap  replication  of  ICER. 
Variable  Mean  95%  confidence  interval 
Incremental  cost  of  ECMO 
Incremental  likelihood  of  survival 
Incremental  cost-effectiveness  ratio 
£13,824  (£5,958  -  £40,747) 
0.27  (0.15  -  0.39) 
£52,244  (32,521  -  95,137) 
When  these  simulations  are  undertaken,  there  can  be  a  tendency  for  replication  bias,  but 
this  is  considered  insignificant  if  measured  as  a  ratio  of  variance  of  under  0.1.  Bias  within 
the  replication  was  measured  as  a  ratio  of  variance  of  just  0.08  and  as  such  was  not 
considered  important"".  The  confidence  intervals  around  the  incremental  costs  and  effects 
104 alone  do  not  include  zero  and  are  positive,  whereas  the  ICER  confidence  interval  is 
stretched  somewhat  (figure  8.3). 
The  results  show  the  cost-effectiveness  ratio  to  be  fairly  uncertain  given  the  stochastic 
nature  of  the  bootstrapping  technique.  It  is  often  considered  unnecessary  to  simulate  the 
individual  cost  distributions  and  instead  the  difference  (CT  -  CC)  is  used  with  a  normal 
distribution.  This  is based  on  the  theory  that  the  distribution  around  the  mean  difference 
between  two  non-normal  distributions  is itself  normal. 
8.4  Undertaking  subgroup  analysis  with  the  ECMO  trial  data  set. 
Having  looked  at  the  analysis  of  the  study  as  a  whole,  we  now  turn  our  attention  to  the 
analysis  of  specific  subgroups.  The  potential  subgroups  in  the  study  were  that  of  birth 
weight,  gestation  age,  diagnosis  and  oxygenation  index  (0!  ).  These  are  listed  in  table  8.6. 
There  were  two  subgroups  by  birth  weight,  two  by  gestation,  three  by  diagnosis; 
congenital  diaphragmatic  hernia  (CDH),  idiopathic  persistent  foetal  circulation  (IPFC) 
and  persistent  pulmonary  hypertension  (PPH),  and  two  by  01. 
A  literature  search  was  conducted  using  `PubMed',  `Medline'  and  `HealthPro',  looking 
for  evidence  of  any  relationship  between  a  series  of  patient  characteristics  at 
randomisation  and  the  likely  outcome  of  the  usual  treatment  of  new  born  babies  with 
severe  respiratory  failure.  A  search  was  made  for  published  research  showing  a  strong 
empirical  relationship  between  the  primary  outcome  and  the  following  characteristics; 
sex,  age,  birth  weight,  gestation  age,  diagnosis  and  initial  oxygenation  index 
105 (OI)108109,110,111,112,113,114,  us  An  empirical  relationship  between  a  characteristic  variable  and 
the  primary  outcome  (survival)  was  assumed  to  be  present  where  an  odds-ratio  for 
survival  was  significant  at  the  5%  level  in  at  least  one  paper. 
The  selected  subgroups  for  outcome  variation  were  birth  weight,  diagnosis,  gestation  age, 
and  initial  01.  These  were  selected  for  having  a  strong  empirical  relationship  with 
outcomes.  Any  relationship  between  the  other  variables  and  the  primary  outcome  were 
either  too  small  or  inconclusive.  The  intention  is  to  compare  the  relative  value  of  the 
various  statistical  descriptive  measures  of  each  distribution,  both  the  overall  data  and  the 
individual  subgroups,  for  relevance  to  the  decision-maker. 
The  results  in  table  8.6  (and  in  figure  8.4)  show  that  overall  the  ECMO  intervention  had 
relatively  wide  confidence  intervals  (95%)  spanning  from  £35,521  to  £95,137,  which 
would,  under  classical  analysis,  make  the  acceptance  of  the  intervention  unlikely.  The 
subgroups  show  a  wide  variety  in  both  means  and  their  measures  of  variance,  shown  here 
in  terms  of  confidence  intervals.  Although  many  have  confidence  intervals  (C.  I.  )  that  are 
extremely  wide,  such  as  the  `CDH  diagnosis',  the  `gestation  >  275  days'  and  `0!  >  60', 
there  are  also  a  number  which  have  very  narrow  C.  I.,  such  as  the  `diagnosis  of  IPFC'  or 
`PPH'  and  `0I  =  40-59' 
106 Table  8.6:  Deterministic  ICERs  of  subgroups  with  confidence  intervals  of  stochastic 
analysis 
Subgroup  (no.  )  f  ICER  95  percentile  Percentile< 
confidence  intervals  £50,000/LS 
Birth  weight  <  3300  (1)  65,627  (39,639  -  137,317)  20% 
>  3300  (2)  28,738  (9,498  -  75,952)  85% 
Gestation  <  275days  (3)  63,417  (28,638  -  206,888)  30% 
>275  days  (4)  39,281  (22,637  91,789)  70% 
Diagnosis  CDH  (5)  164,900  (81,305  -  539,475)  0% 
IPFC  (6)  16,340  (1,958  -  44,430)  95% 
PPH  (7)  33,356  (16,568  -  77,879)  80% 
01  category  40-59  (8)  42,359  (22,334  -  86,210)  70% 
>60  (9)  74,218  (29,945  -  318,934)  20% 
Total  study  (10)  £52,244  (32,521  -  95,137)  45% 
For  details  of  simulations  see  appendix  2. 
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O  O  O  a  ý  U  c7  c7  ý  ý 8.5  Using  evidence  from  subgroup  analysis  and  traditional  analysis  for  policy 
To  compare  the  benefits  of  evidence  derived  from  subgroup  analysis  and  traditional 
analysis  in  making  policy  decisions,  we  need  a  policy  objective  to  address.  For  the 
purposes  of  illustration  let  us  use  a  hypothetical  policy  that  states  that  for  a  new  health 
care  technology  to  be  incorporated  into  practice  it  must  achieve  a  life  saved  at  a  cost  of 
under  £50,000.  In  essence  we  are  setting  an  upper  limit  of  incremental  cost-effectiveness 
for  new  interventions  that  wish  scarce  resources  to  be  diverted  towards  them.  This  is  not 
unlike  the  role  that  is  being  asked  of  the  National  Institute  of  Clinical  Excellence  with 
regard  to  new  technologies,  but  we  have  oversimplified  it  to  illustrate  and  quantify  the 
potential  benefits  of  subgroup  analysis. 
If  we  start  with  the  evidence  from  the  overall  study  it  is  clear  that  at  a  cost  per  life  saved 
of  £52,244,  our  policy  makers  would  be  directed  to  look  elsewhere  to  invest  in  a  new 
technology.  Our  directive  states  that  if  we  divert  resources  away  from  current  activities 
into  universal  ECMO  treatment  this  will  not  be  a  better  use  of  scarce  resources. 
Nevertheless  if  we  turn  our  attention  to  the  results  of  the  subgroup  analyses  there  is 
evidence  to  suggest  that  for  those  neonates  diagnosed  with  IPFC  this  is  very  much  a  cost- 
effective  use  of  resources.  As  such,  our  directive,  if  offered  the  option,  would  be  clear  in 
concluding  that  the  introduction  of  the  ECMO  technology  for  all  those  diagnosed  with 
IPFC  would  indeed  be  a  worthwhile  use  of  scarce  resources.  Even  in  terms  of  measures  of 
uncertainty  the  upper  limit  of  the  95%  confidence  intervals  for  this  subgroup  does  not 
cross  the  £50,000  threshold. 
III This  brings  us  onto  the  issue  of  uncertainty.  Although  the  mean  cost  per  life  saved  for  the 
PPH  subgroup  is  just  £33,356,  the  upper  limit  of  the  confidence  interval  extends  beyond 
the  £50,000  barrier  (at  £77,879).  This  would  be  thought  of  by  many  as  a  good  reason  to 
exclude  the  intervention  as  not  being  of  statistical  significance,  whereas  in  reality  80%  of 
the  distribution  around  the  mean  is below  the  £50,000  barrier.  There  are  additional 
examples  of  this  with  regards  to  birth  weight  over  3300  grams  (85%),  gestation  over  275 
days  (70%)  and  01  category  40-59  (70%). 
With  all  of  these  subgroups  it  is  more  likely  than  not  that  the  ECMO  technology  would, 
for  the  patient  in  question,  represent  a  cost-effective  treatment  option.  The  decision  to 
proceed  here,  becomes  a  subjective  one.  Probability  dictates  that  cost-effective  treatment 
is  likely,  but  not  certain.  The  cost-effectiveness  ratio  of  treating  this  baby  with  ECMO  is 
likely  to  be  very  favourable. 
Analysis  of  the  incremental  cost-effectiveness  of  ECMO  shows  us  that  with  a 
hypothetical  limitation  of  new  health  care  technologies  of  £50,000  per  life  saved,  ECMO 
would  not  be  considered  a  cost-effective  use  of  resources.  In  fact  traditional  statistical 
norms  would  probably  not  allow  the  introduction  of  this  new  technology  if  the  limit  were 
set  at  £60,000  because  the  95%  confidence  intervals  do  not  both  lie  inside  this  range. 
Nevertheless  the  analysis  of  the  subgroups  show  that  within  the  study  overall  there  are 
those  for  which  the  cost-effectiveness  of  ECMO  has  its  mean  value  lying  under  the 
instituted  limit  of  £50,000.  In  addition  it  also  has  the  full  range  of  it's  confidence  intervals 
(IPFC  subgroup  -  95%  C.  I.  1,958  -  44,430)  under  £50,000.  If  the  allocation  of  resources 
112 that  leads  to  a  state  of  optimisation  of  health  benefit  relies  on  performing  interventions 
only  if  they  provide  that  benefit  at  less  than  £50,000  then  here  is  a  group  of  patients  and 
an  intervention  that  fits  the  bill. 
Under  the  same  argument  of  optimisation,  we  are  aware  from  evidence  in  table  8.6  that 
other  groups  of  patients  would  more  likely  than  not  benefit  from  the  intervention  at  a  cost 
of  less  than  £50,000.  In  the  case  of  groups  2,4,6,7  and  8  patients  are  between  40%  and 
70%  more  likely  to  benefit  at  a  cost  of  less  than  £50,000  per  life  saved  than  not.  In  total 
five  of  the  nine  subgroups  can  justifiably  be  thought  to  be  more  likely  than  not  to  receive 
a  treatment  that  will  turn  out  to  be  cost  effective  if  undertaking  ECMO. 
So  if  our  mean  ratio  as  a  whole  is  over  the  £50,000  barrier,  at  £52,244,  how  can  it  be  the 
case  that  five  from  nine  subgroups  have  means  lying  under  the  same  barrier?  The  answer 
is  that  the  mean  of  the  whole  sample  is  dragged  up  by  those  subgroups  that  are  over  the 
barrier  to  a  greater  extent  than  the  groups  that  are  under  (i.  e.  there  is  a  skewed 
distribution).  This  is likely  to  be  common  wherever  you  have  a  distribution  that  is  heavily 
skewed  to  the  right.  As  can  be  seen  in  figure  8.4  (and  from  table  8.6)  those  subgroup 
means  that  lie  over  the  £50,000  have  upper  distribution  intervals  that  extend  away  well 
over  the  £150,000  and  three  of  them  over  the  £200,000  line.  In  comparison,  of  the  five 
groups  that  have  means  lying  under  the  £50,000  line,  none  approach  the  zero  line.  From 
this  a  logical  step  may  be  to  calculate  the  mean  ICER  for  ECMO  after  truncating  the 
distribution  through  the  exclusion  of  outliers.  This  would  inevitably  bring  down  the 
overall  mean  for  the  intervention  as  a  whole,  but  still  would  not  add  the  value  that  the 
113 evidence  from  the  subgroup  analysis  does  in  pinpointing  the  areas  of  best  investment  for 
the  ECMO  technology. 
The  likelihood  of  this  occurring  can  be  anticipated  by  looking  at  figure  8.3,  which  shows 
that  despite  the  mean  lying  over  £50,000,  the  bulk  of  the  histogram  of  the  probability 
distribution  lies  under  £50,000.  This  suggests  that  a  randomly  chosen  case  would  be  more 
likely  to  have  a  cost-effectiveness  ratio  of  under  £50,000  than  one  of  over  £50,000. 
Having  acknowledged  this  it  is  the  use  of  subgroup  analysis  that  allows  us  to  better 
identify  those  patients  that  lie  under  the  £50,000  line  and  those  that  lie  over  it.  This  will 
not  always  be  possible  as  in  many  circumstances  there  will  be  no  defining  covariates  (as 
was  the  case  in  ECMO)  and  the  distribution  will  be  truly  random. 
The  use  of  a  hypothetical  maximum  tariff  put  on  health  benefit  is  just  an  example  of  one 
method  that  could  be  used  to  direct  resource  allocation  towards  the  goal  of  welfare 
maximisation.  It  is  one  of  the  simpler  ones,  but  whatever  system  were  used  to  achieve  this 
end,  the  concept  behind  how  overall  health  gain  can  be  increased  within  a  limited  budget 
from  using  subgroup  evidence  for  directing  resource  allocation  is  still  valid. 
To  take  our  example  further  let  us  assume  that  there  was  only  one  need  for  health  care, 
and  that  was  to  maximise  health  benefits  for  new  born  infants  with  severe  respiratory 
failure.  There  are  two  methods  of  treatment;  conventional  management  and  conventional 
management  with  the  addition  of  ECMO.  We  are  left  with  a  policy  decision  with  which  to 
make  the  best  use  of  our  limited  resources  which  involves  choosing  from  one  of  three 
options. 
114 1.  Incorporate  ECMO  into  standard  care 
2.  Do  not  incorporate  ECMO  into  standard  care 
3.  Selectively  incorporate  ECMO  into  standard  care 
If  the  choice  were  between  1  and  2,  then  given  that  the  average  cost-effectiveness 
(ACER)  of  conventional  treatment  without  ECMO  is  estimated  at  £  18,000  per  survivor 
without  severe  disability,  and  with  ECMO  it  is  estimated  at  £32,000  it  is  unlikely  that 
ECMO  would  be  funded.  Nevertheless  if  the  policy  were  selective  within  subgroups,  then 
the  marginal  cost  of  ECMO  would  be  considered  an  efficient  use  of  resources  within  a 
limited  budget  for  neonates  diagnosed  with  IPFC.  In  fact  every  pound  spent  on  ECMO  in 
these  groups  would  result  in  more  health  gain  than  a  pound  spent  on  conventional 
management. 
Furthermore  if  we  look  at  multi-characteristic  subgroups  such  as  neonates  with  a  birth 
weight  over  3300  grams  and  a  diagnosis  of  IPFC,  we  find  an  ICER  of  just  £9,513.  Here,  a 
pound  spent  on  ECMO  for  this  group  of  patients  is likely  to  gain  twice  the  health  gain  of 
a  pound  spent  on  conventional  management.  The  probability  is  not  95%  but  the 
simulation  shows  it  to  be  70%  likely  that  the  ICER  of  ECMO  for  this  group  will  fall 
under  the  ACER  of  conventional  management.  To  continue  with  a  strategy  of  not 
incorporating  ECMO  into  treatment  for  such  a  group  of  patients  is  to  disregard  a  likely 
improvement  in  overall  health  gain. 
115 8.6  Comparing  evidence  from  traditional  and  subgroup  analysis 
To  measure  the  potential  value  of  subgroup  analysis  there  is  a  need  to  compare  the  results 
of  a  policy  decision  based  on  this  method  with  a  policy  decision  based  on  the  more 
traditional  methods.  To  do  this  we  will  take  the  evidence  from  both  types  of  analysis  and 
assume  the  appropriate  decision  based  on  our  hypothetical  directive.  This  is  to  ensure  that 
new  technologies  must  show  that  they  save  lives  at  a  cost  of  less  than  £50,000.  We  also 
assume  that  this  figure  is  chosen  due  to  the  fact  that  the  health  care  that  is  already  funded 
is done  so  at  a  level  not  above  the  cost  of  £50,000  for  every  life  year  gained. 
The  decision  given  traditional  methods  of  analysis  is  a  simple  one.  The  ICER  is  £52,244 
and  as  such  the  ECMO  technology  would  not  be  considered  cost-effective  and  as  such 
there  will  be  no  change  to  resource  allocation  and  no  resulting  increase  or  decrease  in 
overall  health  gain. 
In  the  case  of  subgroup  analysis,  the  results  can  be  used  in  two  ways;  to  incorporate  those 
subgroups  for  which  the  95%  confidence  intervals  fall  below  £50,000  (option  one). 
Option  two  would  be  to  incorporate  those  subgroups  for  which  more  than  50%  of  the 
likely  distribution  has  a  cost-effectiveness  that  falls  below  £50,000. 
For  option  one  this  is  simply  the  subgroup  who  are  diagnosed  with  IPFC  with  a  mean 
ICER  of  £16,340  (95%  C.  I.  £1,958  -  £44,430).  If  the  ECMO  technology  was  offered  just 
to  this  group  the  resulting  mean  health  gain  per  patient  would  be  £33,660  (£50,000  - 
£16,340)  per  patient  treated,  or  the  equivalent  to 
=1x  life  saved  x  £33,660 
£50,000 
116 =  0.67  lives  saved  per  patient  treated. 
We  would  also  be  95%  certain  that  the  mean  health  gain  would  be  at  least  £5,570  per 
patient  treated  or 
=1  x  life  saved  x  £5,570 
£50,000 
=  0.11  lives  saved  per  patient  treated. 
Table  8.7:  Mean  ICERs  for  subgroups,  proportionate  confidence  in  mean  and 
proportion  of  total  patients. 
Subgroup  (no)  ICER  Percentile< 
X50,000/LS 
Proportion 
of  n  (total) 
Allocate 
resources  to 
Birthweight  <  3300  (1)  65,627  20%  51%  No 
>  3300  (2)  28,738  85%  49%  Yes 
Gestation  <  275days  (3)  63,417  30%  46%  No 
>275  days  (4)  39,281  70%  54%  Yes 
Diagnosis  CDH  (5)  164,900  0%  20%  No 
IPFC  (6)  16,340  95%  17%  Yes 
PPH  (7)  33,356  80%  63%  Yes 
01  category  40-59  (8)  42,359  70%  60%  Yes 
>60  (9)  74,218  20%  40%  No 
Total  study  (10)  £52,244  45%  100%  - 
With  option  two  the  conclusion  would  be  to  incorporate  the  ECMO  technology  far  more 
than  with  option  one,  as  it  would  include  subgroups  2,4,6,7  and  8.  This  would  leave  us 
with  the  policy  summarised  in  table  8.7.  We  can  show  that  the  mean  health  gain  per 
patient  treated  can  be  estimated  if  we  assume  the  same  proportions  of  each  subgroup  as 
was  witnessed  in  the  study.  As  with  option  one  we  can  show  the  anticipated  mean  health 
117 gain  on  the  basis  of  resources  gained  or  an  equivalent  lives  saved  per  patient  treated 
assuming  that  all  other  interventions  currently  being  provided  have  a  marginal  cost- 
effectiveness  of  £50,000  per  life  saved. 
Table  8.8:  Mean  ICERs  for  subgroups,  proportionate  confidence  in  mean, 
proportion  of  total  patients  and  marginal  lives  saved  per  patient  treated. 
Subgroup  selected  (no)  ICER  Percentile<  Proportion  Marginal 
f50,000/LS  of  n  (total)  lives  saved 
per  patient 
treated 
Birthweight  >  3300  (2) 
Gestation  >275  days  (4) 
Diagnosis  IPFC  (6) 
PPH  (7) 
01  category  40-59  (8) 
28,738  85%  49%  0.43 
39,281  70%  54%  0.21 
16,340  95%  17%  0.67 
33,356  80%  63%  0.33 
42,359  70%  60%  0.15 
Total  I-  80%  100%  0.27 
The  results  in  table  8.8  show  the  mean  lives  saved  per  subgroup  per  patient  treated,  and 
also  the  total  mean  health  gain  per  person  treated  given  the  weighting  of  the  proportion  of 
total  patients  from  each  subgroup.  However  this  figure  of  a  mean  0.27  lives  saved  per 
person  treated  is  not  significant  at  the  5%  level.  We  do  however  have  80%  confidence 
that  there  will  be  a  positive  mean  improvement  in  overall  health  gain  given  this  strategy. 
In  other  words  it  is 80%  probable  that  for  every  100  babies  treated  with  ECMO  27  lives 
(without  severe  disability)  will  be  saved  at  a  cost  of  less  than  £50,000  per  life  year  saved. 
The  obvious  conclusion  from  this  is  that  without  the  use  of  subgroup  analysis  in  making  a 
118 decision  on  funding  ECMO  technology  for  certain  groups  of  new  born  babies  the  result 
could  be  a  not  considerable  number  of  lives  lost. 
8.7  Summary 
We  have  shown  in  the  analysis  of  this  particular  data  set  that  when  the  goal  of  health  care 
is  to  maximise  health  gain  within  the  financial  constraints  set  upon  it,  whatever  they  may 
be,  the  decision  to  treat  is  a  complex  one.  The  choice  as  to  whether  to  introduce 
treatments  in  health  care  has  historically  tended  to  be  a  simple  yes  or  no.  This  has  merit  in 
having  a  transparency  and  measure  of  robustness  that  ensures  that  policy  makers  are  never 
seen  to  be  making  the  wrong  decision.  The  question  this  chapter  and  indeed  this  thesis 
puts  forward  is  while  being  seen  to  be  making  the  right  decision,  are  we  in  fact  denying 
ourselves  the  opportunity  to  get  closer  to  achieving  our  primary  goal,  that  of  maximising 
health  gain. 
119 9.  Discussion 
9.1  Introduction 
Policy  makers  with  the  goal  of  maximising  health  gain  for  a  population  require  evidence 
on  the  health  benefits  of  potential  uses  of  scarce  health  care  resources  and  the  cost  of 
achieving  them.  This  evidence  has  historically  been  based  on  the  average  effectiveness  of 
an  intervention  on  a  representative  sample,  with  the  assumption  that  questions  about  the 
value  to  a  population  of  a  given  intervention  should  be  answered  with  a  single  value.  The 
problem  with  this  is  that  it  ignores  the  fact  that  a  population  is heterogeneous.  Just  as  it  is 
important  for  a  doctor  to  relate  the  results  of  a  trial  specifically  to  the  characteristics  of  the 
patient,  it  is imperative  that  policy  makers  take  the  evidence  from  economic  evaluations 
and  relate  them  to  any  given  population  or  elements  within  that  population. 
The  mean  cost-effectiveness  ratio  of  an  intervention  is  the  average  of  a  group  of  patient 
specific  total  costs  and  patient  specific  measures  of  effectiveness  for  a  heterogeneous 
sample.  As  such  the  population  from  which  the  study  was  sampled  will  often  be  made  up 
of  some  patients  for  whom  an  intervention  is  highly  cost-effective  and  some  for  which 
that  intervention  will  not  be  cost-effective.  The  question  is  whether  it  is  possible  for  us  to 
predict  those  people  for  whom  the  cost-effectiveness  ratios  will  be  high  and  those  people 
for  which  a  specific  intervention  will  have  a  low  cost-effectiveness  ratio.  If  this  is 
possible,  will  the  ability  to  do  this  lead  to  a  better  use  of  finite  resources  to  improve 
overall  health  gain? 
120 This  thesis  started  with  the  hypothesis  that  policy  decisions  regarding  resource  allocation 
in  health  care  could  be  improved  by  a  greater  concentration  on  the  use  of  the  results  of 
subgroup  analysis.  It  is  argued  that  information  on  the  heterogeneity  of  populations  is 
valuable  in  maximising  health  gain.  The  methods  used  in  economic  evaluation  have 
progressed  enormously  over  the  last  twenty  years,  and  one  of  the  biggest  areas  of  progress 
has  been  in  the  movement  away  from  deterministic  measurement  of  cost-effectiveness 
ratios  and  towards  stochastic  methods.  It  is  these  methods  that  have  allowed  us  to 
measure  uncertainty  and  show  the  distributions  around  the  means  of  these  ratios.  The 
most  common  measure  of  this  variance  has  been  the  confidence  interval. 
The  purpose  of  the  confidence  interval,  and  of  statistical  inference  in  general,  is  to 
measure  the  degree  of  certainty  we  have  in  our  estimated  mean.  The  reason  such  a 
technique  is  required  is  that  most  of  the  things  we  wish  to  measure  we  cannot  do  with 
great  accuracy,  and  as  such  attempt  to  cancel  out  this  `white  noise'  by  making  our 
measurement  repeatedly  and  taking  an  average.  If  our  method  of  measurement  were  100% 
reliable  this  technique  would  not  be  required. 
When  collecting  the  patient  specific  costs  and  outcomes  that  are  required  for  stochastic 
analysis  the  variation  in  our  data  is  not  just  made  up  of  the  white  noise  of  measurement 
distortion,  but  also  includes  genuine  variation  due  to  real  heterogeneity  of  our  sample. 
This  in  turn  is  due  to  the  fact  that  true  heterogeneity  exists  within  a  population.  The  use  of 
statistical  inference  where  we  know  that  any  variation  will  be  due  to  the  inadequacies  of 
the  measurement  tool  is  sensible  and  scientific.  Where  we  aware  that  the  cause  of 
variation  is  at  least  in  part  due  to  the  heterogeneity  of  the  variable  being  measured, 
121 consideration  must  be  given  to  whether  this  method  is  less  reliable.  In  truth,  we  know  that 
if  another  sample,  however  large,  was  used  to  measure  this  variable  we  could  not 
guarantee  a  similar  result  without  a  similarly  heterogeneous  sample. 
These  issues  raise  a  number  of  issues  that  relate  both  to  study  design  for  cost- 
effectiveness  analyses  and  the  interpretation  of  the  results  of  these  studies  when 
translating  them  into  policy.  We  look  at  both  of  these  areas  in  turn. 
9.2  Implications  for  cost-effectiveness  analysis 
As  we  seek  to  describe  in  more  detail  the  relationship  between  specific  health  care 
technologies  and  their  relative  value  in  different  situations  we  start  to  question  the 
reliance  on  classical  statistical  inference  methods,  which  rely  so  heavily  on  certainty. 
Where  we  have  a  closer  grasp  of  what,  and  by  how  much,  other  determinant  variables 
effect  our  chosen  measure  of  outcome  this  will  inevitably  help  to  determine  the  extent  to 
which  that  outcome  was  achieved  by  the  intervention  being  studied. 
The  purpose  of  inference  is  to  try  to  show  that  a  relationship  between  an  intervention  and 
an  outcome  exists  beyond  any  reasonable  doubt.  This  will  be  the  goal  of  a  study  where, 
prior  to  the  start  of  the  trial,  our  knowledge  of  any  relationship  is  zero.  However,  this  is 
rarely  the  case  as  we  often  do  have  knowledge  of  relationships  between  factors  and  likely 
outcomes,  both  in  terms  of  cost  (as  shown  in  chapter  7)  and  in  effects  (as  shown  in 
chapter  8).  As  such  what  we  are  searching  for  is  not  so  much  proof  as  a  greater  belief  in 
what  we  already  anticipated. 
122 In  the  previous  chapter  we  compared  the  relative  merits  of  traditional  analysis  against 
subgroup  analysis.  The  conclusions  were  that  subgroup  analysis  could  achieve  an 
improvement  in  overall  health  gain  based  on  the  hypothetical  objectives  described.  These 
conclusions  were  based  on  a  higher  likelihood  of  a  positive  increase  in  health  gain 
compared  to  traditional  analysis.  The  difference  was  not  measured  by  inference,  but  by 
probability.  This  brings  us  onto  assessing  the  relative  merits  of  policy  decisions  based  on 
probability  versus  those  based  on  the  need  to  prove  an  outcome  beyond  any  reasonable 
doubt. 
9.3  Implications  for  policy  decisions 
This  thesis  argues  for  optimisation  in  the  use  of  data  from  economic  evaluations  rather 
than  the  current  aspiration  for  certainty.  It  is  the  evidence  that  an  event  is  more  likely  than 
not  to  happen  that  most  decisions  are  made  on.  More  certainty  becomes  necessary  when 
the  costs  of  getting  the  decision  wrong  outweigh  the  benefits  of  getting  it  right.  This  is 
often  the  case  in  medical  research,  where  society  needs  to  be  assured  that  a  new  drug  is 
both  effective  and  safe.  The  question  remains  is  -  is  this  a  lesser  concern  when  dealing 
with  less  dichotomous  outcomes  such  as  cost-effectiveness? 
The  costs  of  approving  a  new  drug  or  technology  that  turn  out  to  have  significant  negative 
side  effects  are  likely  to  be  high.  However,  the  approving  of  a  new  drug  or  technology 
that  has  been  shown  to  be  effective  based  on  less  certain  proof  of  its  cost-effectiveness  is 
unlikely  to  be  considered  by  society  as  such  a  high  cost  if  proved  later  to  be  incorrect. 
123 It  can  be  argued  that  it  is  just  as  important  to  measure  cost-effectiveness  correctly  as  it  is 
to  measure  the  effects  of  an  intervention  correctly  as  the  results  of  getting  it  wrong  are  the 
misallocation  of  resources.  This  could  lead  to  someone  somewhere  missing  out  on 
valuable  treatment.  This  is  not  in  dispute,  but  it  is  suggested  that  a  measurement  of  a 
continuous  variable  such  as  a  cost-effectiveness  ratio  is  more  transparent  represented  as  a 
measure  of  probability.  Whereas  a  dichotomous  outcome,  for  example  to  answer  whether 
something  is  to  be  considered  safe  or  not,  may  benefit  more  from  being  measured  using  a 
method  that  has  the  intention  of  showing  some  degree  of  confidence  or  certainty. 
In  theory  for  every  potential  intervention  and  for  every  potential  receiver  of  that 
intervention  there  is  a  specific  relationship  that  will  produce  a  unique  cost-effectiveness 
ratio.  The  maximisation  of  health  gain  comes  from  finding  the  cost-effectiveness  of  every 
intervention  for  every  individual  within  our  population.  Only  then  can  decisions  be  made 
on  a  shift  in  resource  allocation  that  will  improve  overall  health  gain.  The  problem  can 
therefore  be  seen  as  one  of  availability  of  information  more  than  of  economic  theory. 
This  thesis  has  shown  that  there  is  a  wide  variance  in  a  singular  measure  of  cost- 
effectiveness  and  therefore  there  exists  the  possibility  for  an  improvement  in  health  gain 
if  decision-makers  were  given  access  to  more  of  the  information  available  in  a  form  that 
would  aid  them  in  making  decisions.  It  is  suggested  that  a  greater  use  of  subgroup 
evidence  should  be  made  available  to  decision-makers.  This  use  of  more  specific  cost- 
effectiveness  ratios  for  more  specific  groups  within  the  population  could  be  a  movement 
towards  welfare  maximisation,  which  could  result  in  greater  efficiency  in  the  delivery  of 
health  care. 
124 9.4  In  defence  of  subgroup  analysis 
A  number  of  concerns  could  be  raised  in  the  increased  use  of  subgroup  analysis  to  inform 
policy  decisions.  Two  of  these  are  that  of  sample  size  and  that  of  `fishing'  for  results  that 
may  not  be  there.  It  is  commonly  believed  that  because  subgroups  have  smaller  sample 
sizes,  the  rigour  of  the  results  may  suffer.  Statistical  power,  however,  relies  on  two  things, 
effect  size  and  sample  size,  and  as  such  subgroups  can  often  have  narrower  confidence 
intervals  and  by  definition  be  more  robust  than  the  overall  effect  size  of  a  study  due  to  the 
greater  effect  size  outweighing  the  smaller  sample  size.  In  addition  the  greater 
homogeneity  of  subgroups,  chosen  on  the  basis  of  reducing  the  heterogeneity  present  in 
the  overall  study  population,  will  reduce  the  measure  of  variance  (standard  deviation)  and 
correspondingly  reduce  the  width  of  the  confidence  intervals. 
In  terms  of  the  issue  of  `fishing'  it  is  imperative  that  subgroups  are  selected  based  on 
sound  evidence  as  was  done  in  chapters  7&8.  On  a  more  instinctive  level  it  seems  that 
those  against  the  use  of  subgroup  analysis  are  actually  saying  we  should  put  our  faith  in 
statistical  techniques  for  one  group  of  numbers  (the  overall  trial  results),  but  that  the 
techniques  may  be  unreliable  used  in  another  set  of  numbers  (the  subgroups).  This  is  both  ￿ 
illogical  and  lacks  objectivity. 
9.5  Summary 
Inevitably  the  response  to  a  proposal  for  a  greater  use  of  subgroup  analysis  as  a  means  of 
increasing  overall  health  gain  is  an  argument  for  optimisation  over  certainty,  for 
125 probability  over  statistical  significance.  It  is  argued  that  it  is  imperative  that  we  are  able  to 
assess  whether  an  intervention  can  improve  the  health  of  a  patient,  but  the  question  we 
really  want  an  answer  to  is  to  what  extent  can  it  improve  the  health  of  the  patient?  The 
certainty  associated  with  statistical  significance  can  only  be  used  to  answer  a  normative 
question.  If  the  p  value  is less  than  0.05  or  the  confidence  intervals  do  not  include  zero  we 
are  95%  certain  we  have  an  effective  intervention.  We  are  not  95%  certain  that  the  level 
of  effectiveness  is  equivalent  to  the  mean. 
Such  a  normative  answer  would  not  allow  us  to  assess  the  value  of  the  intervention 
compared  to  others  that  could  be  funded  in  its  place.  In  most  cases  we  are  using  an 
estimate  of  the  effectiveness  of  an  intervention  for  decision  making  that  has  no  greater 
specific  validity  than  any  other  figure  that  might  lie  within  the  confidence  range.  The 
confidence  is  in  the  range  not  in  the  mean.  As  such  the  mean  provides  a  measure  of 
likelihood,  not  of  certainty. 
The  use  of  such  an  estimate  is  not  something  that  this  thesis  is intending  to  degrade.  It  is 
the  belief  of  this  thesis  that  most  effect-size  information  at  our  disposal  is  not  much  more 
than  a  measure  of  likelihood  and  those  measures  of  likelihood  gained  from  subgroup 
analysis  are  just  as  robust  and  valuable  as  those  gained  from  the  totals  of  trials.  It  is  also 
suggested  that  in  many  cases  the  measure  of  likelihood  in  a  subgroup  might  be  more 
robust  than  those  based  on  a  total,  due  to  the  variation  of  the  subgroup  being  limited  to 
the  white  noise  of  measurement  distortion  and  not  the  effects  of  heterogeneity. 
126 Figure  9.1:  Mean,  variance  and  distribution  for  total  study  and  for  subgroup  I&  II 
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For  example,  we  have  a  variable  that  we  believe  to  be  a  factor  in  the  effect  size  of  an 
intervention  and  we  therefore  define  two  subgroups  (I  &  II)  of  those  with  and  those 
without  the  presence  of  this  variable.  If  the  variable  is  a  factor  that  does  influence  the 
effect  size  it  is  likely  that  the  distribution  around  the  mean  effect  within  each  of  those 
subgroups  will  be  narrower  than  that  around  those  receiving  the  intervention  as  a  whole  as 
the  variation  will  be  limited  solely  to  measurement  distortion.  As  such  the  variance 
around  that  mean  would  be  smaller  (see  figure  9.1).  When  an  intervention  is  introduced 
on  the  basis  of  an  anticipated  effectiveness  defined  by  the  estimated  mean,  the  benefit  will 
be  maximised  where  the  true  effectiveness  lies  closest  to  that  estimated  mean,  or  where 
the  true  variance  from  that  mean  is  small. 
The  value  of  evidence  from  subgroup  analysis  will  always  be  a  matter  of  debate  as  far  as 
statisticians  are  concerned  because  it  is  their  objective  to  search  for  a  definitive  proof. 
127 This  they  have  subjectively  categorised  as  95%  probable  and  for  which  in  general  we 
require  sizeable  sample  sizes  to  achieve.  In  reality  we  must  question  whether  the  value  of 
this  definition  of  certainty  has  been  pitched  too  high,  and  whether  the  trade-off  of  being 
able  to  use  data  to  answer  more  questions  with  less  certainty  may  indeed  outweigh  the 
benefits  from  answering  fewer  questions  with  greater  certainty. 
128 10.  Conclusions 
The  goal  of  health  economics  and  of  most  health  systems  is  primarily  one  of  welfare 
improvement  with  an  underlying  trend  towards  the  maximisation  of  expected  welfare. 
This  thesis  questions  whether  the  current  system  of  collecting  and  using  evidence  for 
policy  making  in  health  care  is  the  best  available  method,  given  this  goal,  and  concludes 
that  it  may  well  not  be. 
Given  the  heterogeneous  nature  of  a  population,  it  is  likely  that  for  most  health  care 
interventions  the  cost  of  care  and  the  outcome  from  that  intervention  will  vary  widely  as  a 
result  of  this  heterogeneity.  The  mean  ICERs  that  we  tend  to  use  for  policy  decisions  will 
therefore  be  surrounded  by  a  distribution  of  patient  specific  ICERs  that  may  differ  greatly 
from  the  mean.  This  thesis  believes  the  variation  surrounding  these  ICERs  can  be  traced 
specifically  to  the  heterogeneity  of  the  population,  and  in  some  instances  be  used  to 
greater  predict  the  likely  ICER  of  an  intervention  for  that  population. 
In  addition  it  is believed  that  using  the  relationship  between  different  characteristics  of  a 
population  and  the  outcomes  of  different  health  care  interventions,  will  lead  to  a  more 
efficient  use  of  health  care  resources.  The  under-utilisation  of  this  information  could  mean 
that  we  continue  with  an  inefficient  use  of  health  care  resources. 
This  thesis  suggests  that  there  remains  an  over  reliance  in  cost-effectiveness  analysis  on 
classical  statistical  techniques.  This  dependency  on  certainty  stems  from  the  fact  that  the 
methods  involved  were  originally  devised  to  measure  dichotomous  outcomes  not 
continuous  outcomes  such  as  cost-effectiveness  ratios. 
129 It  is  argued  that  more  consideration  be  given  to  the  heterogeneous  nature  of  populations 
when  both  analysing  and  using  data  from  economic  evaluations  in  making  policy 
decisions.  In  addition  it  is  suggested  that  optimisation  in  resource  allocation  can  be 
improved  with  a  greater  concentration  on  likelihood  of  relative  cost-effectiveness  rather 
than  the  current  over  reliance  on  arbitrary  measures  of  certainty. 
It  is  the  belief  of  this  thesis  that  the  implications  of  this  given  the  evidence  from  chapter  8 
are  that  the  health  benefits  being  produced  from  the  scarce  health  care  resources  are  not 
being  maximised.  It  is  also  the  belief  of  this  thesis  that  this  is due  to  the  fact  that  the 
heterogeneity  of  populations  are  not  considered  enough  in  decision-making  and  that 
subgroup  analysis  is  underused. 
These  points  can  only  be  confirmed  with  greater  research  into  available  evidence  from 
large  trials  where  subgroup  analysis  is  likely  to  be  advantageous,  or  where  there  are 
empirical  predictors  of  outcomes.  In  addition  there  needs  to  be  an  audit  of  interventions  or 
technologies  which  have  been  accepted  into  clinical  practice  due  to  its  overall  cost- 
effectiveness,  but  which  may  have  subgroups  of  the  population  receiving  treatment  which 
may  not  be  cost-effective  for  them  and  therefore  not  an  optimal  use  of  scarce  resources. 
Such  research  would  serve  to  validate  the  results  of  this  thesis  and  potentially  confirm  the 
value  of  greater  use  of  subgroup  analysis  in  policy  decision-making. 
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147 Appendix  1 
Results  of  simulations  of  PRAIS  UK  data  set 
Figures  1-6  Histograms  of  simulation  results 
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Figure  1:  Histogram  of  total  sample  -  PRAIS  UK 
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Figure  2:  Histogram  of  subgroup  by  age:  <  60  -  PRAIS  UK 
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150 Age  -  60-74  subgroup  plot 
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Figure  3:  Histogram  of  subgroup  by  age:  60-74  -  PRAIS  UK 
151 Age  -  75+  subgroup  plot 
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Figure  4:  Histogram  of  subgroup  by  age:  75+  -  PRAIS  UK 
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Figure  5:  Histogram  of  subgroup  by  ECG:  Normal  -  PRAIS  UK 
153 ECG  -  Complications  subgroup  plot 
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Figure  6:  Histogram  of  subgroup  by  ECG:  complications  -  PRAIS  UK 
154 PRAIS  UK  study  data  (n=1046) 
Patient  Procedures  Hospital  Drug  cost  Admission 
study  no.  cost  stay  cost  cost 
1  500.00  833.00  9.87  1342.87 
2  0.00  357.00  5.49  362.49 
3  0.00  357.00  3.42  360.42 
4  1428.00  476.00  5.64  1909.64 
5  0.00  943.00  6.06  949.06 
6  0.00  934.00  2.88  936.88 
7  0.00  586.00  20.79  606.79 
8  0.00  824.00  11.60  835.60 
9  620.00  1190.00  10.10  1820.10 
10  0.00  476.00  7.04  483.04 
11  120.00  1529.00  89.50  1738.50 
12  0.00  1547.00  18.33  1565.33 
13  0.00  952.00  8.08  960.08 
14  0.00  0.00  0.00  0.00 
16  120.00  595.00  7.05  722.05 
17  0.00  238.00  2.86  240.86 
18  0.00  943.00  20.82  963.82 
19  0.00  119.00  1.12  120.12 
20  0.00  1062.00  21.54  1083.54 
21  0.00  357.00  0.87  357.87 
22  0.00  0.00  0.00  0.00 
23  0.00  238.00  3.66  241.66 
24  0.00  824.00  7.15  831.15 
25  0.00  467.00  4.06  471.06 
26  0.00  238.00  2.90  240.90 
27  1428.00  238.00  2.24  1668.24 
28  0.00  833.00  12.32  845.32 
29  0.00  952.00  17.28  969.28 
30  120.00  476.00  4.48  600.48 
31  120.00  943.00  26.94  1089.94 
32  500.00  952.00  11.28  1463.28 
33  0.00  595.00  3.60  598.60 
34  120.00  824.00  25.30  969.30 
35  0.00  238.00  2.94  240.94 
36  0.00  595.00  5.05  600.05 
37  0.00  595.00  5.70  600.70 
38  120.00  1172.00  8.58  1300.58 
39  0.00  595.00  5.90  600.90 
40  1548.00  2133.00  53.30  3734.30 
41  1548.00  2948.00  70.78  4566.78 
42  0.00  2234.00  66.53  2300.53 
43  0.00  1776.00  34.83  1810.83 
44  0.00  1520.00  7.07  1527.07 
45  1428.00  1172.00  41.58  2641.58 
46  0.00  2600.00  60.72  2660.72 
47  0.00  714.00  10.98  724.98 
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48  1428.00  357.00  2.37  1787.37 
49  0.00  1904.00  22.88  1926.88 
50  0.00  357.00  1.56  358.56 
51  1428.00  467.00  20.82  1915.82 
52  1428.00  2023.00  13.77  3464.77 
53  0.00  714.00  0.60  714.60 
54  0.00  357.00  5.10  362.10 
55  0.00  467.00  19.32  486.32 
56  0.00  833.00  7.98  840.98 
57  120.00  595.00  3.95  718.95 
58  0.00  952.00  6.48  958.48 
59  0.00  2838.00  61.60  2899.60 
60  120.00  119.00  0.52  239.52 
61  0.00  119.00  0.79  119.79 
62  0.00  467.00  2.28  469.28 
63  0.00  238.00  0.78  238.78 
64  0.00  119.00  0.50  119.50 
65  0.00  348.00  0.52  348.52 
66  0.00  943.00  4.74  947.74 
67  0.00  1547.00  10.53  1557.53 
68  0.00  1520.00  2.73  1522.73 
69  0.00  1529.00  3.51  1532.51 
70  0.00  476.00  1.56  477.56 
71  0.00  824.00  7.70  831.70 
72  0.00  357.00  4.80  361.80 
73  0.00  824.00  1.45  825.45 
74  0.00  467.00  4.28  471.28 
75  0.00  1172.00  2.34  1174.34 
76  120.00  1300.00  27.39  1447.39 
77  0.00  824.00  3.95  827.95 
78  0.00  943.00  3.00  946.00 
79  120.00  357.00  2.43  479.43 
80  0.00  0.00  14.52  14.52 
81  0.00  952.00  6.48  958.48 
82  0.00  467.00  0.78  467.78 
83  0.00  357.00  3.36  360.36 
84  0.00  2243.00  64.50  2307.50 
85  0.00  476.00  3.16  479.16 
86  0.00  3561.00  33.88  3594.88 
87  0.00  3406.00  97.89  3503.89 
88  0.00  595.00  6.05  601.05 
89  2810.00  1904.00  20.00  4734.00 
91  500.00  476.00  0.40  976.40 
92  120.00  476.00  0.40  596.40 
93  500.00  0.00  1.58  501.58 
94  0.00  476.00  3.24  479.24 
95  0.00  1291.00  38.53  1329.53 
96  120.00  952.00  9.68  1081.68 
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97  2048.00  1181.00  22.98  3251.98 
98  0.00  595.00  4.05  599.05 
99  2810.00  1181.00  17.30  4008.30 
100  0.00  476.00  4.84  480.84 
101  0.00  0.00  0.00  0.00 
102  0.00  119.00  0.81  119.81 
103  0.00  238.00  0.78  238.78 
104  0.00  1071.00  3.51  1074.51 
105  0.00  0.00  0.00  0.00 
106  0.00  1071.00  14.40  1085.40 
107  0.00  348.00  0.39  348.39 
108  0.00  348.00  0.29  348.29 
109  0.00  119.00  0.79  119.79 
110  0.00  0.00  0.00  0.00 
111  0.00  833.00  10.78  843.78 
112  0.00  238.00  1.62  239.62 
113  0.00  1547.00  10.53  1557.53 
114  0.00  595.00  7.70  602.70 
115  0.00  586.00  2.43  588.43 
116  0.00  348.00  1.21  349.21 
117  0.00  238.00  1.58  239.58 
118  0.00  0.00  0.00  0.00 
119  0.00  119.00  0.39  119.39 
120  0.00  119.00  1.21  120.21 
121  120.00  238.00  3.08  361.08 
122  0.00  586.00  21.99  607.99 
123  0.00  1062.00  5.67  1067.67 
124  0.00  943.00  25.08  968.08 
125  0.00  357.00  5.49  362.49 
126  120.00  586.00  20.73  726.73 
127  0.00  586.00  21.78  607.78 
128  0.00  595.00  7.15  602.15 
129  0.00  476.00  6.16  482.16 
130  0.00  476.00  4.56  480.56 
131  0.00  824.00  7.05  831.05 
132  0.00  824.00  9.15  833.15 
133  1428.00  357.00  4.35  1789.35 
135  1428.00  833.00  9.45  2270.45 
136  1428.00  1053.00  40.15  2521.15 
137  0.00  714.00  8.58  722.58 
138  0.00  705.00  1.56  706.56 
139  1428.00  595.00  10.80  2033.80 
140  0.00  357.00  5.49  362.49 
141  0.00  934.00  1.56  935.56 
142  0.00  357.00  4.74  361.74 
143  1428.00  833.00  8.47  2269.47 
144  0.00  119.00  0.39  119.39 
145  0.00  357.00  2.43  359.43 
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146  0.00  0.00  0.00  0.00 
147  0.00  476.00  6.16  482.16 
148  0.00  586.00  3.42  589.42 
149  120.00  714.00  4.74  838.74 
150  0.00  348.00  0.39  348.39 
151  0.00  714.00  12.18  726.18 
152  0.00  705.00  3.24  708.24 
153  120.00  238.00  1.58  359.58 
154  0.00  595.00  4.05  599.05 
155  0.00  467.00  1.62  468.62 
156  0.00  357.00  2.43  359.43 
157  0.00  714.00  2.34  716.34 
158  0.00  1190.00  19.30  1209.30 
159  120.00  595.00  3.95  718.95 
160  120.00  1859.00  4.74  1983.74 
161  120.00  238.00  0.58  358.58 
162  0.00  714.00  9.24  723.24 
163  0.00  238.00  2.28  240.28 
164  0.00  714.00  4.74  718.74 
165  0.00  238.00  1.62  239.62 
166  0.00  714.00  7.26  721.26 
167  0.00  238.00  0.58  238.58 
168  0.00  705.00  6.32  711.32 
169  500.00  0.00  0.85  500.85 
170  0.00  595.00  6.05  601.05 
171  0.00  119.00  1.21  120.21 
172  0.00  357.00  4.62  361.62 
173  120.00  0.00  0.00  120.00 
174  120.00  943.00  25.20  1088.20 
175  500.00  0.00  0.00  500.00 
176  620.00  1071.00  12.69  1703.69 
177  0.00  714.00  8.64  722.64 
178  0.00  1053.00  5.20  1058.20 
179  0.00  238.00  1.58  239.58 
180  0.00  119.00  0.79  119.79 
181  0.00  119.00  1.43  120.43 
182  0.00  586.00  4.29  590.29 
183  0.00  238.00  2.02  240.02 
184  0.00  357.00  3.03  360.03 
185  0.00  357.00  2.43  359.43 
186  0.00  0.00  0.00  0.00 
187  0.00  238.00  1.62  239.62 
188  0.00  586.00  5.49  591.49 
189  0.00  1291.00  40.07  1331.07 
190  0.00  705.00  8.64  713.64 
191  0.00  952.00  11.28  963.28 
192  0.00  705.00  8.64  713.64 
193  0.00  238.00  2.86  240.86 
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194  0.00  705.00  6.96  711.96 
195  0.00  238.00  1.58  239.58 
196  0.00  1309.00  22.66  1331.66 
197  0.00  943.00  8.46  951.46 
198  0.00  705.00  3.16  708.16 
199  2810.00  3689.00  56.73  6555.73 
200  120.00  586.00  4.23  710.23 
201  120.00  238.00  1.58  359.58 
202  0.00  4156.00  29.37  4185.37 
203  0.00  1062.00  7.77  1069.77 
204  120.00  238.00  1.42  359.42 
205  2310.00  2820.00  43.52  5173.52 
206  0.00  476.00  1.56  477.56 
207  0.00  1776.00  32.23  1808.23 
208  0.00  476.00  4.84  480.84 
209  1928.00  238.00  2.28  2168.28 
210  500.00  1895.00  15.68  2410.68 
211  0.00  934.00  3.24  937.24 
212  0.00  467.00  1.04  468.04 
213  500.00  5485.00  247.68  6232.68 
214  500.00  714.00  10.98  1224.98 
215  0.00  1282.00  10.05  1292.05 
216  500.00  1282.00  58.65  1840.65 
217  0.00  815.00  2.07  817.07 
218  2048.00  815.00  1.50  2864.50 
219  500.00  1053.00  48.25  1601.25 
220  0.00  476.00  4.44  480.44 
221  500.00  238.00  3.74  741.74 
222  1928.00  476.00  9.64  2413.64 
223  0.00  1062.00  26.51  1088.51 
224  120.00  1520.00  12.81  1652.81 
225  0.00  1071.00  3.51  1074.51 
226  120.00  238.00  2.82  360.82 
227  0.00  357.00  5.49  362.49 
228  120.00  238.00  1.04  359.04 
229  500.00  1071.00  10.08  1581.08 
230  500.00  467.00  1.44  968.44 
231  500.00  1071.00  12.69  1583.69 
232  500.00  705.00  20.98  1225.98 
233  500.00  357.00  5.49  862.49 
234  0.00  357.00  4.23  361.23 
235  120.00  238.00  4.86  362.86 
236  500.00  476.00  11.32  987.32 
237  0.00  238.00  2.82  240.82 
238  500.00  952.00  14.64  1466.64 
239  2810.00  2023.00  23.97  4856.97 
240  0.00  476.00  5.72  481.72 
241  0.00  714.00  7.68  721.68 
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242  0.00  476.00  4.04  480.04 
243  500.00  705.00  22.22  1227.22 
244  2810.00  1776.00  39.38  4625.38 
245  0.00  119.00  1.12  120.12 
246  620.00  595.00  9.15  1224.15 
247  0.00  119.00  0.10  119.10 
248  2048.00  1309.00  27.94  3384.94 
249  0.00  824.00  7.35  831.35 
250  0.00  1648.00  43.10  1691.10 
251  120.00  357.00  3.93  480.93 
252  0.00  357.00  2.43  359.43 
253  0.00  1419.00  10.10  1429.10 
254  0.00  119.00  0.81  119.81 
255  0.00  348.00  0.72  348.72 
256  0.00  0.00  0.00  0.00 
257  0.00  2737.00  32.89  2769.89 
258  0.00  1657.00  33.66  1690.66 
259  0.00  238.00  0.78  238.78 
260  0.00  1071.00  11.52  1082.52 
261  0.00  1630.00  71.46  1701.46 
262  2310.00  2856.00  67.92  5233.92 
263  0.00  595.00  10.30  605.30 
264  0.00  348.00  0.91  348.91 
265  0.00  586.00  3.03  589.03 
266  0.00  476.00  3.24  479.24 
267  0.00  3927.00  47.19  3974.19 
268  500.00  2582.00  91.62  3173.62 
269  0.00  1053.00  40.15  1093.15 
270  120.00  1428.00  17.16  1565.16 
271  0.00  1291.00  45.32  1336.32 
272  0.00  705.00  21.82  726.82 
273  0.00  586.00  21.99  607.99 
274  0.00  824.00  8.00  832.00 
275  2310.00  1309.00  20.13  3639.13 
276  2310.00  7086.00  167.64  9563.64 
277  0.00  833.00  10.01  843.01 
278  500.00  1895.00  38.06  2433.06 
279  2810.00  4798.00  190.59  7798.59 
280  0.00  119.00  1.21  120.21 
281  0.00  1309.00  11.44  1320.44 
282  0.00  476.00  7.72  483.72 
283  0.00  833.00  11.20  844.20 
284  0.00  1172.00  4.86  1176.86 
285  0.00  1776.00  37.30  1813.30 
286  0.00  2023.00  22.27  2045.27 
287  120.00  1428.00  19.20  1567.20 
288  0.00  2380.00  16.20  2396.20 
289  0.00  4376.00  81.74  4457.74 
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290  0.00  3561.00  33.04  3594.04 
291  500.00  238.00  2.42  740.42 
292  0.00  1172.00  4.86  1176.86 
293  0.00  1062.00  22.17  1084.17 
294  0.00  1181.00  6.32  1187.32 
295  0.00  2362.00  57.16  2419.16 
296  1428.00  357.00  2.76  1787.76 
297  120.00  357.00  1.17  478.17 
298  120.00  476.00  2.00  598.00 
299  0.00  1657.00  4.68  1661.68 
300  0.00  714.00  3.00  717.00 
301  0.00  238.00  1.62  239.62 
302  0.00  1547.00  18.72  1565.72 
303  120.00  238.00  3.66  361.66 
304  0.00  476.00  1.56  477.56 
305  0.00  238.00  3.08  241.08 
306  1928.00  1895.00  46.74  3869.74 
307  0.00  119.00  1.21  120.21 
308  0.00  586.00  4.29  590.29 
309  0.00  357.00  3.63  360.63 
310  0.00  586.00  5.49  591.49 
311  500.00  2124.00  57.64  2681.64 
312  0.00  714.00  10.56  724.56 
313  0.00  238.00  2.86  240.86 
314  0.00  357.00  5.28  362.28 
315  0.00  119.00  0.50  119.50 
316  0.00  952.00  20.40  972.40 
317  1928.00  2142.00  38.88  4108.88 
318  0.00  238.00  3.52  241.52 
319  0.00  586.00  6.00  592.00 
320  0.00  833.00  12.81  845.81 
321  0.00  467.00  1.00  468.00 
322  0.00  595.00  1.95  596.95 
323  0.00  943.00  7.26  950.26 
324  0.00  357.00  2.43  359.43 
325  0.00  824.00  2.15  826.15 
326  0.00  476.00  8.04  484.04 
327  0.00  467.00  3.86  470.86 
328  0.00  595.00  6.05  601.05 
329  0.00  119.00  0.79  119.79 
330  0.00  943.00  4.74  947.74 
331  0.00  238.00  1.62  239.62 
332  0.00  2975.00  12.50  2987.50 
333  0.00  714.00  10.44  724.44 
334  0.00  0.00  0.00  0.00 
335  0.00  119.00  0.40  119.40 
336  0.00  467.00  1.00  468.00 
337  0.00  238.00  1.00  239.00 
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338  0.00  0.00  0.00  0.00 
339  0.00  714.00  4.86  718.86 
340  0.00  476.00  2.00  478.00 
341  120.00  595.00  7.15  722.15 
342  0.00  833.00  17.85  850.85 
343  0.00  1062.00  28.82  1090.82 
344  0.00  952.00  4.16  956.16 
345  0.00  1785.00  18.15  1803.15 
346  0.00  238.00  3.52  241.52 
347  0.00  595.00  4.05  599.05 
348  500.00  1785.00  26.40  2311.40 
349  0.00  1062.00  31.62  1093.62 
350  120.00  0.00  0.00  120.00 
351  0.00  357.00  4.23  361.23 
352  120.00  1190.00  7.20  1317.20 
353  0.00  238.00  2.86  240.86 
354  0.00  2142.00  24.12  2166.12 
355  0.00  833.00  7.84  840.84 
356  0.00  595.00  9.15  604.15 
357  0.00  705.00  4.04  709.04 
358  0.00  934.00  4.04  938.04 
359  0.00  0.00  0.00  0.00 
360  120.00  238.00  3.08  361.08 
361  1428.00  0.00  17.10  1445.10 
362  120.00  0.00  4.56  124.56 
363  1428.00  0.00  8.69  1436.69 
364  0.00  0.00  9.68  9.68 
365  0.00  0.00  7.98  7.98 
366  0.00  0.00  1.17  1.17 
367  0.00  0.00  0.00  0.00 
368  0.00  0.00  13.77  13.77 
369  0.00  0.00  7.32  7.32 
370  1428.00  0.00  2.37  1430.37 
371  0.00  0.00  7.26  7.26 
372  0.00  0.00  2.37  2.37 
373  1428.00  0.00  12.10  1440.10 
374  0.00  0.00  8.47  8.47 
375  0.00  0.00  11.76  11.76 
376  0.00  0.00  0.00  0.00 
377  0.00  0.00  5.04  5.04 
378  0.00  0.00  1.95  1.95 
379  0.00  0.00  3.24  3.24 
380  120.00  0.00  8.47  128.47 
381  0.00  1062.00  5.53  1067.53 
382  0.00  238.00  2.36  240.36 
383  120.00  357.00  2.37  479.37 
384  0.00  595.00  5.70  600.70 
385  0.00  357.00  4.32  361.32 
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386  0.00  357.00  3.54  360.54 
387  0.00  833.00  8.47  841.47 
388  120.00  595.00  6.05  721.05 
389  0.00  238.00  1.62  239.62 
390  0.00  119.00  0.79  119.79 
391  0.00  238.00  0.78  238.78 
392  1428.00  952.00  9.12  2389.12 
393  0.00  357.00  2.43  359.43 
394  0.00  824.00  3.95  827.95 
395  0.00  0.00  0.00  0.00 
396  0.00  595.00  3.55  598.55 
397  0.00  238.00  2.22  240.22 
398  0.00  1172.00  40.26  1212.26 
399  0.00  238.00  1.44  239.44 
400  0.00  238.00  1.58  239.58 
401  0.00  119.00  0.50  119.50 
402  0.00  238.00  1.58  239.58 
403  0.00  705.00  19.66  724.66 
404  0.00  1181.00  3.12  1184.12 
405  120.00  357.00  1.50  478.50 
406  620.00  1776.00  32.23  2428.23 
407  2810.00  5712.00  73.92  8595.92 
408  0.00  238.00  0.78  238.78 
409  0.00  119.00  0.81  119.81 
410  0.00  1785.00  1.50  1786.50 
411  0.00  714.00  2.34  716.34 
412  500.00  476.00  2.00  978.00 
413  120.00  476.00  4.48  600.48 
414  0.00  0.00  0.00  0.00 
415  120.00  833.00  12.67  965.67 
416  0.00  586.00  21.30  607.30 
417  120.00  1181.00  4.00  1305.00 
418  120.00  943.00  0.60  1063.60 
419  0.00  357.00  5.10  362.10 
420  0.00  357.00  1.17  358.17 
421  0.00  1181.00  11.28  1192.28 
422  0.00  833.00  9.87  842.87 
423  0.00  1172.00  8.04  1180.04 
424  0.00  357.00  4.23  361.23 
425  0.00  357.00  4.23  361.23 
426  0.00  1300.00  29.19  1329.19 
427  500.00  357.00  6.90  863.90 
428  0.00  1776.00  41.59  1817.59 
429  0.00  4084.00  23.97  4107.97 
430  0.00  1538.00  23.76  1561.76 
431  0.00  0.00  0.00  0.00 
432  0.00  943.00  4.86  947.86 
433  0.00  595.00  7.15  602.15 
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434  0.00  1520.00  12.81  1532.81 
435  0.00  714.00  4.32  718.32 
436  0.00  824.00  7.05  831.05 
437  0.00  595.00  7.05  602.05 
438  2810.00  2023.00  19.04  4852.04 
439  0.00  696.00  3.22  699.22 
440  0.00  943.00  12.96  955.96 
441  120.00  1071.00  17.10  1208.10 
442  0.00  238.00  87.24  325.24 
443  0.00  4495.00  133.34  4628.34 
444  0.00  476.00  4.56  480.56 
445  120.00  476.00  3.16  599.16 
446  0.00  476.00  7.04  483.04 
447  0.00  238.00  3.08  241.08 
448  0.00  476.00  7.32  483.32 
449  0.00  238.00  1.62  239.62 
450  0.00  824.00  5.60  829.60 
451  0.00  952.00  8.88  960.88 
452  0.00  238.00  3.08  241.08 
453  0.00  815.00  38.19  853.19 
454  0.00  833.00  10.57  843.57 
455  120.00  119.00  1.83  240.83 
456  120.00  833.00  12.81  965.81 
457  120.00  467.00  1.64  588.64 
458  0.00  586.00  21.72  607.72 
459  120.00  238.00  0.20  358.20 
460  0.00  705.00  23.82  728.82 
461  0.00  595.00  0.50  595.50 
462  0.00  952.00  2.32  954.32 
463  0.00  595.00  2.50  597.50 
464  0.00  1053.00  7.70  1060.70 
465  0.00  357.00  2.13  359.13 
466  0.00  714.00  3.00  717.00 
467  0.00  348.00  0.39  348.39 
468  500.00  0.00  0.00  500.00 
469  0.00  1181.00  3.12  1184.12 
470  0.00  476.00  1.56  477.56 
471  0.00  348.00  0.00  348.00 
472  0.00  1538.00  4.29  1542.29 
473  0.00  476.00  4.88  480.88 
474  0.00  2335.00  7.90  2342.90 
475  0.00  705.00  4.48  709.48 
476  0.00  595.00  5.70  600.70 
477  0.00  238.00  0.78  238.78 
478  0.00  1547.00  20.02  1567.02 
479  500.00  3451.00  73.66  4024.66 
480  0.00  357.00  2.37  359.37 
481  0.00  705.00  7.72  712.72 
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482  120.00  705.00  3.24  828.24 
483  500.00  952.00  6.48  1458.48 
484  0.00  119.00  0.00  119.00 
485  120.00  1053.00  36.95  1209.95 
486  120.00  1300.00  10.89  1430.89 
487  0.00  119.00  0.39  119.39 
488  500.00  1300.00  23.79  1823.79 
489  0.00  348.00  0.81  348.81 
490  0.00  476.00  4.84  480.84 
491  0.00  934.00  37.84  971.84 
492  120.00  595.00  3.95  718.95 
493  0.00  714.00  4.74  718.74 
494  0.00  238.00  1.58  239.58 
495  0.00  696.00  2.62  698.62 
497  500.00  2014.00  46.95  2560.95 
498  120.00  476.00  3.24  599.24 
499  120.00  833.00  8.47  961.47 
500  120.00  238.00  1.62  359.62 
501  0.00  586.00  1.17  587.17 
502  1428.00  1181.00  4.16  2613.16 
503  0.00  238.00  1.58  239.58 
504  0.00  943.00  4.74  947.74 
505  0.00  833.00  0.00  833.00 
506  0.00  238.00  1.58  239.58 
507  0.00  1053.00  6.05  1059.05 
508  0.00  348.00  0.39  348.39 
509  0.00  586.00  2.37  588.37 
510  0.00  586.00  2.43  588.43 
511  0.00  238.00  2.42  240.42 
512  0.00  238.00  1.58  239.58 
513  0.00  833.00  4.34  837.34 
514  0.00  952.00  12.32  964.32 
515  0.00  238.00  1.04  239.04 
516  0.00  595.00  2.00  597.00 
517  0.00  476.00  3.24  479.24 
518  0.00  357.00  1.50  358.50 
519  0.00  1428.00  6.24  1434.24 
520  0.00  1062.00  2.73  1064.73 
521  0.00  357.00  2.43  359.43 
522  500.00  1071.00  10.26  1581.26 
523  0.00  476.00  3.40  479.40 
524  0.00  357.00  3.75  360.75 
525  0.00  833.00  5.67  838.67 
526  0.00  119.00  1.21  120.21 
527  0.00  1547.00  20.80  1567.80 
528  0.00  357.00  2.07  359.07 
529  0.00  1776.00  9.36  1785.36 
530  0.00  1309.00  10.12  1319.12 
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531  0.00  0.00  0.00  0.00 
532  620.00  238.00  0.78  858.78 
533  0.00  0.00  0.00  0.00 
534  500.00  714.00  7.68  1221.68 
535  500.00  3718.00  9.48  4227.48 
536  0.00  238.00  0.20  238.20 
537  120.00  238.00  1.62  359.62 
538  0.00  1401.00  60.48  1461.48 
539  120.00  3828.00  189.42  4137.42 
540  120.00  357.00  1.50  478.50 
551  0.00  705.00  3.16  708.16 
552  0.00  833.00  10.08  843.08 
553  0.00  476.00  3.24  479.24 
554  500.00  0.00  3.42  503.42 
555  0.00  943.00  9.24  952.24 
556  0.00  348.00  1.41  349.41 
557  1428.00  119.00  0.10  1547.10 
558  0.00  4870.00  36.00  4906.00 
559  0.00  467.00  4.00  471.00 
560  500.00  0.00  0.00  500.00 
561  0.00  238.00  2.42  240.42 
562  0.00  833.00  7.84  840.84 
563  0.00  467.00  1.00  468.00 
564  0.00  238.00  1.58  239.58 
565  500.00  1776.00  36.52  2312.52 
566  1548.00  833.00  3.50  2384.50 
567  120.00  119.00  0.79  239.79 
568  0.00  238.00  1.00  239.00 
569  0.00  943.00  21.24  964.24 
570  0.00  824.00  19.00  843.00 
571  0.00  119.00  1.21  120.21 
572  0.00  0.00  6.16  6.16 
573  0.00  595.00  6.25  601.25 
574  0.00  357.00  0.30  357.30 
575  1428.00  238.00  0.20  1666.20 
576  0.00  238.00  2.30  240.30 
577  0.00  1547.00  6.50  1553.50 
578  0.00  595.00  93.80  688.80 
579  1428.00  476.00  9.32  1913.32 
580  0.00  348.00  1.21  349.21 
581  0.00  1053.00  3.95  1056.95 
582  1548.00  1053.00  6.05  2607.05 
583  0.00  2124.00  49.94  2173.94 
584  0.00  119.00  0.43  119.43 
585  0.00  357.00  0.87  357.87 
586  1428.00  0.00  0.00  1428.00 
587  0.00  1428.00  20.88  1448.88 
588  1428.00  1071.00  10.89  2509.89 
166 Patient  Procedures  Hospital  Drug  cost  Admission 
study  no.  cost  stay  cost  cost 
589  1548.00  952.00  9.68  2509.68 
590  120.00  2023.00  15.64  2158.64 
591  0.00  3076.00  8.58  3084.58 
592  0.00  467.00  1.62  468.62 
593  0.00  943.00  4.74  947.74 
594  0.00  357.00  4.62  361.62 
595  0.00  696.00  2.28  698.28 
596  0.00  1181.00  22.98  1203.98 
597  0.00  595.00  2.50  597.50 
598  0.00  348.00  1.14  349.14 
599  0.00  238.00  1.62  239.62 
600  0.00  833.00  5.67  838.67 
601  1428.00  476.00  3.24  1907.24 
602  0.00  934.00  3.16  937.16 
603  0.00  696.00  2.24  698.24 
604  0.00  1309.00  21.23  1330.23 
605  0.00  934.00  39.16  973.16 
606  0.00  348.00  1.21  349.21 
607  0.00  1282.00  2.50  1284.50 
608  0.00  595.00  5.70  600.70 
609  0.00  348.00  0.92  348.92 
610  0.00  595.00  4.05  599.05 
611  0.00  0.00  12.32  12.32 
612  0.00  0.00  0.39  0.39 
613  0.00  0.00  1.95  1.95 
614  0.00  0.00  4.05  4.05 
615  0.00  0.00  2.43  2.43 
616  0.00  0.00  1.84  1.84 
617  0.00  0.00  2.00  2.00 
618  0.00  0.00  5.53  5.53 
619  0.00  0.00  0.50  0.50 
620  0.00  0.00  4.86  4.86 
621  0.00  0.00  2.37  2.37 
622  0.00  0.00  5.37  5.37 
623  0.00  0.00  7.70  7.70 
624  0.00  0.00  3.66  3.66 
625  0.00  0.00  6.00  6.00 
626  0.00  0.00  0.58  0.58 
627  120.00  0.00  0.00  120.00 
628  0.00  0.00  4.00  4.00 
629  0.00  0.00  0.79  0.79 
630  0.00  0.00  0.58  0.58 
631  1548.00  0.00  3.16  1551.16 
652  0.00  0.00  0.00  0.00 
653  500.00  1071.00  12.69  1583.69 
654  0.00  595.00  7.05  602.05 
655  0.00  2023.00  6.63  2029.63 
656  0.00  1657.00  14.52  1671.52 
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657  1428.00  1401.00  2.34  2831.34 
658  0.00  4394.00  10.15  4404.15 
659  0.00  1062.00  3.50  1065.50 
660  2810.00  2133.00  29.14  4972.14 
661  500.00  1785.00  26.40  2311.40 
662  500.00  1181.00  32.74  1713.74 
663  0.00  238.00  0.78  238.78 
664  0.00  357.00  1.17  358.17 
665  500.00  357.00  3.63  860.63 
666  500.00  714.00  12.00  1226.00 
667  0.00  119.00  0.50  119.50 
668  0.00  2005.00  9.23  2014.23 
669  1928.00  4870.00  60.96  6858.96 
670  0.00  1062.00  28.40  1090.40 
671  2810.00  2142.00  14.22  4966.22 
675  0.00  357.00  2.37  359.37 
676  0.00  714.00  9.24  723.24 
677  0.00  1172.00  43.56  1215.56 
678  1428.00  4165.00  152.90  5745.90 
692  0.00  357.00  2.07  359.07 
693  120.00  1300.00  30.90  1450.90 
694  0.00  1648.00  44.40  1692.40 
695  1928.00  2618.00  29.26  4575.26 
696  0.00  586.00  0.30  586.30 
697  0.00  2261.00  57.95  2318.95 
698  120.00  1071.00  13.86  1204.86 
699  0.00  943.00  25.74  968.74 
700  0.00  595.00  5.05  600.05 
701  0.00  1062.00  20.00  1082.00 
702  0.00  238.00  0.80  238.80 
703  0.00  943.00  4.86  947.86 
704  500.00  595.00  7.05  1102.05 
705  0.00  476.00  2.00  478.00 
706  0.00  1181.00  22.82  1203.82 
707  0.00  238.00  1.00  239.00 
708  0.00  595.00  5.70  600.70 
709  0.00  1071.00  14.22  1085.22 
710  0.00  714.00  7.26  721.26 
711  120.00  952.00  11.28  1083.28 
712  0.00  357.00  4.23  361.23 
713  0.00  824.00  8.80  832.80 
714  120.00  714.00  4.74  838.74 
715  0.00  1886.00  106.96  1992.96 
716  0.00  943.00  10.98  953.98 
717  0.00  238.00  1.00  239.00 
718  0.00  1410.00  17.28  1427.28 
719  0.00  238.00  1.00  239.00 
720  0.00  476.00  8.88  484.88 
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721  0.00  357.00  5.22  362.22 
722  0.00  238.00  2.82  240.82 
723  0.00  833.00  9.87  842.87 
724  0.00  705.00  3.24  708.24 
725  0.00  714.00  12.96  726.96 
726  0.00  595.00  9.15  604.15 
727  0.00  1776.00  13.13  1789.13 
728  0.00  476.00  3.16  479.16 
729  0.00  952.00  6.48  958.48 
730  0.00  476.00  4.84  480.84 
732  0.00  1547.00  25.09  1572.09 
733  120.00  238.00  1.58  359.58 
734  0.00  0.00  0.00  0.00 
735  0.00  119.00  0.79  119.79 
736  0.00  1071.00  10.89  1081.89 
737  0.00  705.00  3.16  708.16 
738  0.00  348.00  0.71  348.71 
739  0.00  467.00  1.62  468.62 
740  0.00  238.00  1.58  239.58 
741  0.00  119.00  0.79  119.79 
742  0.00  833.00  5.67  838.67 
743  0.00  119.00  0.81  119.81 
744  120.00  119.00  0.79  239.79 
745  0.00  595.00  3.95  598.95 
746  0.00  595.00  7.05  602.05 
747  0.00  348.00  1.21  349.21 
748  0.00  348.00  0.79  348.79 
749  0.00  1062.00  8.47  1070.47 
750  0.00  348.00  1.21  349.21 
751  0.00  119.00  2.00  121.00 
752  0.00  357.00  3.42  360.42 
753  0.00  952.00  6.48  958.48 
754  0.00  476.00  7.64  483.64 
755  0.00  476.00  4.84  480.84 
756  120.00  238.00  2.22  360.22 
757  120.00  1190.00  17.00  1327.00 
758  120.00  238.00  2.24  360.24 
759  0.00  0.00  0.00  0.00 
760  0.00  0.00  0.00  0.00 
761  0.00  1172.00  7.08  1179.08 
762  0.00  696.00  2.42  698.42 
763  120.00  1190.00  12.10  1322.10 
764  500.00  1895.00  38.06  2433.06 
765  0.00  119.00  0.39  119.39 
766  0.00  119.00  0.81  119.81 
767  120.00  238.00  1.58  359.58 
768  0.00  2499.00  17.01  2516.01 
769  0.00  595.00  4.05  599.05 
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770  0.00  833.00  5.04  838.04 
771  0.00  0.00  12.32  12.32 
772  0.00  0.00  11.22  11.22 
773  0.00  0.00  2.68  2.68 
774  0.00  0.00  5.10  5.10 
775  0.00  0.00  5.60  5.60 
776  0.00  238.00  2.82  240.82 
777  120.00  0.00  1.00  121.00 
778  0.00  0.00  8.82  8.82 
779  0.00  0.00  2.16  2.16 
780  0.00  0.00  5.80  5.80 
781  0.00  0.00  5.22  5.22 
782  120.00  0.00  2.82  122.82 
784  0.00  0.00  0.00  0.00 
785  0.00  0.00  30.24  30.24 
786  1428.00  0.00  0.00  1428.00 
787  0.00  0.00  4.56  4.56 
788  0.00  0.00  8.80  8.80 
789  1428.00  0.00  7.32  1435.32 
790  1428.00  0.00  10.80  1438.80 
791  0.00  238.00  1.62  239.62 
792  120.00  238.00  0.58  358.58 
793  0.00  595.00  8.50  603.50 
794  0.00  467.00  1.44  468.44 
795  0.00  943.00  6.72  949.72 
796  0.00  824.00  2.60  826.60 
797  1428.00  467.00  2.42  1897.42 
798  0.00  119.00  0.10  119.10 
799  0.00  1895.00  11.06  1906.06 
800  0.00  467.00  1.00  468.00 
801  0.00  943.00  7.86  950.86 
802  0.00  595.00  7.90  602.90 
803  0.00  476.00  4.04  480.04 
804  0.00  1172.00  41.58  1213.58 
805  0.00  2838.00  53.20  2891.20 
806  120.00  1428.00  20.88  1568.88 
807  0.00  357.00  3.03  360.03 
808  0.00  0.00  0.00  0.00 
809  0.00  476.00  4.04  480.04 
810  0.00  952.00  8.96  960.96 
811  0.00  467.00  3.66  470.66 
812  0.00  2142.00  32.94  2174.94 
813  0.00  595.00  7.15  602.15 
814  120.00  943.00  24.96  1087.96 
815  0.00  1987.00  81.66  2068.66 
816  0.00  2380.00  63.20  2443.20 
817  0.00  238.00  0.20  238.20 
818  0.00  119.00  0.72  119.72 
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820  0.00  3204.00  35.75  3239.75 
821  0.00  238.00  2.02  240.02 
822  0.00  357.00  3.03  360.03 
823  0.00  833.00  12.81  845.81 
824  0.00  1529.00  43.08  1572.08 
825  0.00  238.00  1.42  239.42 
826  1428.00  357.00  4.23  1789.23 
827  0.00  824.00  25.65  849.65 
828  0.00  833.00  7.07  840.07 
829  0.00  0.00  0.00  0.00 
830  0.00  833.00  7.84  840.84 
831  0.00  815.00  5.79  820.79 
832  0.00  357.00  3.63  360.63 
833  500.00  238.00  2.42  740.42 
834  0.00  357.00  3.63  360.63 
835  0.00  357.00  1.50  358.50 
836  120.00  238.00  0.20  358.20 
837  0.00  357.00  3.42  360.42 
838  0.00  1547.00  25.09  1572.09 
839  0.00  824.00  6.05  830.05 
840  0.00  119.00  1.14  120.14 
841  0.00  833.00  97.81  930.81 
842.  815.00  1.17  #VALUE! 
843  0.00  934.00  2.00  936.00 
844  0.00  238.00  2.42  240.42 
845  0.00  1062.00  8.47  1070.47 
846  0.00  0.00  0.00  0.00 
847  0.00  2719.00  15.39  2734.39 
848  0.00  586.00  2.43  588.43 
849  0.00  119.00  0.50  119.50 
850  0.00  595.00  6.40  601.40 
851  0.00  595.00  2.60  597.60 
852  0.00  0.00  0.00  0.00 
853  0.00  348.00  0.79  348.79 
854  0.00  348.00  1.14  349.14 
855  0.00  119.00  0.79  119.79 
856  0.00  348.00  0.39  348.39 
857  0.00  0.00  0.00  0.00 
858  0.00  0.00  0.00  0.00 
859  0.00  348.00  1.21  349.21 
860  500.00  1785.00  1.50  2286.50 
861  0.00  119.00  0.10  119.10 
862  0.00  1181.00  3.12  1184.12 
863  0.00  238.00  0.20  238.20 
864  0.00  833.00  10.78  843.78 
865  0.00  2609.00  32.00  2641.00 
866  0.00  0.00  0.00  0.00 
867  500.00  3727.00  170.06  4397.06 
171 Patient  Procedures  Hospital  Drug  cost  Admission 
study  no.  cost  stay  cost  cost 
868  0.00  119.00  0.39  119.39 
869  0.00  1776.00  1.30  1777.30 
870  0.00  348.00  0.79  348.79 
871  0.00  357.00  1.17  358.17 
872  0.00  0.00  0.00  0.00 
873  0.00  1666.00  32.48  1698.48 
874  500.00  943.00  33.48  1476.48 
875  0.00  238.00  0.20  238.20 
876  120.00  714.00  8.46  842.46 
877  2810.00  1419.00  34.80  4263.80 
878  0.00  952.00  8.08  960.08 
879  0.00  1062.00  7.07  1069.07 
880  120.00  357.00  3.03  480.03 
881  620.00  1071.00  13.86  1704.86 
882  500.00  586.00  4.23  1090.23 
883  500.00  714.00  10.98  1224.98 
884  2810.00  2600.00  25.38  5435.38 
885  0.00  1071.00  9.09  1080.09 
886  0.00  1062.00  3.50  1065.50 
887  0.00  833.00  12.81  845.81 
888  2810.00  2252.00  32.30  5094.30 
889  120.00  943.00  4.32  1067.32 
890  500.00  1300.00  9.09  1809.09 
891  500.00  1053.00  45.05  1598.05 
892  0.00  0.00  6.72  6.72 
893  0.00  0.00  0.00  0.00 
894  0.00  1785.00  15.60  1800.60 
895  620.00  595.00  8.65  1223.65 
896  0.00  0.00  0.00  0.00 
897  0.00  0.00  15.84  15.84 
898  0.00  1071.00  0.90  1071.90 
899  0.00  0.00  11.90  11.90 
900  0.00  0.00  3.66  3.66 
901  0.00  0.00  8.58  8.58 
902  0.00  0.00  4.05  4.05 
903  0.00  0.00  1.01  1.01 
904  0.00  2142.00  27.72  2169.72 
905  0.00  0.00  0.00  0.00 
906  0.00  0.00  0.00  0.00 
907  0.00  0.00  0.00  0.00 
908  0.00  0.00  18.48  18.48 
909  120.00  0.00  4.29  124.29 
910  120.00  0.00  0.00  120.00 
911  0.00  0.00  0.00  0.00 
912  120.00  2499.00  38.43  2657.43 
913  0.00  824.00  25.65  849.65 
914  1428.00  595.00  7.35  2030.35 
915  0.00  1291.00  45.32  1336.32 
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916  120.00  595.00  3.60  718.60 
917  0.00  2380.00  36.80  2416.80 
918  0.00  476.00  6.96  482.96 
919  0.00  476.00  6.16  482.16 
920  0.00  2499.00  45.36  2544.36 
921  0.00  476.00  1.56  477.56 
922  0.00  833.00  10.29  843.29 
923  0.00  1428.00  18.48  1446.48 
924  0.00  1181.00  3.12  1184.12 
953  120.00  0.00  11.28  131.28 
954  0.00  0.00  1.04  1.04 
955  0.00  0.00  0.00  0.00 
956  120.00  952.00  11.28  1083.28 
957  0.00  0.00  4.29  4.29 
958  0.00  0.00  11.00  11.00 
959  0.00  0.00  0.00  0.00 
960  0.00  0.00  3.08  3.08 
961  0.00  0.00  0.00  0.00 
962  0.00  0.00  0.00  0.00 
963  0.00  0.00  5.28  5.28 
964  120.00  0.00  0.00  120.00 
965  0.00  0.00  0.00  0.00 
966  1548.00  0.00  6.72  1554.72 
967  0.00  0.00  9.50  9.50 
968  0.00  0.00  7.15  7.15 
969  0.00  0.00  0.00  0.00 
970  0.00  0.00  0.00  0.00 
971  0.00  0.00  0.00  0.00 
972  120.00  0.00  0.00  120.00 
973  0.00  2811.00  11.34  2822.34 
974  120.00  1181.00  30.10  1331.10 
975  500.00  2014.00  12.15  2526.15 
976  0.00  467.00  0.58  467.58 
977  120.00  815.00  1.56  936.56 
978  0.00  586.00  2.37  588.37 
979  0.00  0.00  0.00  0.00 
980  620.00  943.00  23.76  1586.76 
981  0.00  1172.00  41.58  1213.58 
982  0.00  1767.00  8.69  1775.69 
983  120.00  1300.00  10.26  1430.26 
984  120.00  1172.00  39.84  1331.84 
985  0.00  705.00  19.34  724.34 
986  0.00  586.00  19.86  605.86 
987  2930.00  5712.00  38.88  8680.88 
988  500.00  1181.00  25.62  1706.62 
989  0.00  476.00  3.24  479.24 
990  0.00  1767.00  7.92  1774.92 
991  0.00  2582.00  76.08  2658.08 
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992  0.00  586.00  3.63  589.63 
1002  120.00  833.00  10.01  963.01 
1007  500.00  1419.00  27.90  1946.90 
1009  0.00  238.00  2.28  240.28 
1010  0.00  357.00  1.17  358.17 
1011  0.00  238.00  2.08  240.08 
1012  120.00  952.00  6.48  1078.48 
1013  120.00  1181.00  6.48  1307.48 
1014  620.00  6080.00  343.48  7043.48 
1015  0.00  2133.00  45.78  2178.78 
1016  120.00  943.00  21.36  1084.36 
1017  0.00  476.00  4.84  480.84 
1018  0.00  586.00  3.75  589.75 
1019  0.00  934.00  4.84  938.84 
1020  0.00  357.00  4.62  361.62 
1021  620.00  3085.00  77.46  3782.46 
1022  0.00  1062.00  10.78  1072.78 
1023  500.00  2719.00  36.67  3255.67 
1024  0.00  1190.00  11.40  1201.40 
1025  500.00  4147.00  70.51  4717.51 
1026  0.00  476.00  3.24  479.24 
1027  1428.00  1767.00  12.54  3207.54 
1028  0.00  1190.00  15.40  1205.40 
1029  0.00  348.00  0.79  348.79 
1030  0.00  943.00  104.50  1047.50 
1031  0.00  467.00  0.58  467.58 
1032  0.00  815.00  2.43  817.43 
1033  120.00  1163.00  52.66  1335.66 
1034  120.00  467.00  2.42  589.42 
1035  0.00  357.00  2.43  359.43 
1036  0.00  714.00  10.26  724.26 
1037  0.00  357.00  2.43  359.43 
1038  0.00  586.00  2.37  588.37 
1039  0.00  952.00  3.12  955.12 
1040  0.00  586.00  1.17  587.17 
1041  0.00  1053.00  1.45  1054.45 
1042  0.00  1044.00  2.13  1046.13 
1043  0.00  934.00  36.24  970.24 
1044  0.00  348.00  0.40  348.40 
1045  0.00  705.00  3.24  708.24 
1046  0.00  952.00  6.32  958.32 
1047  0.00  1071.00  18.27  1089.27 
1048  0.00  238.00  0.78  238.78 
1049  0.00  238.00  2.42  240.42 
1050  0.00  238.00  1.00  239.00 
1051  0.00  3671.00  54.87  3725.87 
1052  0.00  833.00  5.67  838.67 
1053  0.00  1529.00  16.20  1545.20 
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1054  0.00  586.00  0.30  586.30 
1055  0.00  238.00  4.00  242.00 
1056  0.00  348.00  0.81  348.81 
1057  0.00  1904.00  20.48  1924.48 
1058  0.00  3094.00  10.14  3104.14 
1059  0.00  119.00  1.21  120.21 
1060  0.00  238.00  1.62  239.62 
1061  0.00  952.00  10.48  962.48 
1062  0.00  348.00  0.50  348.50 
1063  0.00  119.00  0.79  119.79 
1064  0.00  476.00  4.84  480.84 
1065  0.00  476.00  87.88  563.88 
1066  0.00  119.00  0.79  119.79 
1067  120.00  476.00  2.08  598.08 
1068  0.00  467.00  2.62  469.62 
1069  0.00  0.00  0.50  0.50 
1070  120.00  0.00  8.28  128.28 
1071  0.00  0.00  0.00  0.00 
1072  0.00  0.00  14.21  14.21 
1073  0.00  0.00  0.81  0.81 
1074  0.00  0.00  0.50  0.50 
1075  0.00  0.00  0.00  0.00 
1076  0.00  0.00  0.00  0.00 
1077  0.00  0.00  0.20  0.20 
1078  0.00  0.00  0.00  0.00 
1079  0.00  0.00  0.00  0.00 
1080  0.00  0.00  2.43  2.43 
1081  0.00  0.00  0.00  0.00 
1082  120.00  0.00  3.00  123.00 
1083  0.00  0.00  1.16  1.16 
1084  0.00  0.00  2.34  2.34 
1085  0.00  0.00  1.54  1.54 
1086  0.00  0.00  1.56  1.56 
1087  0.00  0.00  0.00  0.00 
1088  0.00  0.00  0.00  0.00 
1089  0.00  357.00  6.99  363.99 
1090  0.00  595.00  3.95  598.95 
1091  500.00  952.00  14.64  1466.64 
1092  0.00  119.00  0.39  119.39 
1093  0.00  238.00  2.42  240.42 
1094  500.00  357.00  3.63  860.63 
1095  0.00  595.00  4.05  599.05 
1096  1428.00  238.00  1.44  1667.44 
1097  0.00  119.00  0.39  119.39 
1098  0.00  714.00  7.08  721.08 
1099  0.00  119.00  0.39  119.39 
1100  0.00  2802.00  122.16  2924.16 
1401  0.00  1053.00  1.45  1054.45 
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1402  0.00  348.00  0.71  348.71 
1403  0.00  1172.00  7.26  1179.26 
1404  0.00  238.00  1.62  239.62 
1405  0.00  1410.00  36.12  1446.12 
1406  0.00  1181.00  9.68  1190.68 
1407  0.00  1071.00  7.11  1078.11 
1408  0.00  824.00  21.55  845.55 
1409  0.00  238.00  1.62  239.62 
1421  0.00  357.00  3.63  360.63 
1422  0.00  714.00  2.34  716.34 
1423  0.00  705.00  4.84  709.84 
1424  0.00  4414.00  11.06  4425.06 
1425  0.00  0.00  1.12  1.12 
1426  120.00  705.00  20.18  845.18 
1427  0.00  1181.00  3.12  1184.12 
1428  0.00  357.00  2.37  359.37 
1429  500.00  1300.00  7.11  1807.11 
1430  0.00  1172.00  40.74  1212.74 
1431  0.00  586.00  3.63  589.63 
1432  0.00  476.00  6.16  482.16 
1441  0.00  1190.00  8.10  1198.10 
1442  0.00  815.00  3.63  818.63 
1443  500.00  714.00  3.00  1217.00 
1444  500.00  3397.00  130.11  4027.11 
1445  2930.00  0.00  0.00  2930.00 
1446  120.00  476.00  3.24  599.24 
1447  120.00  1181.00  23.86  1324.86 
1448  0.00  357.00  3.63  360.63 
1449  500.00  476.00  4.04  980.04 
1450  0.00  238.00  1.58  239.58 
1451  0.00  1309.00  17.60  1326.60 
1452  500.00  1419.00  30.60  1949.60 
1453  120.00  1053.00  2.50  1175.50 
1454  0.00  1053.00  6.05  1059.05 
1455  620.00  952.00  14.08  1586.08 
1456  0.00  1062.00  0.70  1062.70 
1457  120.00  119.00  0.50  239.50 
1458  0.00  476.00  3.68  479.68 
1459  0.00  934.00  36.16  970.16 
1460  0.00  357.00  4.74  361.74 
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Results  of  simulations  of  ECMO  data  set 
Tables  I-  10  Simulation  statistics 
Figures  1-  10  Histograms  of  simulation  results. 
Data  tables  of  the  ECMO  study 
Subgroup  1  Birth  weight  <  3300  grams 
Subgroup  2  Birth  weight  >  3300  grams 
Subgroup  3  Gestation  <  275  days 
Subgroup  4  Gestation  >  275  days 
Subgroup  5  Diagnosis  CDH 
Subgroup  6  Diagnosis  IPFC 
Subgroup  7  Diagnosis  PPH 
Subgroup  8  OI  category  I  (<60) 
Subgroup  9  01  category  II  (>60) 
177 Table  1:  Descriptive  statistics  of  probability  distribution  -  subgroupl 
Name  Ee  -  Ec  R  effect  E  effect  C  Ce  -  Cc 
Minimum  =  -  0.03  -  5,772,243  0.28  0.02  7,875 
Maximum  =  0.68  3,197,265  0.88  0.46  29,973 
Mean  =  0.30  75,847  0.54  0.24  19,711 
Std  Deviation  =  0.09  99,133  0.07  0.06  3,003 
Variance  =  0.01  9,827,286,000  0.00  0.00  9,017,402 
Skewness  =  0.01  -  10  0.01  -  0.01  -0 
Kurtosis  =  3.06  1,517  3.04  2.97  3 
Mode  =  0.19  54,404  0.46  0.17  18,020 
5%  Perc  =  0.15  39,639  0.42  0.14  14,731 
10%  Perc  =  0.18  44,183  0.45  0.16  15,871 
15%  Perc  =  0.20  47,349  0.47  0.18  16,575 
20%  Perc  =  0.22  50,424  0.48  0.19  17,153 
25%  Perc  =  0.24  52,877  0.49  0.20  17,700 
30%  Perc  =  0.25  55,517  0.50  0.21  18,151 
35%  Perc  =  0.26  58,028  0.51  0.22  18,562 
40%  Perc  =  0.28  60,416  0.52  0.23  18,941 
45%  Perc  =  0.29  62,982  0.53  0.23  19,325 
50%  Perc  =  0.30  65,716  0.54  0.24  19,735 
55%  Perc  =  0.31  68,795  0.55  0.25  20,104 
60%  Perc  =  0.32  71,967  0.56  0.25  20,478 
65%  Perc  =  0.34  75,418  0.57  0.26  20,879 
70%  Perc  =  0.35  79,531  0.58  0.27  21,286 
75%  Perc  =  0.36  84,395  0.59  0.28  21,730 
80%  Perc  =  0.38  90,397  0.60  0.29  22,237 
85%  Perc  =  0.39  98,819  0.61  0.30  22,815 
90%  Perc  =  0.42  111,543  0.63  0.32  23,569 
95%  Perc  =  0.45  137,317  0.65  0.34  24,637 
178 Figure  1:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  1 
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179 Table  2:  Descriptive  statistics  of  probability  distribution  -  subgroup  2 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E  effect  C 
Minimum  =-  0.11  -  4,211,902  -  4,369  0.55  0.29 
Maximum  =  0.60  50,114,870  18,954  1.04  0.80 
Mean  =  0.26  38,628  7,430  0.79  0.53 
Std  Deviati  0.09  506,517  2,847  0.06  0.07 
Variance  =  0.01  256,559,800,000  8,107,124  0.00  0.00 
Skewness  0.01  97  0  -  0.02  0.01 
Kurtosis  =  2.97  9,554  3  3.05  3.03 
Mode  =  0.25  24,940  6,506  0.71  0.53 
5%  Perc  =  0.11  9,498  2,736  0.69  0.42 
10%  Perc  =  0.14  13,273  3,754  0.71  0.44 
15%  Perc  =  0.16  15,808  4,484  0.73  0.46 
20%  Perc  =  0.18  17,821  5,028  0.74  0.47 
25%  Perc  =  0.20  19,716  5,524  0.75  0.48 
30%  Perc  =  0.21  21,457  5,953  0.76  0.49 
35%  Perc  =  0.22  23,165  6,334  0.77  0.50 
40%  Perc  =  0.24  24,984  6,735  0.78  0.51 
45%  Perc  =  0.25  26,714  7,090  0.78  0.52 
50%  Perc  =  0.26  28,488  7,432  0.79  0.53 
55%  Perc  =  0.27  30,451  7,782  0.80  0.54 
60%  Perc  =  0.28  32,448  8,166  0.81  0.55 
65%  Perc  =  0.29  34,897  8,553  0.81  0.56 
70%  Perc  =  0.31  37,493  8,923  0.82  0.57 
75%  Perc  =  0.32  40,582  9,332  0.83  0.58 
80%  Perc  =  0.34  44,434  9,801  0.84  0.59 
85%  Perc  =  0.35  49,899  10,350  0.85  0.60 
90%  Perc  =  0.38  59,009  11,053  0.87  0.62 
95%  Perc  =  0.41  75,952  12,100  0.89  0.64 
180 Figure  2:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  2 
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Values  in  Thousands Table  3:  Descriptive  statistics  of  probability  distribution  -  subgroup  3 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E  effect  C 
Minimum  =-  0.15  -  186,882,300  1,342  0.26  0.06 
Maximum  =  0.62  106,551,000  29,496  0.84  0.65 
Mean  =  0.24  63,290  15,271  0.58  0.34 
Std  Deviati  0.11  2,424,596  3,636  0.07  0.08 
Variance  =  0.01  5,878,665,000,000  13,220,320  0.00  0.01 
Skewness  0.02  -  39  0  0.00  -  0.02 
Kurtosis  =  2.98  4,024  3  3.02  3.03 
Mode  =  0.20  45,575  11,752  0.52  0.25 
5%  Perc  =  0.07  28,638  9,241  0.47  0.21 
10%  Perc  =  0.10  34,349  10,659  0.49  0.24 
15%  Perc  =  0.13  38,753  11,507  0.51  0.26 
20%  Perc  =  0.15  42,270  12,208  0.52  0.27 
25%  Perc  =  0.17  45,642  12,842  0.53  0.29 
30%  Perc  =  0.19  48,733  13,344  0.54  0.30 
35%  Perc  =  0.20  51,977  13,866  0.55  0.31 
40%  Perc  =  0.21  55,395  14,340  0.56  0.32 
45%  Perc  =  0.23  58,804  14,816  0.57  0.33 
50%  Perc  =  0.24  63,015  15,242  0.58  0.34 
55%  Perc  =  0.25  67,156  15,697  0.59  0.35 
60%  Perc  =  0.27  71,653  16,171  0.60  0.36 
65%  Perc  =  0.28  77,036  16,633  0.61  0.37 
70%  Perc  =  0.29  83,127  17,148  0.62  0.38 
75%  Perc  =  0.31  90,862  17,665  0.63  0.39 
80%  Perc  =  0.33  100,698  18,306  0.64  0.41 
85%  Perc  =  0.35  115,578  19,039  0.65  0.42 
90%  Perc  =  0.38  141,539  19,953  0.67  0.44 
95%  Perc  =  0.42  206,888  21,340  0.70  0.47 
182 Figure  3:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  3 
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*e  <p  ee 
Ne  Ne  i"tKb  Ne Table  4:  Descriptive  statistics  of  probability  distribution  -  subgroup  4 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E  effect  C 
Minimum  =-  0.08  -  5,921,415  3,987  0.42  0.14 
Maximum  =  0.66  1,148,895,000  22,214  0.99  0.70 
Mean  =  0.30  163,231  12,229  0.73  0.43 
Std  Deviati  0.10  11,488,450  2,413  0.07  0.07 
Variance  =  0.01  131,984,500,000,000  5,820,236  0.00  0.00 
Skewness  -  0.00  100  0  0.01  -  0.01 
Kurtosis  =  2.99  9,996  3  3.04  3.08 
Mode  =  0.23  35,917  10,764  0.65  0.36 
5%  Perc  =  0.14  22,637  8,247  0.61  0.31 
10%  Perc  =  0.17  25,691  9,143  0.64  0.34 
15%  Perc  =  0.20  28,186  9,721  0.66  0.36 
20%  Perc  =  0.22  30,167  10,203  0.67  0.37 
25%  Perc  =  0.23  31,826  10,603  0.68  0.38 
30%  Perc  =  0.25  33,525  10,943  0.69  0.39 
35%  Perc  =  0.26  35,302  11,286  0.70  0.40 
40%  Perc  =  0.27  37,024  11,593  0.71  0.41 
45%  Perc  =  0.29  38,831  11,898  0.72  0.42 
50%  Perc  =  0.30  40,650  12,218  0.73  0.43 
55%  Perc  =  0.31  42,823  12,535  0.74  0.44 
60%  Perc  =  0.33  44,936  12,859  0.75  0.45 
65%  Perc  =  0.34  47,456  13,168  0.76  0.46 
70%  Perc  =  0.35  50,287  13,515  0.77  0.47 
75%  Perc  =  0.37  53,707  13,860  0.78  0.48 
80%  Perc  =  0.38  57,918  14,284  0.79  0.49 
85%  Perc  =  0.40  63,594  14,747  0.80  0.50 
90%  Perc  =  0.43  72,668  15,336  0.82  0.52 
95%  Perc  =  0.46  91,789  16,175  0.85  0.54 
184 Figure  4:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  4 
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0  NCO  f!  ýL  pb  t?  cep  Cp  NN`ý'  Nep  Noý` Table  5:  Descriptive  statistics  of  probability  distribution  -  subgroup  5 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E 
Minimum  =-  0.15  -  55,851,440  10,571  -  0.15 
Maximum  =  0.65  370,262,000  62,112  0.65 
Mean  =  0.22  250,358  36,201  0.22 
Std  Deviati  0.10  3,995,778  6,319  0.10 
Variance  =  0.01  15,966,240,000,000  39,933,830  0.01 
Skewness  0.00  80  -0  0.00 
Kurtosis  =  3.03  7,370  3  3.03 
Mode  =  0.07  128,624  35,654  0.07 
5%  Perc  =  0.05  81,035  25,530  0.05 
10%  Perc  =  0.09  94,586  28,042  0.09 
15%  Perc  =  0.12  104,707  29,675  0.12 
20%  Perc  =  0.14  113,024  30,974  0.14 
25%  Perc  =  0.15  120,561  31,990  0.15 
30%  Perc  =  0.17  128,391  32,927  0.17 
35%  Perc  =  0.18  136,066  33,791  0.18 
40%  Perc  =  0.19  144,085  34,645  0.19 
45%  Perc  =  0.21  152,598  35,445  0.21 
50%  Perc  =  0.22  162,146  36,234  0.22 
55%  Perc  =  0.23  171,819  37,029  0.23 
60%  Perc  =  0.25  183,749  37,821  0.25 
65%  Perc  =  0.26  197,361  38,658  0.26 
70%  Perc  =  0.27  213,739  39,511  0.27 
75%  Perc  =  0.29  233,056  40,491  0.29 
80%  Perc  =  0.30  261,027  41,560  0.30 
85%  Perc  =  0.32  300,422  42,764  0.32 
90%  Perc  =  0.35  371,911  44,285  0.35 
95%  Perc  =  0.38  539,475  46,581  0.38 
186 Figure  5:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  5 
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187 Table  6:  Descriptive  statistics  of  probability  distribution  -  subgroup  6 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E  effect  C 
Minimum  0.05  -1042598  -8816.766  0.52  -  0.09 
Maximum  =  1.11  3441217  23747.1  1.21  0.80 
Mean  =  0.49  20105.52  8235.314  0.87  0.38 
Std  Deviati  0.16  42040.23  4274.482  0.09  0.13 
Variance  =  0.02  1.77E+09  1.83E+07  0.01  0.02 
Skewness  0.04  54.75468  -6.83E-02  -  0.04  -  0.00 
Kurtosis  =  2.98  4471.903  2.985778  3.00  2.95 
Mode  =  0.50  12585.84  11473.76  0.80  0.30 
5%  Perc  =  0.23  1957.928  967.4439  0.72  0.17 
10%  Perc  =  0.29  5339.917  2747.382  0.75  0.22 
15%  Perc  =  0.32  7587.487  3842.766  0.78  0.25 
20%  Perc  =  0.36  9139.431  4672.26  0.79  0.27 
25%  Perc  =  0.38  10540.44  5371.251  0.81  0.29 
30%  Perc  =  0.41  12005.91  6017.742  0.82  0.31 
35%  Perc  =  0.43  13259.48  6637.041  0.84  0.33 
40%  Perc  =  0.45  14495.47  7218.548  0.85  0.35 
45%  Perc  =  0.47  15747.94  7751.034  0.86  0.37 
50%  Perc  =  0.49  16927.39  8303.717  0.87  0.38 
55%  Perc  =  0.51  18283.21  8795.231  0.88  0.40 
60%  Perc  =  0.53  19654  9346.19  0.89  0.41 
65%  Perc  =  0.55  21322.99  9918.157  0.90  0.43 
70%  Perc  =  0.57  22950.97  10506.01  0.92  0.45 
75%  Perc  =  0.59  24867.26  11165.74  0.93  0.47 
80%  Perc  =  0.62  27231.59  11853.43  0.94  0.49 
85%  Perc  =  0.65  30425.55  12682.44  0.96  0.51 
90%  Perc  =  0.69  35061.55  13708.04  0.99  0.55 
95%  Perc  =  0.75  44429.67  15148.89  1.02  0.59 
188 Figure  6:  Probability  distribution  of  R=  (CE  -  CC)  /  (EE  -  Ec)  -  subgroup  6 
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00  NA  Oýý  9p 
Values  in  Thousands Table  7:  Descriptive  statistics  of  probability  distribution  -  subgroup  7 
Name  Ee  -  Ec  R  Ce  -  Cc  effect  E  effect  C 
Minimum  -  0.05  -  2,078,959  575  0.52  0.25 
Maximum  0.57  4,609,683  15,838  0.97  0.72 
Mean  =  0.25  39,502  8,325  0.75  0.50 
Std  Deviat  0.08  72,574  2,120  0.06  0.06 
Variance  0.01  5,266,931,000  4,492,929  0.00  0.00 
Skewness  0.06  25  0  0.01  -  0.04 
Kurtosis  =  3.00  1,905  3  2.96  3.02 
Mode  =  0.26  20,599  8,603  0.66  0.41 
5%  Perc  =  0.11  16,568  4,919  0.65  0.40 
10%  Perc  0.14  19,319  5,665  0.67  0.42 
15%  Perc  0.16  21,522  6,159  0.69  0.44 
20%  Perc  0.18  23,129  6,519  0.70  0.45 
25%  Perc  0.19  24,891  6,865  0.71  0.46 
30%  Perc  0.21  26,504  7,165  0.72  0.47 
35%  Perc  0.22  28,036  7,459  0.73  0.48 
40%  Perc  0.23  29,629  7,751  0.73  0.48 
45%  Perc  0.24  31,267  8,035  0.74  0.49 
50%  Perc  0.25  33,037  8,306  0.75  0.50 
55%  Perc  0.26  34,966  8,563  0.76  0.51 
60%  Perc  0.27  37,013  8,847  0.77  0.51 
65%  Perc  0.28  39,341  9,142  0.77  0.52 
70%  Perc  0.30  41,758  9,442  0.78  0.53 
75%  Perc  0.31  44,932  9,762  0.79  0.54 
80%  Perc  0.32  48,455  10,120  0.80  0.55 
85%  Perc  0.34  53,762  10,548  0.81  0.56 
90%  Perc  0.36  61,427  11,106  0.83  0.58 
95%  Perc  0.40  77,879  11,833  0.85  0.60 
190 Figure  7:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  EC)  -  subgroup  7 
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I'll  0  cl  ý+0  qO  All-  cp  Nlzýb Table  8:  Descriptive  statistics  of  probability  distribution  -  subgroup  8 
Name  Ee  -  Ec  =R  mrvý  Ce  -  Cc  effect  E  effect  C 
Minimum  -  0.05  -  1,934,004  1,956  !  0.54  0.17 
Maximum  0.68  32,194,780  22,127  0.97  0.73 
Mean  =  0.30  49,793  1  12,242  0.76  0.46 
Std  Deviat  0.09  325,215  !  2,647  0.06  0.07 
Variance  0.01  105,764,500,000  .  7,007,751  0.00  0.00 
Skewness-  0.00  97  0  0.02  '  0.01 
Kurtosis  =3  03  9,545.3  2  93  3.02 
Mode  =0  27  20,859  12,184.0.66  0.37 
5%  Pere.  0.65  0.33 
10  /o  Perc  0.18  25  766  8,843  ,  0.67  0.36 
15%  Perc  0  21  28,142  9,511  0.69  0.38 
20  °ßa  Pe  rc  0  22  30,081  10,048  0.70  0.39 
0.40  25%  Perc  0.24  31,896  10,492  ;  0.71 
25  33  733  10,884  I  0.72  0.41 
', 
30%  Pe  rc  0.26t' 
35%  Perc  0.26 
__35,528 
11,235  0  73  0.42 
40%  Pe  rc  0.28  37,265  11,562  0.73  0.43 
45%  Perc  0.29 
..  _. 
39,018  11866  0.74  0.44 
4 
Perc  0.30  40,861 
55 
12,212  !0  75  0.45 
°  Perc  0.31  42,859  12,561  '  0.76  0.46 
60%  Perc  0.32  44,928  12,902  0.77  0.47 
65%  Perc  0.33  47,235  j  13,275  0.77  0.48 
70%  Perc  0.35  49  698  13,624  0.78  0.49 
75%  Perc  0.36  2,95  14,028  0  79  0.50 
80%  Perc  0.38  57,061  t  14,472  0.80.0.51 
85%  Perc  0.39  ;  62  324  14  973  0.811- 
, 
0.52 
90%  Perc  0.42  70,671  15,651  ý.  _  _..  0.83.0.54 
95%  Perc  0.45:  86.210  16,624  0.85  '  0.56 
192 Figure  8:  Probability  distribution  of  R=  (CE  -  Cc)  /  (EE  -  Ec)  -  subgroup  8 
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ep  00  to  <,  o  (p  ,  ýo  co  00  Soo  ý,  ýo Table  9:  Descriptive  statistics  of  probability  distribution  -  subgroup  9 
Name  Ee  -  Ec  R  Ce  Cc  effect  E  effect  C 
Minimum  -  0.18  1,253  970 
- 
65 
-  -  - 
0.23  0.00 
Maximum  0.67  324,426  9,6J7  2  ,  0.81  0.57 
Mean  -  0.21  153,227  16,278  0.51  0.30 
Std  Deviat  0.11  3,447,760  3,530.  0  08  0.08 
Variance  0.01  11,887,050,007,000  12,459,730  0.01  0.01 
Skewness  -  0.01  85ý  0  0  02  0.01 
Kurtosis  '='  _  .....  2.96 
Mode  = 
5%  Perc 
10%  Perc 
15%  Perc 
20%  Perc 
25%  Perc 
30%  Perc 
35%  Perc 
40%  Perc 
'45%  Perc 
50°ßo  Perc 
55%  Perc 
60%  Perc 
65%  Perc 
70%  Perc 
75%  Perc 
80%  Perc 
85%  Perc 
90%  Pert 
95%  Perc 
0.13 
0.03 
0.07 
0.09 
51,353 
29,945 
ýý.  38,990 
43,778 
0.12  48,048 
0  13  52,221 
0.15  56,124 
0.17  ....  ____.  _  _  ....  ý....  60,166 
..  , ___.  0.18  "  .  64,804 
0.20  69,441 
0.21  74,564 
0.22  79,487 
0.24  65,513 
0.25  9..  461 
0.27  101,976 
0.29  113751 
0.30  129,637 
0.33  154,528 
0.35 
... .  . _. 
196,576 
0.39  318,934 
12,219  0.41, 
. 
0.21 
__,.  _ 
10,494  Q.  38ä  0.17 
11,745  0.41  i;  0.20 
12,633  ä__. 
....  _. 
0.43 
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15,46i  'l  0.49  0.28 
15'm  . 
50  0.29 
16277  0.51  0.30 
16,720  0.62  0.31 
_.  __..  _..... 
17,157  0.53 
_.  _  .. 
0.32 
17 
__ 
0.54 
_. 
0.33 
18,087  0.55,  0.34 
18x648 
_.  _  __ 
0.56.  0.35 
19,221  0.58.  0.37 
19,916  0.59  0.38 
20,836  ,  0.61  0.40 
22,160  0.64  0.43 
194 Figure  9:  Probability  distribution  of  R=  (CE  -  CC)  /  (EE  -  Ec)  -  subgroup  9 
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195 Table  10:  Descriptive  statistics  of  probability  distribution  -  ECMO  study 
Name  Et-Ec  R  Et  Ec 
1 
Ct-Cc 
Minimum  0.01  16,949  0.44  0.19  6,271 
Maximum  0.54  2,214,339  0  85  0.58  22,597 
Mean  =  0.27  56,757. 
_  ,..  _. 
0.66  s_.  0.39  13,868 
Std  Deviat  0.07  33,675  .  0.05,0.05  2,110 
Variance  0.01 
..  __.  _.. 
1,134,020,  ä00  0.00  0.00  4,454,027 
:  Skewness-  0.01  31  0.01  0  Q3 
__..  __  ....  _. 
0 
Kurtosis  =  3.05  1,821  3.02  3.0,2, 
_ 
3 
Mode  =0  19  38,791  1  0.58  0.35  13,497 
5%  Perc  0.15  32,351  0.57  1  0.31  10,397 
1O%  Pere  0.18  35,939  0.59  0.33 
_  __  .  __11.181  15%  Pere  0.20  38,329  0.61  i  0.34  11,692 
11  20%  Pere  0.21  40,357  0.62  0.35  12,104 
25%  Pere  0.22  42.431  0.62  0  36  ,  12,441 
30°fo  Pere  0.23  44,238_  0.63 
_ 
0.36  j  12,760 
35%  Perc  0.24  45,961  0.64  1  0.37  13,051 
40%  Pere  0.25  47,754  0.65  0.38  13,319 
45%  Pere  0.26  49,543.0.65  0  38  13,585 
50%  Pere  0.27  51,383  3  066  0.39  13,848 
55%  Pere  0.28  53,459  0  67  0.40  14,122 
60%  Pere  0.29  55,687  0  67  0.40  14,391 
65%  Pere  0.30  50,23  4j  068  041  , 41  14,652 
70°l°  Pere  0.31  60,997  0.68  0,42  I  14,  µW  955  4 
75°7°  Pere  0.32  64,365  0  69  1  0.42  115,284 
80%  Pere  0.33  68.154  j  0.70T-  0  43  15,663 
85%  Pere  0.34  73.187  p  0.71  0  44  1  16,078 
90%  Pere  0.36  81,462  0.72 
_0 
45  1,6,612 
95%  Pere  0.38  95.137  '  0.74  0.47  17,325 
196 Figure  10:  Probability  distribution  of  R=  (CE  -  C(')  /  (Ei;  -  E()  -  ECMO  study 
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197 ECMO  Study  data  tables 
Patient  Survival  w/o  Admission  Transport  Readmission  Post-  Total  costs  Total  costs 
Study  no.  severe  costs  costs  costs  discharge  at  one  year 
disability  costs 
1  1  7181.00  640.74  879.20  2446.20  10267.94  10404.20 
2  0  2071.50  0.00  0.00  0.00  2071.50  2233.35 
3  1  4345.00  0.00  0.00  1439.00  5784.00  6496.14 
4  1  14630.50  653.24  220.10  1202.60  16486.34  16630.17 
5  1  19765.50  640.74  592.50  2682.50  23088.74  23429.39 
6  0  2664.00  0.00  0.00  0.00  2664.00  2922.96 
7  1  5925.00  303.97  2567.50  4115.50  10344.47  11315.57 
8  1  14349.30  5262.97  659.40  2212.40  21824.67  21494.68 
9  0  23954.00  0.00  0.00  0.00  23954.00  24135.68 
10  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
11  1  9888.70  753.20  0.00  1236.00  11877.90  11562.23 
12  0  12357.00  459.67  0.00  0.00  12816.67  12831.81 
13  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
14  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
15  1  7033.60  298.14  1978.20  3570.70  10902.44  11224.68 
16  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
17  0  1281.50  627.05  0.00  0.00  1908.55  1940.92 
18  1  12189.50  640.74  0.00  1075.50  13905.74  14094.99 
19  1  5377.70  737.89  0.00  484.00  6599.59  7428.38 
20  0  12159.50  822.00  0.00  0.00  12981.50  12989.07 
21  0  10346.50  369.67  0.00  0.00  10716.17  10723.74 
22  0  1281.50  338.07  0.00  0.00  1619.57  1651.94 
23  0  13921.50  0.00  0.00  0.00  13921.50  16025.55 
24  1  3555.00  1126.49  879.80  1614.80  6296.29  6432.55 
25  0  1303.80  450.56  0.00  0.00  1754.36  1764.43 
26  1  7019.00  640.74  0.00  1749.00  9408.74  9469.30 
27  1  97086.40  1095.19  0.00  0.00  98181.59  93451.24 
28  0  25832.50  634.50  8887.50  10203.00  36670.00  36965.23 
29  0  1281.50  366.33  0.00  0.00  1647.83  1655.40 
30  0  6811.50  0.00  0.00  0.00  6811.50  7750.23 
31  0  1303.80  0.00  0.00  0.00  1303.80  1313.87 
32  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
33  0  1479.00  280.66  0.00  0.00  1759.66  1824.40 
34  1  3077.20  0.00  3160.00  4502.50  7579.70  7720.68 
35  1  6122.50  0.00  1580.00  3676.50  9799.00  10802.47 
36  1  7019.00  1190.19  440.20  1691.20  9900.39  9960.95 
37  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
38  1  8132.60  0.00  0.00  1501.50  9634.10  10006.69 
39  1  13482.40  1423.33  0.00  1452.00  16357.73  15901.92 
40  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
41  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
42  0  19411.50  5000.00  0.00  0.00  24411.50  24419.07 
43  1  12422.50  6694.94  0.00  1471.00  20588.44  20717.13 
44  1  14433.00  6732.58  0.00  3360.50  24526.08  24662.34 
45  1  3752.50  1811.05  0.00  1563.50  7127.05  7742.08 
198 Patient  Survival  w/o  Admission  Transport  Readmission  Post-  Total  costs  Total  costs 
Study  no.  severe  costs  costs  costs  discharge  at  one  year 
disability  costs 
46  1  3297.00  0.00  879.20  3098.20  6395.20  6546.25 
47  0  1304.10  0.00  0.00  0.00  1304.10  1313.87 
48  1  16876.30  728.21  1320.60  4069.10  21673.61  21417.27 
49  0  2906.10  295.23  0.00  0.00  3201.33  3448.06 
50  1  11794.50  0.00  0.00  954.00  12748.50  12922.61 
51  1  5424.90  280.66  0.00  1024.50  6730.06  7281.78 
52  0  2071.50  0.00  0.00  0.00  2071.50  2233.35 
53  1  9108.70  815.68  0.00  1062.50  10986.88  10803.37 
54  1  9723.50  1267.23  0.00  2874.50  13865.23  13682.13 
55  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
56  0  1874.00  0.00  0.00  0.00  1874.00  2003.48 
57  1  6193.50  6693.27  0.00  1312.00  14198.77  14297.18 
58  1  11931.50  646.99  0.00  1408.50  13986.99  13819.03 
59  1  10395.30  12524.65  660.30  2033.80  24953.75  24886.50 
60  0  1304.10  0.00  0.00  0.00  1304.10  1313.87 
61  1  13188.00  0.00  220.10  1473.10  14661.10  15265.30 
62  1  37412.20  331.66  11652.50  14218.50  51962.36  52539.32 
63  0  45070.10  977.25  0.00  0.00  46047.35  46964.14 
64  1  8995.60  722.34  0.00  1393.50  11111.44  11770.38 
65  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
66  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
67  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
68  1  5201.90  1164.87  0.00  1790.00  8156.77  8286.69 
69  0  1874.00  403.80  0.00  0.00  2277.80  2407.28 
70  0  37475.00  814.83  0.00  0.00  38289.83  39198.23 
71  1  12800.70  1032.25  0.00  1598.50  15431.45  15042.13 
72  1  24172.90  1534.81  1077  5.00  13238.00  38945.71  38644.77 
73  0  1281.50  342.60  0.00  0.00  1624.10  1656.47 
74  1  10017.00  640.74  197.50  1088.50  11746.24  11852.22 
75  0  2071.50  0.00  0.00  0.00  2071.50  2233.35 
76  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
77  1  17664.00  922.25  0.00  2645.50  21231.75  21352.87 
78  1  5816.70  298.14  0.00  1610.00  7724.84  8574.37 
79  1  2962.50  765.68  0.00  999.50  4727.68  4841.23 
80  1  5495.00  0.00  0.00  2233.00  7728.00  7979.75 
81  1  18885.00  280.66  879.20  2501.70  21667.36  21140.77 
82  1  80777.50  0.00  0.00  1868.00  82645.50  95884.83 
83  0  1281.50  344.87  0.00  0.00  1626.37  1658.74 
84  1  17988.00  280.66  0.00  1106.50  19375.16  19647.68 
85  0  6517.50  0.00  2567.50  4791.00  11308.50  12376.71 
86  1  10392.90  709.47  0.00  1063.00  12165.37  12100.52 
87  1  4740.00  280.66  2765.00  4343.50  9364.16  10141.04 
88  1  9191.50  634.50  0.00  1714.50  11540.50  11684.33 
89  1  3383.00  634.27  1318.80  2768.80  6786.07  7080.99 
90  1  3580.50  359.34  0.00  2092.00  6031.84  5937.53 
91  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
92  1  12645.50  4444.22  0.00  672.50  17762.22  17667.91 
199 Patient  Survival  w/o  Admission  Transport  Readmission  Post-  Total  costs  Total  costs 
Study  no.  severe  costs  costs  costs  discharge  at  one  year 
disability  costs 
93  0  13662.60  6955.82  6278.60  6278.60  26897.02  26563.97 
94  1  12110.40  856.17  0.00  548.00  13514.57  14736.63 
95  1  7967.20  1280.03  660.30  1741.30  10988.53  10921.17 
96  1  3516.80  0.00  0.00  1096.00  4612.80  4773.92 
97  0  4046.50  0.00  0.00  0.00  4046.50  4532.05 
98  0  13972.50  4099.00  0.00  0.00  18071.50  18079.07 
99  0  24617.50  0.00  0.00  0.00  24617.50  24685.63 
100  1  8679.10  418.63  0.00  2483.50  11581.23  11589.62 
101  1  8690.00  0.00  0.00  954.50  9644.50  11068.78 
102  1  12817.50  499.67  0.00  921.00  14238.17  14382.00 
103  0  3454.00  492.08  0.00  0.00  3946.08  4334.52 
104  0  45710.00  904.79  0.00  0.00  46614.79  47391.67 
105  1  15634.40  709.47  1758.40  2982.90  19326.77  19254.35 
106  1  3736.60  0.00  1318.80  2577.80  6314.40  6485.59 
107  1  7110.00  0.00  3297.30  4281.80  11391.80  12557.12 
108  1  27215.00  6327.55  0.00  1452.00  34994.55  35342.77 
109  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
110  1  34697.30  1203.26  1758.40  3812.90  39713.46  39561.05 
111  1  17628.50  646.99  0.00  1688.50  19963.99  20153.24 
112  0  41167.50  4069.99  0.00  0.00  45237.49  45245.06 
113  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
114  0  1303.80  0.00  0.00  0.00  1303.80  1313.87 
115  0  11263.00  709.36  0.00  0.00  11972.36  12154.04 
116  1  10110.80  0.00  0.00  1001.50  11112.30  11575.52 
117  0  30289.50  0.00  0.00  0.00  30289.50  30297.07 
118  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
119  0  66270.30  1487.03  0.00  0.00  67757.33  64814.42 
120  1  11217.60  1167.10  0.00  1030.50  13415.20  13378.56 
121  0  47310.00  906.61  0.00  0.00  48216.61  48807.07 
122  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
123  1  12360.60  1886.42  0.00  1043.50  15290.52  15276.04 
124  1  3425.30  562.45  219.80  1205.30  5193.05  5675.54 
125  0  28836.00  1283.64  0.00  0.00  30119.64  30210.48 
126  0  1281.50  5000.00  0.00  0.00  6281.50  6313.87 
127  0  1303.80  0.00  0.00  0.00  1303.80  1313.87 
128  1  9768.10  878.82  2417.80  4480.80  15127.72  14900.02 
129  1  3357.50  0.00  0.00  1234.50  4592.00  5142,29 
130  1  5537.30  790.69  0.00  1169.00  7496.99  7431.32 
131  1  52031.40  1138.23  1538.60  5037.10  58206.73  57862.26 
132  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
133  0  1303.80  280.66  0.00  0.00  1584.46  1594.53 
134  1  2765.00  0.00  879.20  1988.20  4753.20  4859.18 
135  0  2466.50  516.95  0.00  0.00  2983.45  3210.04 
136  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
137  0  10687.60  280.66  0.00  0.00  10968.26  12693.64 
138  0  18118.20  653.24  0.00  0.00  18771.44  18331.18 
139  1  7216.50  6096.59  0.00  951.50  14264.59  14332.72 
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140  1  10270.00  286.49  0.00  1154.00  11710.49  13393.73 
141  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
142  1  9207.00  568.99  0.00  2264.00  12039.99  11790.81 
143  1  13558.50  765.61  0.00  1846.50  16170.61  16156.02 
144  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
145  1  6912.50  280.66  220.10  2454.60  9647.76  10780.71 
146  1  32871.10  667.30  197.50  1541.50  35079.90  34996.66 
147  1  4587.70  347.69  0.00  1972.50  6907.89  7607.20 
148  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
149  0  1676.50  902.41  0.00  0.00  2578.91  2601.62 
150  1  8295.00  0.00  1320.60  3052.60  1134  7.60  12707.14 
151  1  22996.10  810.69  4615.80  7629.30  31436.09  30974.35 
152  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
153  1  16392.10  709.65  0.00  2001.50  19103.25  18920.97 
154  0  60107.50  6337.04  0.00  0.00  66444.54  66830.61 
155  0  3651.50  0.00  0.00  0.00  3651.50  4072.31 
156  0  1479.00  0.00  0.00  0.00  1479.00  1543.74 
157  1  9464.30  0.00  1320.60  3813.10  13277.40  13697.51 
158  1  18780.10  412.10  0.00  1513.00  20705.20  20563.13 
159  1  12027.50  646.99  0.00  968.50  13642.99  13756.54 
160  1  4345.00  1002.24  0.00  1419.50  6766.74  7478.88 
161  0  55671.50  0.00  0.00  0.00  55671.50  55679.07 
162  1  15811.70  790.69  0.00  2060.50  18662.89  18618.24 
163  1  13627.50  0.00  5135.00  7426.50  21054.00  23287.53 
164  1  2962.50  0.00  592.50  1391.00  4353.50  4839.05 
165  1  8006.50  634.50  0.00  1267.00  9908.00  10006.41 
166  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
167  0  25245.50  8444.33  0.00  0.00  33689.83  33712.54 
168  1  10143.50  665.73  0.00  688.00  11497.23  11747.04 
169  0  2269.00  283.57  0.00  0.00  2552.57  2746.79 
170  1  27736.50  659.90  0.00  813.50  29209.90  29717.09 
171  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
172  1  2567.50  0.00  395.00  1711.00  4278.50  4699.31 
173  1  11652.50  280.66  0.00  2317.50  14250.66  16160.49 
174  1  6547.10  878.82  0.00  750.00  8175.92  8125.80 
175  1  9857.70  6734.82  0.00  767.00  17359.52  17247.29 
176  1  13410.00  280.66  0.00  1047.50  14738.16  14904.70 
177  0  55020.30  2951.77  0.00  0.00  57972.07  57955.13 
178  0  1303.80  0.00  0.00  0.00  1303.80  1313.87 
179  1  13379.10  306.89  2417.80  3670.80  17356.79  18459.50 
180  0  1281.50  0.00  0.00  0.00  1281.50  1313.87 
181  0  13901.50  0.00  0.00  0.00  13901.50  14045.33 
182  0  3256.50  343.31  0.00  0.00  3599.81  3955.88 
183  0  1281.50  0.00  0.00  0.00  1281.50  1289.07 
184  0  1281.50  359.67  0.00  0.00  1641.17  1648.74 
191  0  1303.80  0.00  0.00  0.00  1303.80  1313.87 
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SUMMARY 
The  statistic  of  interest  in  most  health  economic  evaluations  is  the  incremental  cost-effectiveness  ratio.  Since 
the  variance  of  a  ratio  estimator  is intractable,  the  health  economics  literature  has  suggested  a  number  of 
alternative  approaches  to  estimating  confidence  intervals  for  the  cost-effectiveness  ratio.  In  this  paper, 
Monte  Carlo  simulation  techniques  are  employed  to  address  the  question  of  which  of  the  proposed  methods 
is  most  appropriate.  By  repeatedly  sampling  from  a  known  distribution  and  applying  the  different  methods 
of  confidence  interval  estimation,  it  is  possible  to  calculate  the  coverage  properties  of  each  method  to  see  if 
these  correspond  to  the  chosen  confidence  level.  As  the  results  of  a  single  Monte  Carlo  experiment  would  be 
valid  only  for  that  particular  set  of  circumstances,  a  series  of  experiments  was  conducted  in  order  to  examine 
the  performance  of  the  different  methods  under  a  variety  of  conditions  relating  to  the  sample  size,  the 
coefficient  of  variation  of  the  numerator  and  denominator  of  the  ratio,  and  the  covariance  between  costs  and 
effects  in  the  underlying  data.  Response  surface  analysis  was  used  to  analyse  the  results  and  substantial 
differences  between  the  different  methods  of  confidence  interval  estimation  were  identified.  The  methods, 
both  parametric  and  non-parametric,  which  assume  a  normal  sampling  distribution  performed  poorly,  as 
did  the  approach  based  on  simply  combining  the  separate  intervals  on  costs  and  effects.  The  choice  of 
method  for  confidence  interval  estimation  can  lead  to  large  differences  in  the  estimated  confidence  limits  for 
cost-effectiveness  ratios.  The  importance  of  such  differences  is  an  empirical  question  and  will  depend  to 
a  large  extent  on  the  role  of  hypothesis  testing  in  economic  appraisal.  However,  where  it  is  suspected  that  the 
sampling  distribution  is  skewed,  normal  approximation  methods  produce  particularly  poor  results  and 
should  be  avoided.  Copyright  ©  1999  John  Wiley  &  Sons,  Ltd. 
1.  INTRODUCTION 
The  purpose  of  the  economic  appraisal  of  health  care  interventions  is  to  inform  public  health 
decision  makers  of  the  relative  value  for  money  (or  cost-effectiveness)  of  funding  alternative 
interventions.  Where  the  intervention  in  question  generates  improved  health  outcomes  for 
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patients,  but  at  increased  overall  cost,  the  appropriate  summary  measure  of  cost-effectiveness  is 
the  incremental  cost-effectiveness  ratio  (ICER).  The  ICER  measures  the  additional  cost  of  one 
intervention  over  another  (say  treatment  A  and  treatment  B)  per  unit  difference  in  effectiveness. 
Where  data  have  been  obtained  from  two  samples  of  patients  receiving  the  different  treatments, 
the  ICER  is  calculated  as  in  equation  (1): 
CA  -  CAC 
,, 
k- 
-EB-äE 
(1) 
where  CA  and  EA  are  the  mean  costs  and  effects  for  the  sample  receiving  treatment  A  and  C  and 
Ea  are  the  mean  costs  and  effects  for  the  sample  receiving  treatment  B. 
When  sample  data  on  costs  and  effects  are  available  it  is  natural  to  consider  the  use  of 
statistical  techniques  to  calculate  confidence  intervals  around  such  point  estimates.  Unfortunate- 
ly,  the  calculation  of  confidence  intervals  for  a  ratio  is  far  from  straightforward  since  the 
probability  of  obtaining  a  zero  or  near  zero  value  on  the  denominator  of  the  ratio  is  non- 
negligible,  which  suggests  that  the  moments  of  the  ICER  may  be  undefined.  In  practice,  this  is 
a  very  real  problem  since  it  is  common  for  clinical  trials  to  be  designed  to  detect  the  smallest 
meaningful  clinical  difference  between  treatments  and  is  likely  to  lead  to  a  large  number  of  studies 
showing  differences  in  treatment  effects  which  are  close  to  zero.  '  Clearly,  this  presents  a  problem 
for  the  use  of  standard  parametric  statistical  methods.  Recent  research  has  focused  on  parametric 
approximations  to  the  confidence  interval  for  the  ICER.  2-5  In  addition,  several  commentators 
have  also  proposed  the  non-parametric  approach  of  bootstrapping  as  a  method  for  estimating 
confidence  intervals,  '  2.6,7  and  this  approach  has  been  successfully  demonstrated  using  clinical 
trial  data.  "  In  the  face  of  all  the  possible  methods,  one  question  quickly  surfaces.  Which  of  these 
methods  is  the  most  appropriate? 
In  this  paper  we  present  the  results  of  a  Monte  Carlo  simulation  exercise  designed  to  evaluate 
the  alternative-methods  of  calculating  confidence  intervals  for  the  ICER  statistic,  under  a  variety 
of  different  conditions.  The  experiments  require  a  massive  number  of  iterations  which,  even  a  few 
years  ago,  would  have  put  this  exercise  beyond  our  reach,  but  which  is  now  possible  thanks  to  the 
increasing  power  of  personal  computers. 
2.  METHODS 
This  section  is  split  into  three.  The  first  two  parts  describe  in  some  detail  the  alternative 
parametric  and  non-parametric  methods  that  have  been  proposed  for  estimating  the  confidence 
limits  for  the  ICER.  The  third  part  of  this  section  presents  the  overall  Monte  Carlo  simulation 
experiment  designed  to  evaluate  each  of  the  methods. 
2.1.  Parametric  approaches  to  estimating  the  ICER  confidence  interval 
Three  main  methods,  based  on  the  parametric  approach  for  calculating  confidence  intervals  for 
an  ICER,  have  recently  appeared  in  the  literature.  "  Each  of  these  methods  is  explored  in  turn, 
highlighting  the  assumptions  on  which  it  is based. 
2.1.1.  The  confidence  box  approach 
A  number  of  commentators  have  advocated  the  cost-effectiveness  plane  (CE  plane)  for  presenting 
the  results  of  economic  evaluation  and  for  aiding  policy  decisions.  9"0  O'Brien  and  colleagues 
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Figure  I.  Confidence  limits  on  the  cost-effectiveness  plane  and  the  `confidence  box'  approach  to  estimating  confidence 
limits  for  the  ICER 
showed  how  the  CE  plane  could  also  be  used  to  present  the  confidence  limits  for  the  estimate  of 
incremental  cost-effectiveness.  2  Figure  1,  which  is  based  on  the  representation  by  O'Brien  and 
colleagues,  shows  the  results  of  a  hypothetical  prospective  economic  evaluation  on  the  CE  plane. 
The  difference  in  effect  between  two  therapies  is  shown  on  the  horizontal  axis  with  mean  effect 
difference  AE  and  upper  and  lower  confidence  limits  for  the  effect  difference  (AE'  and  AE`) 
represented  by  the  horizontal  `I'  bar.  Similarly,  the  difference  in  cost  between  two  therapies  is 
shown  on  the  vertical  axis  with  mean  cost  difference  AC,  and  upper  and  lower  confidence  limits 
for  the  cost  difference  (AC'  and  iCL)  represented  by  the  vertical  'I'  bar.  These  'I'  bars  intersect  at 
point  (DE,  AC),  hence  the  ray  that  connects  this  point  of  intersection  to  the  origin  has  a  slope 
equal  to  the  value  of  the  ICER.  O'Brien  and  colleagues  argue  that  combining  the  limits  of  the 
confidence  intervals  for  costs  and  effects  separately  gives  natural  best  and  worst case  limits  on  the 
ratio;  that  is,  the  upper  limit  of  the  cost  difference  over  the  lower  limit  of  the  effect  difference 
(AC"/4E')  gives  the  highest  values  of  the  ratio  (worst  case)  and  the  lower  limit  of  costs  divided  by 
the  upper  limit  of  effects  (,  &C'/AE)  gives  the  lowest  (best)  value  of  the  ratio. 
2.1.2.  The  Taylor  series  approximation 
Rather  than  use  these  extreme  limits,  which  are  likely  to  overestimate  the  true  interval,  O'Brien 
and  colleagues  argue  that  it  is  possible  to  use  the  Taylor  series  approximation  of  the  variance  of 
a  function  of  two  random  variables  to  estimate  the  variance  of  a  ratio.  '  The  advantage  of  this 
method  is  that  it  accounts  for  the  covariance  between  the  numerator  and  denominator.  Having 
approximated  the  variance  of  the  ICER  statistic  in  this  way,  assuming  the  sampling  distribution 
of  the  ICER  to  be  normal  allows  the  confidence  interval  to  be  estimated  in  the  traditional  manner. 
The  Taylor  approximation  shows  that  where  y  is  a  function  of  two  random  variables  x1  and  x2, 
the  variance  of  y can  be  expressed  in  terms  of  the  partial  derivatives  of  y  with  respect  to  xI  and  x2, 
weighted  by  the  variances  and  covariance  of  x1  and  x2.  The  Taylor  series  formula  is 
(3)2  i 
var(y)  zi  var(xj)  + 
ay 
var(xz)  +  2( 
ay 
1)  _) 
cov(xs,  x=).  (2) 
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Equation  (2)  can  now  be  solved  for  the  case  of  the  ICER  presented  in  equation  (1)  by  substituting 
AC  for  xl  and  zE  for  x2.  *  Hence  equation  (3)  gives  the  Taylor  series  approximation  of  the 
variance  of  the  ratio  estimator,  using  the  sample  estimates  of  the  means  and  variances  (since  by 
definition,  the  population  values  cannot  be  observed): 
i 
var(fZ) xz  var(dC)  + 
e-R4 
var(0  -23  cov(i  , 
dE).  (3) 
Factoring  Rz  =  OC2/DE2  from  the  right-hand  side  simplifies  (3)  to 
var(R)  ., 
Rz 
rvar(AC) 
+ 
var(eE) 
_2 
cov(AC,  AE)I 
Noting  that  the  coefficient  of  variation  for  a  random  variable  x  is  defined  cv(x)  =  Jvar(x)/z  and 
that  the  correlation  coefficient  between  two  random  variables  x  and  y  is  defined 
px,,  =  cov(x,  y)/,  /  var(x)  var(y))  further  simplifies  the  exposition: 
var(ft)  -- 
kz  [cv(AC)2  +  cv(4  2-  2pcv(61C)cv(4E)].  (4) 
Employing  standard  parametric  assumptions  gives  the  confidence  interval  as 
(h  -  Z,  /2  -, 
/var(k),  E+  za/2  Jvar(R)) 
where  z812  =  qb  -  I[1 
-  a/2],  0'  1  is  the  inverse  of  the  cumulative  distribution  of  the  standard 
normal  function,  and  100(1  -  a)  per  cent  is  the  confidence  level. 
O'Brien  and  colleagues  recognize  that  although  the  assumption  of  a  normal  distribution  may 
be  justified  in  the  case  of  large  samples,  it  is  unlikely  that  the  distribution  of  a  ratio  will  follow 
a  well-behaved  distribution  in  general.  2  However,  even  if  samples  are  large,  the  distribution  is 
likely  to  be  skewed  where  the  coefficient  of  variation  of  the  denominator  of  the  ICER  (effect 
difference)  is  high.  ' 
2.1.3.  Fieller's  method 
An  alternative  method  of  calculating  confidence  intervals  around  ratios  has  been  described  by 
Fieller.  "  This  approach  has  been  advocated  for  use  in  calculating  confidence  intervals  around 
ICERs  by  both  Willan  and  O'Brien3  and  Chaudhary  and  Stearns.  5  The  method  is described  in 
general  terms  by  Cochran.  12 
The  advantage  of  Fieller's  method  over  the  Taylor  series  expansion  is  that  it  takes  into  account 
the  skew  of  the  ratio  estimator.  The  method  assumes  that  the  numerator  and  denominator  of  the 
ratio  follow  a  joint  normal  distribution  function  such  that  (in  the  case  of  the  ICER)  AC  -  RAE  is 
normally  distributed.  Hence,  dividing  through  by  the  standard  deviation  equation  (5)  follows  the 
standard  normal  distribution: 
AC  -  RAE 
N(0,1).  (5) 
. 
J{var(iC)  +  R2  var(AE)  -  2R  cov(AC,  AE)) 
'  The  partial  derivatives  of  the  ICER  with  respect  to  AC  and  AE  are  1/AE  -and  AC/sE3,  respectively. 
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Setting  this  expression  equal  to  z212  and  rearranging  gives  the  following  quadratic  equation  in 
R  (using  the  simplified  notation  introduced  in  equation  (4)): 
R2[1  -  z;,  zcv(OL)2]  -  2Rf[1  -  zCO  pcv(0E)co(0C)]  +  IA2[1  -  z,  2cu(AC)]  =0  (6) 
where  R  is defined  from  equation  (1). 
Solving  equation  (6)  for  R  using  the  standard  quadratic  formula*  gives  the  confidence  inter- 
val  as 
R 
rl 
-  Za/2  pcv(eC)CV(AE)1 
L1-  ZQ  CV(AE)2  J 
±ZQ, 
Z 
RLý/{CV(AC  +  CV(AE)2  - 
2ý0(eC)CV(A  'E)- 
Where  the  sampling  distribution  of  the  ICER  is  skewed,  this  confidence  interval  will  not  be 
symmetrically  positioned  around  the  point  estimate.  This  method  has  been  criticized  on  the 
grounds  that  the  assumption  of  joint  normality  may  be  hard  to  justify  where  sample  sizes  are 
small.  5 
2.2.  Bootstrap  approaches  to  estimating  the  ICER  confidence  interval 
Given  the  unknown  nature  of  the  ICER's  sampling  distribution,  there  is  reason  to  be  cautious  of 
the  parametric  approaches  to  confidence  interval  estimation.  A  number  of  commentators  have 
suggested  the  non-parametric  approach  of  bootstrapping  as  a  possible  method  of  estimating 
confidence  limits  for  the  ICER.  1.2.6.7  The  advantage  of  such  intervals  is  that  they  do  not  depend 
on  parametric  assumptions  concerning  the  sampling  distribution  of  the  ICER. 
The  bootstrap  approach  for  the  simple  one  sample  case  is  straightforward.  Suppose  a  particu- 
lar  population  has  a  real  but  unobserved  probability  distribution  F  from  which  a  random  sample 
x  of  n  observations  is  taken,  and  the  statistic  of  interest  s(x)  is  calculated.  The  concern  of 
inferential  statistics  is  to  make  statements  about  the  population  parameter  0  based  on  the  sample 
drawn  from  that  population.  In  the  `bootstrap  world',  the  observed  random  sample  x  is  treated  as 
the  empirical  estimate  of  F  by  weighting  each  observation  in  x  by  the  probability  l/n.  Successive 
random  samples  of  size  n  are  then  drawn  from  x  with  replacements  to  give  the  bootstrap  samples 
(re-samples from  the  original  sample).  The  statistic  of  interest  is  calculated  for  each  of  these 
samples  and  these  bootstrap  replicates  of  the  original  statistic  make  up  the  empirical  estimate  of 
the  sampling  distribution  for  that  statistic.  This  estimated  sampling  distribution  can  be  used  in 
a  variety  of  ways  to  construct  confidence  intervals. 
In  principle,  the  bootstrap  estimate  of  the  ICER  sampling  distribution  can  be  obtained  in 
a  very  similar  way  to  that  of  the  simple  one  sample  case.  However,  since  the  ICER  is  estimated  on 
the  basis  of  four  estimators  from  two  samples  (equation  (1))  care  must  be  taken  to  bootstrap  each 
sample  appropriately.  For  data  structures  which  are  more  complicated  than  a  one  sample 
structure,  Efron  and  Tibshirani  advocate  that  the  bootstrap  mechanism  for  the  observed  data 
The  solution  formula  for  a  quadratic  equation  of  the  form  ax2  +  bx  +c-0  is  -b±  (J(b'  -  4ac))/2a. 
Clearly,  sampling  from  x  without  replacement  would  simply  yield  x  itself.  Hence  it  is  the  sampling  with  replacement 
which  provides  the  variability  through  the  chance  that  some  observations  will  appear  in  the  bootstrap  sample  more  than 
once  while  others  will  be  omitted  altogether. 
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Figure  2.  Bootstrap  estimation  of  the  sampling  distribution  of  the  ICER  calculated  from  clinical  trial  data  (overlaid  is 
a  normal  distribution  with  the  same  mean  and  variance) 
mirror  the  mechanism  by  which  those  original  data  were  obtained.  '-'  In  the  case  of  the  IC  R, 
where  data  on  resource  use  and  outcome  exists  for  two  groups  of  patients  of  size  n,  and 
nº,  receiving  treatments  A  and  B,  respectively,  this  will  involve  a  three-stage  process: 
1.  Sample  with  replacement  n,  cost/effect  pairs  from  the  sample  of  patients  who  received 
treatment  A  and  calculate  the  bootstrap  estimates  CZ  and  F*  for  the  bootstrap 
sample. 
2.  Sample  with  replacement  nºº  cost/effect  pairs  from  the  sample  of  patients  receiving  treatment 
B  and  calculate  the  bootstrap  estimates  C,  *, *  and  £;  for  the  bootstrap  sample. 
3.  Calculate  the  bootstrap  replicate  of  the  ICER  given  by  the  equation 
R*=C"-C"-AC*  (7) 
A*-ý,  *,  -0E*. 
Repeating  this  three-stage  process  many  times  gives  a  vector  of  bootstrap  estimates,  which  is  an 
empirical  estimate  of  the  sampling  distribution  of  the  ICER  statistic.  For  example,  the  histogram 
in  Figure  2  shows  the  estimated  sampling  distribution  from  a  previously  reported  study  which 
used  the  bootstrap  to  estimate  the  sampling  distribution  of  the  ICER  calculated  from  data 
generated  by  an  economic  evaluation  conducted  alongside  a  clinical  trial.  " 
Once  the  sampling  distribution  of  the  ICER  has  been  estimated  in  this  wary,  several 
approaches  exist  to  estimate  confidence  limits  using  the  bootstrap  estimate  of  the  sampling 
distribution. 
Copyright  (i')  1999  John  Wiley  &  Sons,  Ltd.  Statut.  Mrd.  IN33245  ):  n  (1499) 
207 CONFIDENCE  INTERVALS  FOR  COST-EFFECTIVENESS  RATIOS  3251 
2.2.1.  Normal  approximation 
One  method  for  confidence  interval  estimation  is  to  take  the  bootstrap  estimate  of  standard  error, 
given  by 
R*b)2}  (8) 
tl 
b=1  ll 
(where  B  is  the  total  number  of  bootstrap  replications)  and  assume  that  the  sampling  distribution 
of  the  statistic  is  normal.  The  resulting  100(1  -  a)  per  cent  confidence  interval  is 
(A  -  zQ12  , 
fi  +Zog/26" 
While  comfortingly  familiar,  this  method  may  be  seriously  misleading  if  the  sampling  distribution 
is  not  normal.  It  ignores  the  wealth  of  information  in  the  bootstrap  estimate  of  the  sampling 
distribution,  which,  as  can  be  seen  clearly  from  Figure  2,  may  be  far  from  normal. 
2.2.2.  Percentile 
The  percentile  method  avoids  this  problem  by  making  direct  use  of  the  empirical  sampling 
distribution.  The  1O0(a/2)  and  100(1  -  a/2)  percentile  values  of  the  bootstrap  sampling  distribu- 
tion  estimate  are  used  as  the  upper  and  lower  confidence  limits  for  the  ICER.  The  attraction  of 
this  method  is  its  simplicity  and  its  avoidance  of  the  assumption  of  normality  for  the  ICER. 
However,  it  has  received  considerable  criticism  from  some  commentators;  for  example,  Hall 
(reference  14,  p.  36)  describes  the  percentile  method  as  equivalent  to  ` 
... 
looking  up  the  wrong 
statistical  tables  backwards'.  "  That  is,  skewed  estimation  can  cause  trouble  for  the  percentile 
method.  In  particular,  in  this  context,  the  percentile  method  assumes  that  the  bootstrap  replicates 
of  the  ICER  are  unbiased,  whereas  it  is  known  that  ratio  estimators  are  biased  and  that  bootstrap 
replicates  will  magnify  the  bias  of  the  sample  estimate.  '  5 
2.2.3.  Bias-corrected  and  accelerated 
Efronlb  suggests  a  modification  of  the  percentile  method,  which  seeks  to  adjust  for  the  bias  and 
skew  of  the  sampling  distribution.  This  is  the  bias-corrected  and  accelerated  (BCa)  percentile 
method,  which  involves  algebraic  adjustments  to  the  percentiles  selected  to  serve  as  the  confi- 
dence  interval  endpoints.  The  adjusted  percentiles  are  given  by 
lr  +  Zs/2  1 
Of  +  Z.,  2)) 
2+Z(1--12) 
GC2=ý  ý-}-  ý9ý 
1 
-Q(1+z(1-.  120 
where  b(.  )  is  the  standard  normal  cumulative  distribution  function  and  z.  is  the  100a  percentile 
point  of  the  standard  normal  distribution.  Two  adjustments  to  the  percentiles  are  incorporated 
into  equation  (9):  1  adjusts  the  sampling  distribution  for  the  bias  of  the  estimator,  while  a  adjusts 
for  the  skew  of  the  sampling  distribution.  Setting  B-0  yields  the  adjustment  for  bias  on  the 
percentiles  chosen  to  serve  as  endpoints,  and  is  equivalent  to  the  bias-corrected  method 
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advocated  by  Chaudhary  and  Stearn:  ' 
al  =  4)(21  +  z«12) 
«z  =  «(2i  +  Z(1-a/2))"  (1O) 
This  bias  correction,  i,  is  given  by  1=  c  -1(Q)  where  Q  is  the  proportion  of  bootstrap  replicates 
which  are  less  than  the  sample  estimate,  R.  Therefore,  if  the  bootstrap  sampling  distribution  has 
median  R,  Q=0.5  which  gives  i=0  and  (in  the  absence  of  a  skew  adjustment)  the  percentiles 
from  equation  (10)  correspond  to  those  from  the  straightforward  percentile  method.  However, 
where  the  sampling  distribution  is  not  centred  on  Ra  correction  is  made  for  this  bias.  Notice  that 
the  non-linear  relationship  between  the  z-score  and  its  probability  results  in  the  percentile  end 
points  being  shifted  at  unequal  rates.  It  is  also  worth  noting  that  the  bias  correction  adjustment  of 
the  BCa  method,  while  not  employing  distributional  assumptions  concerning  the  sampling 
distribution  of  the  ICER  itself,  does  make  use  of  parametric  assumptions  concerning  the 
distribution  of  the  observed  bias.  This  reliance  on  parametric  assumptions  has  been  cited  as 
a  potential  weakness  of  the  BCa  method.  " 
The  acceleration  constant  adjusts  for  the  skew  of  the  sampling  distribution.  Efron  and 
Tibshirani  suggest  using  a  jack-knife  estimate  for  &:  13 
U  1) 
where  R!  `*  is  the  jack-knife  replicate  of  the  ICER  with  the  ith  observation  removed,  R**  =ER'*ln 
for  i=I  to  n  and  n=  nc  +  nT.  In  terms  of  the  adjustments  to  the  percentiles  given  in  equation  (9), 
in  the  absence  of  a  bias  correction  adjustment,  the  skew adjustment  is  given  by 
1aý2 
a1  - 
ý(1 
- 
&zýyz 
(12) 
z(l 
_  Q/z) 
a2  -  ý(1 
-  &z  ti  -adz) 
Equation  (11)  shows  that  if  the  sampling  distribution  is  symmetric,  ä=0  and  equation  (12)  shows 
that  no  adjustment  to  the  percentile  interval  endpoints  is  made. 
2.2.4.  Parametric  bootstrap 
Efron  and  Tibshirani  outline  a  simulation-based  method  of  confidence  interval  estimation  that 
they  refer  to  as  a  parametric  bootstrap  approach.  13  Notice  that  from  equation  (1),  the  difference 
in  costs  on  the  numerator  and  the  difference  in  effects  on  the  denominator  of  the  ICER  are  both 
simply  the  difference  between  two  normally  distributed  variables,  the  two  sample  means*  The 
difference  of  two  means  is  also  normally  distributed.  The  parametric  bootstrap  approach  involves 
using  this  property  of  the  distribution  of  the  numerator  and  denominator  in  combination  with  the 
observed  means,  variance  and  covariance  to  estimate  the  parameters  of  the  sampling  distribution 
of  the  cost  and  effect  differences.  Sampling  from  each  of  these  two  distributions,  while  allowing  for 
*  They  are  normally  distributed  if  the  sample  sizes  are  large  enough  to  invoke  the  central  limit  theorem  or  if  both  costa 
and  effects  are  normally  distributed. 
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the  estimated  covariance  between  them,  gives  an  estimate  of  the  ICER.  Repeating  this  process 
many  times  generates  an  empirical  estimate  of  the  sampling  distribution  of  the  ICER.  The 
100(a/2)  and  100(1  -  a/2)  percentiles  of  this  estimated  distribution  are  used  as  estimates  for  the 
upper  and  lower  limits  of  the  confidence  interval,  as  with  the  percentile  method. 
2.3.  The  Monte  Carlo  simulation  experiments 
A  simulation  experiment  was  designed  to  test  the  coverage  properties  of  each  method  for 
calculating  confidence  intervals  in  terms  of  the  percentage  number  of  times  the  true  parameter 
falls  outside  the  interval.  Recall  that  a  precise  100(1  -  a)  per  cent  confidence  interval  will  contain 
the  true  population  parameter  100(1  -  a)  per  cent  of  the  time  in  repeated  sampling.  Therefore,  the 
expectation  is  that  in  100a  per  cent  of  samples,  the  true  population  parameter  lies  outside  of  the 
interval.  In  deciding  the  levels  of  power  and  significance  to  accept,  analysts  trade  off  between  type 
I  and  type  II  errors.  If  ä,  the  observed  proportion  of  Monte  Carlo  trials  where  the  true  population 
parameter  lies  outside  of  the  interval,  is  greater  than  a,  too  many  type  I  errors  are  committed.  If 
ä  is less  than  a,  too  many  type  II  errors  are  committed.  Clearly,  if  an  analyst  has  specified  an 
acceptable  rate  of  error  in  advance,  the  method  employed  should  deliver  that  chosen  rate  of  error. 
The  Monte  Carlo  experiments  employed  the  same  population  parameter  values  for  the  average 
costs  and  average  effects  of  two  hypothetical  treatments  A  and  B  as  those  used  in  the  experiments 
conducted  by  Wakker  and  Klaassen  `  The  population  mean  cost  for  the  group  receiving 
treatment  A  was  set  at  40,000  and  for  group  B  was  set  at  30,000;  the  population  mean  effects  for 
groups  A  and  B  were  set  as  60  and  50,  respectively.  Hence  the  population  value  of  the  ICER  can 
be  calculated  as 
R- 
CA  -  CB  40,000  -  30,000  10,000 
-  1000.  (13) 
EA  -  EB  60  -  50  10 
However,  in  the  experiments  conducted  by  Wakker  and  Klaassen,  the  standard  deviations 
specified  for  the  population  parameters  were  unrealistically  low.  `  Recall  that  the  coefficient  of 
variation  for  a  random  variable  x  is  defined  as  cv(x)  = 
ý/var(x)/z.  Employing  the  standard 
deviations  and  population  values  specified  by  Wakker  and  Klaassen'  suggests  that  the  average 
observed  coefficient  of  variation  on  the  numerator  of  the  ratio  (the  difference  in  costs)  in  their 
simulation  experiments  was  0.12,  while  the  average  observed  coefficient  of  variation  of  the 
denominator  (effect  difference)  was  approximately  0.02.  Low  coefficients  of  variation  such  as  these 
are  likely  to  give  a  sampling  distribution  for  the  ICER  that  is  very  close  to  a  normal  sampling 
distribution.  -'  However,  we  believe  this  is  unrealistic  and  that  many  economic  evaluations  will 
have  much  higher  coefficients  of  variation  on  both  the  numerator  and  denominator  of  the  ratio 
leading  to  sampling  distributions  which  are  significantly  skewed.  For  example,  the  coefficients  of 
variation  for  the  original  data  on  which  Figure  2  is  based  were  0.55  for  the  numerator  and  0.27  for 
the  denominator.  As  Figure  2  shows,  the  estimated  sampling  distribution  was  far  from  normal. 
Hence  the  standard  deviations  of  the  individual  population  parameters  employed  in  the  Monte 
Carlo  experiments  were  set  such  that  they  generated  a  range  of  specified  levels  of  coefficient  of 
variation  in  the  numerator  and  denominator  (details  of  these  calculations  are  given  in  the 
Appendix). 
The  problem  with  a  single  Monte  Carlo  experiment  is  that  it  will  be  valid  only  for  the  chosen 
parameters  and  conditions  set  in  that  experiment.  Hence  we  designed  a  series  of  experiments 
which  systematically  varied  the  underlying  conditions  most  crucial  to  the  shape  of  the  ICER 
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Table  I.  Overall  performance  of  the  different  methods  across  the  480  experiments 
Confidence 
interval 
Lower 
alpha 
Upper 
alpha 
Overall 
alpha 
Low 
error 
Upper 
error 
Overall 
error 
Taylor  0.0051  0.0615  0.0665  -0.0199  0.0365  0.0165 
Fieller  0.0205  0.0139  0.0524  -0.0045  0.0069  0.0024 
Confidence  box  0.0019  0.0047  0.0066  -0.0231  -0.0203  -0.0434  Norm  approx  0.0047  0-0507  0-0554  -0-0203  0.0257  0-0054 
Percentile  0.0185  0.0376  0.0561  -0.0066  0.0216  0.0061 
BCa  0.0229  0.0364  00593  -0.0021  0-0114  0.0093 
BC  *0.0252  0-0416  0.0668  *0.0002  0.0166  0-0168 
Paraboot  0-0155  0.0342  *0.0497  -0.0095  0.0092  *-0.0003 
*  Non-significant  at  t-ratio  <  2,  employing  an  estimated  standard  error  of  a  proportion  of 
se(p)  ={p(1  -  p)/n}  =  0.0007  (for  lower/upper  alpha/error)  and  0.0010  (for  overall  alpha/error) 
sampling  distribution.  Five  different  correlation  coefficients  for  the  covariance  between  the  costs 
and  effects  in  the  two  groups  were  set:  -0.90;  -045;  0;  0.45,  and  0.90.  Coefficients  of  variation 
for  the  numerator  and  denominator  were  independently  specified  as  10,20,30  and  40  per  cent.  Six 
sample  sizes  were  tested:  10;  30;  50;  60;  80,  and  100.  Population  cost  and  effect  data  are  rarely 
normally  distributed;  in  particular,  cost  data  is  often  significantly  skewed.  Hence,  we  set  the 
underlying  cost  and  effect  data  for  groups  A  and  B  generated  in  the  Monte  Carlo  experiments  to 
be  log-normally  distributed. 
Each  experiment  involved  taking  a  random  sample  of  values  from  one  of  the  specified 
populations  described  above.  On  the  basis  of  the  values  obtained  in  these  samples,  confidence 
intervals  were,  calculated  by  each  of  the  seven  methods  described  in  Sections  2.1  and  2.2.  In 
addition,  the  straightforward  bias-corrected  (BC) bootstrap  interval,  as  employed  by  Chaudhary 
and  Stearns,  5  was  estimated  by  simply  ignoring  the  accelerator  adjustment  described  in  Section 
2.2.3.  The  estimated  intervals  were  then  compared  to  the  true  ICER  from  equation  (13).  Where 
the  true  value  lay  outside  of  the  calculated  interval,  this  result  was  recorded.  This  process  was 
repeated  1000  times  for  each  experiment.  Hence  the  number  of  times  the  true  ICER  lay  outside 
the  interval  divided  by  the  1000  simulations  was  the  estimated  alpha  level  for  that  experiment. 
The  upper  alpha  level  recorded  the  number  of  times the  true  ICER  lay  above  the  interval,  the 
lower  alpha  recorded  the  number  of  times the  true  ICER  lay  below  the  interval,  and  the  overall 
alpha  was  the  addition  of  the  upper  and  lower  alphas.  Varying  all  of  the  conditions  above 
represents  480  different  experiments  (5  correlation  coefficients  x4  coefficients  of  variation  for  the 
numerator  x4  coefficients  of  variation  for  the  denominator  x6  sample  sizes)  for  which  eight 
confidence  intervals  were  calculated,  giving  a  total  of  3840  data  points. 
3.  RESULTS 
The  overall  results  across  the  480  experiments  are  presented  in  Table  I.  For  each  of  the  eight 
methods  the  estimated  upper,  lower  and  overall  alpha  rates  are  shown.  To  aid  interpretation 
`error  rates'  are  also  shown.  These  are  simply  the  value  of  (d  -  a),  the  estimated  value  of  alpha  less 
the  nominal  value  of  alpha  chosen  for  the  experiments.  The  nominal  value  of  alpha  appropriate 
for  the  upper  and  lower  results  is  0.025  and  for  the  overall  results  is  0.05.  Each  of  the  estimated 
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alpha/error  rates  was  tested  for  significance  using  the  binomial  approximation  for  the  standard 
error  of  a  proportion.  *  All  were  significantly  different  from  the  nominal  levels  except  for  the  lower 
estimate  of  the  BC  bootstrap  method  and  the  overall  estimate  for  the  parametric  bootstrap 
method. 
Care  must  be  taken  when  interpreting  the  results  of  the  overall  error  values.  Systematic 
overestimation  in  one  tail  of  the  distribution  combined  with  underestimation  in  the  other  tail  can 
lead  to  a  small  overall  error  generated  by  large  upper  and  lower  errors of  opposite  sign.  This  effect 
is  most  noticeable  in  the  parametric  bootstrap  method  where  the  overall  alpha  is  not  significantly 
different  from  the  nominal  alpha  level.  However,  it  is  clear  that  this  is  a  result  of  the  errors  in  the 
upper  and  lower  alpha  values  cancelling  each  other  out.  Similar,  although  not  so  dramatic,  effects 
are  also  apparent  in  the  results  for  the  Fieller  and  Taylor  series  methods  and  the  normal 
approximation,  percentile  and  BCa  bootstrap  methods. 
On  the  basis  of  the  results  from  Table  1,  Fieller's  method  appears  to  be  performing  most 
consistently  across  experiments,  since  it  has  the  lowest  upper  error,  the  second  lowest  lower  error 
and  the  lowest  overall  error.  The  BCa  and  parametric  bootstrap  performing  best  of  the  non- 
parametric  methods  and  also  outperforming  the  Taylor  method  and  the  box  approach.  However, 
since  these  results  are  based  on  summing  across  the  480  separate  experiments,  the  results 
presented  in  Table  I  could  potentially  mask  underlying  variation  in  the  estimated  errors  between 
experiments  if  overestimates  in  some  experiments  cancel  out  with  underestimates  in  other 
experiments.  These  variations  may  be  systematically  related  to  experimental  factors,  which  would 
have  significant  practical  importance. 
In  order  to  analyse  the  effect  of  these  experimental  factors  on  the  overall  accuracy  of  the  eight 
confidence  interval  methods,  a  technique  known  as  response  surface  analysis  was  used.  `  "'  This 
is  a  technique  based  on  simple  OLS  regression  employing  dummy  variables  for  each  of  the 
methods.  Since  the  technique  requires  a  single  dependent  variable  we  constructed  a  performance 
index  based  on  the  upper  alpha  value,  defined  as  -1ä°  -  aut.  The  negative  sign  was  included  for 
interpretative  purposes  -  the  greater  the  number,  the  better  the  performance.  The  upper  alpha 
value  was  chosen  partly  due  to  the  problem  with  the  overall  alpha  value  detailed  above,  but 
mainly  due  to  the  fact  that  economic  analysts  are  more  interested  in  deciding  whether  an 
observed  ICER  is  below  some  threshold  value  used  for  decision  making  and  might  therefore  be 
more  interested  in  the  upper  alpha  value  being  close  to  its  chosen  nominal  level.  ' 
The  results  of  the  response  surface  analysis  are  presented  in  Table  H.  The  reference  interval 
chosen  was  the  Fieller  method  since  it  seemed  to  perform  best  from  the  results  presented  in  Table 
1.  The  natural  log  of  the  sample  size  was  chosen  as  an  explanatory  variable  since  it  was 
hypothesized  that  performance  would  improve  with  sample  size  asymptotically  to  some  limit. 
The  seven  confidence  interval  dummies  are  presented  on  separate  rows,  with  the  first  row  being 
the  reference  (Fieller)  interval.  The  majority  of  the  coefficients  were  significant  at  the  standard 
levels,  indicating  that  there  are  important  differences  between  the  Fieller  interval  and  other 
methods  across  the  different  experiments. 
The  key  to  interpreting  the  results  of  the  analysis  lies  in  the  sign  of  the  coefficient,  positive 
coefficients  indicate  an  improvement  in  performance  relative  to  Fieller's  method  for  that  variable 
and  negative  coefficients  indicate  worsening  performance  relative  to  the  Fieller  method.  However, 
*  The  binomial  approximation  for  the  standard  error  of  a  proportion  pis  given  by  se(p)  -  V{p(1 
-  p)/n}  where  n  is  the 
sample  size. 
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Table  II.  Results  of  the  response  surface  analysis:  estimated  coetºicients* 
Dummy  variables  Intercept  Interactions 
Log  of  Coefficient  of  Coefficient  of  Correlation 
sample  size  variation  for  variation  for 
numerator  denominator 
Ref(Fieller)  -0.02171  0.00351  -0.01061 
0.0108t  0.00131 
Taylor  -0.0159  0.00271  0.0433  -0.1362t  0.01591 
Confidence  box  0.00431  -0.00411  0.0088t  -0.0123'  -0.00891  Norm  approx  -0.03381  0.00521  0.0299~  -0.04871  0.01421 
Percentile  -0.02571  0-00511  -0.0134t 
0.01781  0.00311 
BCa  -0.0198'  0.0044?  -0.0101t  0.00791  0.0012+ 
BC  -0.03481  0.0069t  -0.02001  0.0192?  0.0056 
Para  boot  -0.0147t  0.00311  -0.0024  0.0056  0.0001 
*  Adjusted  RZ  for  the  model  =  0.74,  n=  3840 
t-  ratio  >2 
10  20  30  40  50  OD  70  00  90  100 
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Figure  3.  Predicted  effect  of  sample  size  on  the  performance  variable  using  results  of  the  response  surface  analysis 
(coefficients  of  variation  =  0.2,  correlation  -  0).  Performance  variable  is defined  as  -  IBu  -  au) 
due  to  the  different  intercept  values,  it  is  not  easy  to  see  the  relative  performance  of  each  method. 
In  order  to  demonstrate  better  the  relative  performance,  the  results  of  the  response  surface 
analysis  presented  in  Table  11  were  used  to  generate  predicted  performance  values  for  each  of  the 
methods.  By  holding  three  of  the  four  quantitative  variables  constant,  it  was  possible  to  examine 
the  effect  of  the  fourth  on  the  performance  of  each  method. 
Figure  3  shows  the  predicted  performance  of  each  method  for  increasing  sample  size  between 
10  and  100,  holding  the  coefficients  of  variation  constant  at  0.2  and  the  correlation  coefficient 
constant  at  0.  The  parametric  methods  are  shown  with  the  weightier  lines  and  solid  symbols.  At 
low  sample  sizes,  Fieller's  method  performs  best  and  the  Taylor  series  performs  worst.  The 
confidence  box  approach  appears  largely  unaffected  by  sample  size.  All  the  other  methods 
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Figure  4.  Predicted  effect  of  coefficient  of  variation  of  the  numerator  on  the  performance  variable  using  results  of  the 
response  surface  analysis  (sample  size  =  50,  coefficient  of  variation  of  the  denominator  -  &2,  correlation  -  0).  Perfor- 
mance  variable  is  defined  as  -  I&°  -  0°I 
improve  with  sample  size,  and  by  n=  100  there  is little  to  choose  between  Fieller's  method  and 
the  bootstrap  methods  with  the  exception  of  the  normal  approximation  bootstrap  method, 
which,  like  the  Taylor  series  method,  performs  poorly. 
Figure  4  shows  the  predicted  performance  of  each  method  for  values  of  the  coefficient  of 
variation  of  the  numerator  between  0.1  and  0.4,  holding  the  coefficient  of  variation  of  the 
denominator  constant  at  0.2,  the  correlation  coefficient  constant  at  0  and  the  sample  size  constant 
at  50.  Again,  Fieller's  method  performs  best  for  all  values  of  the  coefficient  of  variation  of  the 
numerator  and  the  Taylor  series  method  performs  worst.  The  normal  approximation  and  Taylor 
series  methods  improve  in  performance  as  the  coefficient  of  variation  of  the  numerator  increases 
while  the  performance  of  the  other  methods  decrease,  with  the  exception  of  the  confidence  box 
method  which  again  appears  largely  unaffected  by  changes  in  the  coefficient  of  variation  of  the 
numerator. 
Figure  5  shows  the  predicted  performance  of  each  method  for  values  of  the  coefficient  of 
variation  of  the  denominator  between  0.1  and  0.4,  holding  the  coefficient  of  variation  of  the 
numerator  constant  at  0.2,  the  correlation  coefficient  constant  at  0  and  the  sample  size  constant  at 
50.  A  similar  picture  emerges  in  that  Fieller's  method  performs  best  overall,  Taylor  series 
performs  worst  for  all  but  the  lowest  coefficients  of  variation  of  the  denominator  and  the 
confidence  box  method  seems  largely  unaffected.  This  time,  however,  the  performance  of  the 
Taylor  series  and  normal  approximation  bootstrap  methods  worsen  as  the  coefficient  of  variation 
of  the  denominator  increases  while  the  other  methods  improve  in  performance. 
Figure  6  shows  the  predicted  performance  of  each  method  for  values  of  the  correlation 
coefficient  between  -0.9  and  +  0.9,  holding  the  coefficients  of  variation  constant  at  0.2  and  the 
sample  size  constant  at  50.  Fieller's  method  again  performs  best  and  appears  unaffected  by 
variation  in  the  correlation  coefficient  of  the  underlying  data.  All  methods  improve  with 
increasing  correlation  with  the  exception  of  the  confidence  box  method,  which  worsens  dramati. 
cally  as  correlation  increases.  At  the  very  highest  correlation,  the  confidence  box  method 
performs  worse  than  the  Taylor  series  method. 
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Figure  5.  Predicted  effect  of  coefficient  of  variation  of  the  denominator  on  the  performance  variable  using  results  of  the 
response  surface  analysis  (sample  size  =  50,  coefficient  of  variation  of  the  numerator  -  0.2,  correlation  -  0).  Performance 
variable  is defined  as  -  Idu  -  auf 
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Figure  6.  Predicted  effect  of  correlation  in  the  underlying  date  on  the  performance  variable  using  results  of  the  response 
surface  analysis  (sample  size  -  50,  coefficients  of  variation  -  (4).  Performance  variable  is  defined  as  -  Idu  -  auf 
4.  DISCUSSION  AND  CONCLUSIONS 
The  purpose  of  this  paper  was  to  compare  a  number  of  parametric  approximations  of  the 
confidence  limits  around  the  incremental  cost-effectiveness  ratio  with  non-parametric  bootstrap. 
ping  methods.  By  devising  a  series  of  experiments  that  represented  a  realistic  range  of  statistical 
conditions,  we  are  able  to  make  general  conclusions  about  the  relative  performance  of  these 
approaches,  and  the  factors  affecting  their  relative  performance. 
No  single  method  dominated  (or  was  dominated  by)  all  other  methods  across  all  of  the 
experiments.  However,  as  is  shown  by  Figures  3-6,  Fieller's  method  consistently  performed  well 
under  a  wide  variety  of  assumptions,  including  small  sample  sizes,  where  its  assumption  of  joint 
Copyright  (1)  1999  John  Wiley  &  Sons,  Ltd.  stalls.  Mod.  Is.  3245-3262  (1999) 
215 
Cornlatlon  a  BC 
-x-Fm  Uwe CONFIDENCE  INTERVALS  FOR  COST-EFFECTIVENESS  RATIOS  3259 
normality  between  the  cost  and  effect  differences  has  been  questioned.  -'  Of  the  bootstrap  methods, 
a  clear  pattern  emerged  in  terms  of  the  rank  ordering  of  performance.  The  parametric  bootstrap 
performed  the  best  under  most  circumstances,  closely  followed  by  the  BCa  and  then  the 
straightforward  percentile  method.  The  normal  approximation  method  performed  most  poorly  of 
the  bootstrap  methods.  It  is  clear  that  the  `accelerator'  adjustment  presented  by  Efron  as 
a  refinement  to  the  straightforward  bias  corrected  approach  does  improve  the  performance  of  the 
method.  Although  the  term  `parametric  bootstrap'  has  been  adopted  by  Efron  and  Tibshirani,  13 
this  method  is  simply  a  straightforward  Monte  Carlo  simulation  of  the  numerator  and  denomin- 
ator  of  the  ratio  on  the  basis  of  parametric  assumptions  and  the  observed  means  and  variances  of 
the  data.  To  what  extent  this  constitutes  `bootstrapping'  as  the  term  is  commonly  applied  is  an 
open  question. 
The  predicted  effect  of  increasing  sample  size  is  of  particular  interest.  Both  the  parametric  and 
bootstrap  methods  rely  on  asymptotics,  and  it  appears  from  Figure  3  that  the  asymptotics  of  the 
parametric  methods  come  in  to  play  more  quickly  than  those  of  the  bootstrap  methods.  In  many 
ways  this  is  a  surprising  result  since  bootstrapping  has  often  been  linked  to  the  analysis  of  small 
samples  where  standard  parametric  assumptions  are  thought  to  be  violated.  "' 
As  the  correlation  between  the  cost  and  effect  in  the  underlying  data  increased,  the  performance 
of  the  confidence  box  method  worsened.  This  is  due  to  the  fact  that  the  combination  of  limits  for 
the  confidence  box  approach  is  consistent  with  an  assumption  of  perfect  negative  covariance 
between  cost  and  effect.  For  all  other  methods,  performance  increased  with  increasing  correla- 
tion.  Although  there  was  little  to  choose  between  the  methods  when  correlation  was  high,  in 
practical  application  it  would  be  unusual  to  observe  extremely  high  positive  or  negative  correla- 
tions.  In  the  data  from  which  Figure  2  was  generated,  the  correlation  between  cost  and  effect  in 
the  treatment  arm  of  the  trial  was  0.19,  while  in  the  control  arm  of  the  trial  it  was  -005.8  These 
figures  translate  into  very  little  covariance  between  the  numerator  and  denominator  of  the  ICER. 
The  predicted  effect  of  the  coefficient  of  variation  of  the  numerator  and  denominator  was 
interesting  in  that  each  seemed  to  influence  the  methods  in  the  opposite  direction.  The  methods 
based  on  an  assumption  of  the  normal  distribution  worsened  as  the  coefficient  of  variation  of  the 
denominator  increased,  but  improved  as  the  coefficient  of  variation  of  the  numerator  increased. 
For  the  other  methods,  the  converse  was  true,  with  the  exception  of  the  confidence  box  method, 
which  seemed  largely  unaffected  by  either  coefficient  of  variation. 
One  very  clear  result  from  these  experiments  was  the  inadequacy  of  methods  based  principally 
on  the  assumption  of  a  normal  sampling  distribution.  Both  the  parametric  based  Taylor 
approximation  method  and  the  bootstrap  normal  approximation  were  consistently  poor  per- 
formers,  although  the  bootstrap  normal  approximation  seemed  to  outperform  the  Taylor  series 
method  in  general.  It  is  our  belief  that  the  sampling  distribution  of  the  ICER  will  almost  certainly 
exhibit  an  element  of  skewness  in  most  practical  applications,  which  makes  the  normal  distribu- 
tion  assumption  rather  limiting. 
Recent  reviews  of  economic  evaluations  have  suggested  that  many  authors  present  only  point 
estimates  of  cost-effectiveness  without  any  representation  of  the  uncertainty  associated  with  their 
estimates,  20'21  which  suggests  that  any  method  of  interval  estimation  is  preferable  to  point 
estimates  alone.  However,  we  have  shown  that  there  are  substantial  differences  in  the  accuracy  of 
the  methods  advocated  in  the  recent  health  economics  literature.  We  believe  that  the  nominal 
error  rates  accepted  by  analysts  when  calculating  confidence  intervals  should  be  reflected  by  the 
actual  rates  of  error  that  would  occur  in  repeated  application  of  the  method.  Of  course,  these 
error  rates  will  only  occur  if  in  practice  analysts  begin  to  test  hypotheses  on  the  basis  of  the  results 
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of  prospective  economic  evaluation.  We  believe  the  time  is  now  ripe  for  an  analysis  of  the  role  of 
hypothesis  testing  in  economic  appraisal. 
APPENDIX 
This  Appendix  lays  out  the  method  for  generating  variances  of  the  cost  parameters;  the  same 
method  also  applies  to  effects.  Suppose  the  underlying  population  cost  parameters  for  treatments 
A  and  B  are  known  to  be  CA  and  CB,  respectively.  Define  the  mean  difference  in  cost  between  two 
groups  sampled  from  these  populations  as  AC  =  CA  -  Cs.  In  terms  of  the  Monte  Carlo  experi- 
ments,  we  want  to  set  the  coefficient  of  variation  of  the  difference  in  costs,  cv(AC),  since  it  is  this 
which  is  assumed  (in  tandem  with  the  effect  difference)  to  determine  the  shape  of  the  ICER 
sampling  distribution.  Hence,  the  problem  is  to  work  backwards  from  this  coefficient  of  variation 
to  define  values  for  the  population  cost  variance  for  patients  receiving  treatments  A  or  B,  al  and 
oB2,  which  will  generate  the  desired  cv(AC). 
We  know  that  the  coefficient  of  variation  for  the  cost  difference  is  defined  as 
hence  cv(AC)'  =  476,  C/AC, 
QoC  =  ACcv(AC).  (14) 
Assuming  that  random  samples  of  size  nA  and  nB  are  sampled  from  the  population  for  treatments 
A  and  B,  respectively,  then  the  treatment  costs  in  each  group  should  be  independent.  Thus  it  is 
possible  to  relate  the  variance  of  the  cost  difference  to  the  variances  of  the  underlying  treatment 
and  control  group  cost  data: 
i2 
2  CCA  Qca 
(15)  Qec+-. 
nA  nB 
Combining  equations  (14)  and  (15)  gives 
[cv(AC)QC]Z  = 
ncA 
+  nge 
A 
and  rearranging 
nAnB  [cv(AC)  AZ']  2=  nBQCA  +  nAOCe.  (16) 
Further  suppose  that  the  coefficients  of  variation  of  the  underlying  costs  are  the  same,  that  is, 
(7cA/Cn  =  ace/CB  or  equivalently  that 
CA 
QCM=oCO  C. 
B 
Combining  equations  (16)  and  (17)  gives 
nAnB[cv(t1C)QL']Z  =  nsacs(  _fl  +  fA  arc's  C6 
=  02  e[nti  +  na 
(£C, 
9-1)'] 
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and  rearranging 
_ 
{cv(ec)tC32  UCH  ^  WAHR 
nA  +  ne(CA/CB)2 
(18) 
Clearly,  QC',,  can  now  be  calculated  from  equation  (17). 
In  our  experiments,  the  sample  size  in  each  group  was  the  same,  that  is,  nA  =  nB  =  n,  therefore 
equation  (18)  simplifies  to 
_ 
[cv(EC)AC]2  2 
0cB  _nI+  (Cn/CB)Z 
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